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STATEMENT OF JURISDICTION 
This Court has jurisdiction pursuant to Utah Code Ann. § 78-2-2(3)(j). 
ISSUES PRESENTED FOR REVIEW AND STANDARD OF REVIEW 
1. Does the evidence, when viewed in the light most favorable to Appellee Zinetics 
Medical, Inc. ("Zinetics"), support the district court's factual finding that the fair 
value of Zinetics5 stock was less than 4.528 cents per share? This is an issue of fact. 
Argyle v. Argyle, 688 P.2d 468, 471 (Utah 1984) (court's valuation of stock is a 
factual determination). The district court's factual finding on value will only be 
reversed on appeal if it can be demonstrated that the finding is "so lacking in support 
as to be 'against the clear weight of the evidence'." In re Estate ofBartell, 776 P.2d 
885, 886 (Utah 1989). Great deference is given to the district court's finding, 
particularly where, as here, it is based on an evaluation of conflicting testimony. Id.9 
citing Utah R. Civ. P. 52(a). 
2. Did the district court clearly abuse its discretion in rejecting as "fundamentally 
flawed" the valuation model sponsored by Appellants' ("the Minority Shareholders") 
expert, given unrebutted evidence that the model was unreliable? This factual finding 
can only be reversed on appeal if it can be demonstrated that the finding is "so lacking 
in support so as to be 'against the clear weight of the evidence'." Bartell, 116 P.2d 
at 886 (Utah 1989). Great deference is given to the district court's finding, 
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particularly where, as here, it is based on an evaluation of conflicting testimony. Id., 
citing Utah R. Civ. P. 52(a). 
3. Did the district court clearly abuse its discretion in giving no weight to a sham offer 
by the Minority Shareholders to purchase the majority shares of Zinetics stock at ten 
cents a share given factual and expert testimony that the offer was neither realistic nor 
financially feasible? The weight to be afforded to evidence is uniquely a matter for 
the trier of fact, with due regard for its opportunity to judge the credibility of 
witnesses. Yelderman v. Yelderman, 669 P.2d 406, 408 (Utah 1983) (per curiam); 
UtahR. Civ. P. 52(a). 
4. Did the district court clearly err in declining to issue an advisory opinion on whether 
Utah's fair value statute permits application of a minority or marketability discount, 
where the issue of discounts was irrelevant because of the overwhelming evidence 
that the fair value of Zinetics was less than 4.528 cents per share (the amount paid by 
Zinetics) before application of any discounts? This is an issue of law reviewed de 
novo. Justheim v. Division of State Lands, 659 P.2d 1075, 1077 (Utah 1983). 
RELEVANT CONSTITUTIONAL PROVISIONS, 
STATUTES AND RULES 
Section 16-10a-1302 of the Utah Revised Business Corporation Act ("Utah Act") 
provides the governing statutory framework for this case. It is reproduced at Tab 1 of 
Zinetics5 Addenda ("Zin. Add."). 
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STATEMENT OF THE CASE 
This is a statutory proceeding to determine the fair value of the stock of certain 
minority shareholders who dissented from the merger of Zinetics and Medtronic GB5 Inc., 
a wholly-owned subsidiary of Medtronic, Inc. ("Medtronic"). Zinetics is the manufacturer 
of gastrointestinal catheters. Medtronic is a publicly-traded company which manufactures 
implantable medical devices. At the time of the merger, Medtronic already owned 81.7% 
of the 128 million outstanding shares of Zinetics' stock through another wholly-owned 
subsidiary, Synectics, Inc. ("Synectics"), a Swedish company. Invoking the procedures of 
the Utah Act, the Minority Shareholders dissented from the merger pursuant to which they 
were to receive slightly more than 4-1/2 cents per share. Zinetics timely commenced a 
petition under Part 13 of the Utah Act to determine the fair value of its stock on February 12, 
1998. 
The district court, the Honorable Ronald Nehring presiding, conducted a four-day 
trial. It heard testimony from over a dozen separate witnesses, much of it conflicting, and 
received over 100 separate exhibits into evidence. All of Zinetics' fact witnesses had 
extensive experience working for medical products companies. These included Robert 
Paulsen, a Medtronic vice president and corporate acquisition specialist; William Murray, 
formerly the President of Zinetics and a member of its Board of Directors; Hans Neisz; a 
Medtronic engineer, Synectics' Director of Operations, and a Director of Zinetics; and Ross 
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Allen, Synectics' controller. In contrast, the Minority Shareholders called only one witness 
who had ever worked for any medical products company. 
Both parties sponsored expert valuations on the fair value of Zinetics. The Minority 
Shareholders' expert claimed that the value of Zinetics was 18 cents per share prior to the 
merger. The Minority Shareholders further urged the district court to adopt their argument 
that the "true" value of Zinetics had been suppressed by Synectics or Medtronic. Zinetics' 
expert was Merrill Norman of the Salt Lake City firm of Norman/Loebbecke & Associates. 
Mr. Norman opined that the 4-1/2 cents-per-share paid in the merger was substantially 
greater than the fair value of the shares, prior to application of any discounts. 
The district court issued a thoughtful sixteen-page Memorandum Decision ("Mem. 
Dec") that considered all of the factors set forth in Oakridge Energy, Inc. v. Clifton, 
937 P.2d 130 (Utah 1997), this Court's seminal decision on fair value under the Utah Act. 
The district court rejected the Minority Shareholders' claim that the fair value of Zinetics had 
been suppressed, and agreed with the conclusion of Zinetics' expert, Merrill Norman, that 
even without the application of discounts, the fair value of Zinetics' stock was less than the 
merger price of 4.528 cents per share. These factual determinations are overwhelmingly 
supported by competent evidence in the record. The district court's decision should be 
affirmed. 
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STATEMENT OF THE FACTS 
Zinetics manufactured disposable catheters for use with diagnostic equipment 
manufactured by third parties. Zinetics was founded in 1983 and controlled by the Minority 
Shareholders until 1991. Testimony of H. Mack Brown ("Brown Test.") at Tr. 339-40; 
Petitioner's Exhibits 47 ("P.X."). During this time, it lost significant amounts of money in 
large part because it was never able to develop an effective distribution network. Brown 
Test, at Tr. 345; P.X. 4 at p. 7. In 1991, the Minority Shareholders' slate of directors 
unanimously voted in favor of selling 81% (some 100 million shares) of the company to 
Synectics Medical for $255,000, or less than .242 cents a share. Brown Test, at Tr. 359; P.X. 
5, 20(D) and Ex. 47 (Minutes of Board of Directors of Nov. 14, 1991). Synectics was a 
Swedish company that was a leading manufacturer of the diagnostic equipment which 
utilized Zinetics'catheters. Deposition ofHansNeisz("NeiszDep.")1 at p. 16-18. Synectics 
thereafter appointed two out of the three directors of Zinetics. The third director was one of 
the Minority Shareholders, Patrick Hogle, who was a director from 1991 to the cash-out 
merger on February 12,1998. Testimony of Patrick Hogle ("Hogle Test.") at Tr. 443, 469. 
After the sale to Synectics in 1991, Zinetics' fortunes improved because Synectics 
provided Zinetics with access to its worldwide distribution network and customer base. 
From 1992 onward, Zinetics experienced steadily increasing revenues and consistent 
*Mr. Neisz was unable to testify live at trial. His videotaped testimony and transcript was 
provided as part of the record. 
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profitability, and in fact became more profitable than its parent. Testimony of Merrill 
Norman ("Norman Am. Test.")2 at Tr. 200-02; Testimony of William Murray ("Murray Am. 
Test.") at Tr. 34-35; Testimony of Ross Allen ("Allen Am. Test.") at Tr. 534-35. In 
December 1993 and again in December 1995, a majority of the Minority Shareholders voted 
to "ratify, approve and confirm all actions taken by the officers and the Board and Directors 
of the Company since the last meeting of the shareholders." (P.X. 54 and 55). 
In 1996, Medtronic acquired 100% of Synectics. Disagreements then arose between 
Medtronic and the Minority Shareholders over the management and future direction of 
Zinetics. Testimony of Robert Paulsen ("Paulsen Am. Test.") at Tr. 27-30; P.X. 6, 12, 15; 
Murray Am. Test at Tr. 20. Negotiations to resolve the disagreements proved unsuccessful, 
because the parties had radically different views on the inherent value of the company and 
because the Minority Shareholders accused both Medtronic and Synectics of having 
"suppressed" the value of Zinetics. Id. After months of fruitless negotiations, Medtronic 
exercised its right to utilize a cash-out merger under the Utah Act at the price of 4.528 cents 
per share, from which the Minority Shareholders dissented. Paulsen Am. Test, at Tr. 75-77; 
Murray Am. Test, at Tr. 41. 
2Due to difficulties in the transcription of the videotaped trial, the parties have stipulated to 
amend the transcript to correct inaccuracies. The Amended Transcript is referred to as "Am. 
Test." 
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Shortly after Zinetics announced the cash-out merger, the Minority Shareholders 
purported to offer Medtronic ten cents a share for its control block of Zinetics. Testimony of 
Ronald Johnson ("Johnson Am. Test.") at Tr. 433-34; P.X. 20(M). No firm financing for this 
offer was specified, other than that the stock was to be paid for by "Zinetics obtaining 
suitable financing to complete the redemption" and an investment banker's due diligence 
review. P.X. 20(M). Prior to communicating this offer, no member of the Minority 
Shareholders had contacted an investment banker about the feasibility of such an offer and 
no due diligence review had been conducted. Johnson Am. Test, at Tr. 435-36. Unlike the 
Minority Shareholders, Medtronic did consult with its own investment bankers and 
consultants on the viability of the proposed offer. Paulsen Am. Test, at Tr. 81-82. The 
advisors confirmed that the ten-cents-a-share proposal was not feasible. Paulsen Am. Test, 
at Tr. 81; P.X. 20(N) at 2. Zinetics' expert, Merrill Norman, prepared detailed projections 
confirming this. Norman Am. Test, at Tr. 285-96; Norman Report, P.X. 22, Schedules T, U, 
V, and W, Tab 2 to Zin. Add. Zinetics proceeded with the merger. 
At trial, both parties presented expert valuation testimony. Zinetics' valuation expert, 
Norman, extensively analyzed Zinetics and the gastroenterology industry, and repeatedly 
interviewed management of Zinetics, Medtronic and Synectics. Norman Test. atTr. 183-85. 
Based on the data he gathered, Norman valued Zinetics from a number of different 
perspectives. Under his investment approaches, he consistently appraised Zinetics within a 
relatively narrow range, from 1.68 cents per share ($2.17 million for the company as a 
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whole) to 2.01 cents per share, depending on the method used. Norman Am. Test, at Tr. 212-
54; Norman Report, Schedule A, F-L and N; Zin. Add., Tab 2. He also used a market 
approach that valued Zinetics based on comparisons to other medical product companies. 
Norman Am. Test, at Tr. 213-14,254-72, Norman Report, Schedules M and Q, P.X. 51 and 
52. 
Norman concluded that the fair value of Zinetics stock before considering any 
discounts, was less than the 4.528 cents per share paid to the Minority Shareholders. Norman 
Am. Test, at Tr. 272-77; 295-96,336-40; Norman Report at 1-2 and Schedule A, Zin. Add., 
Tab 2. The Minority Shareholders' expert, Robert Reilly also valued Zinetics under an 
investment approach and a market approach. His market approach was based on a 
comparison of Zinetics to eleven guideline companies. Reilly Am. Test, at Tr. 431-32. 
Norman demonstrated, however, that Reilly's guideline companies were not at all 
comparable to Zinetics and that Reilly's market value model was unreliable. Norman Test, 
at Tr. 682-703, and P.X. 66, Tab 3 to Zin. Add. Although given the opportunity to respond 
to Norman's critique {see Tr. at 645), Reilly offered no rebuttal. 
SUMMARY OF ARGUMENT 
The district court's factual finding that the fair value of Zinetics' stock was worth less 
than 4.528 cents a share is folly supported by Merrill Norman's testimony and report. To 
obtain a reversal of this factual finding, the Minority Shareholders must first marshal all the 
evidence supporting it, and then demonstrate that, when viewed in the light most favorable 
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to the district court, the finding is "so lacking in support as to be 'against the clear weight of 
the evidence5." Bartell, 116. P. 26 at 886. The Minority Shareholders cannot satisfy this 
burden. Instead, they improperly ask this Court to reconsider de novo all of their factual 
arguments raised below, which the district court carefully considered - and rejected. On 
appeal, however, this Court does not weigh evidence de novo\ instead, great deference is 
given to the trial court's findings, particularly, where, as here, they are based on an 
evaluation of conflicting testimony. Id., citing Utah R. Civ. P. 52(a). 
The remaining arguments raised by the Minority Shareholders are without merit. 
Because the record demonstrates that the fair value of Zinetics was less than 4.528 cents 
share prior to application of any discounts, the applicability or non-applicability of discounts 
is irrelevant to this appeal. Utah courts refrain from issuing advisory opinions and there is 
no reason to depart from that well-settled rule here. See, e.g., Justheim v. Division of State 
Lands, 659 P.2d 1075, 1077 (Utah 1983) ("It is not our function to render advisory 
opinions."). Further, the claim that the district court should have given weight to certain 
testimony ignores that evaluation of the weight and credibility of evidence is a matter for the 
trier of fact. Yelderman v. Yelderman, 669 P.2d 406,408 (Utah 1983) (per curiam). The 
issue is not whether there are bits of evidence that might support a different conclusion, but 
whether the record evidence is sufficient to support the findings. Finally, the argument that 
the district court erred by not identifying an exact value to Zinetics' shares misses the mark. 
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Fair value is not required to be determined to the hundredth of a penny, and the record amply 
supports the district court's conclusion that fair value was less than the merger price. 
ARGUMENT 
A. The Determination of Fair Value Is a Finding of Fact Committed to the 
District Court's Sound Discretion 
It is black-letter law that "[t]he district court has wide discretion in determining fair 
value" and that the "ultimate determination of fair value is an issue of fact." Swope v. Siegel-
Robert, Inc., 243 F.3d 486,494 (8th Cir. 2001). Utah law is no different. Argyle v. Argyle, 
688 P.2d 468, 471 (Utah 1984) (court's valuation of closely held stock is a "unique[ly] 
factual determination"); Weston v. Weston, 112> P.2d 408,409 (Utah Ct. App. 1989) (court's 
valuation of stock is a factual determination reviewed under the "clearly erroneous" standard 
of Utah R. Civ. P. 52(a)). 
The discretion afforded to the district court in determining value is particularly broad, 
where, as here, the parties present conflicting expert testimony that must be resolved by the 
district court. As this Court noted in Bartell, "great deference is given to the trial court's 
findings, especially when they are based on an evaluation of conflicting live testimony." 
776 P.2d at 886. A district court faced with conflicting expert opinions on value is entitled 
to give the conflicting opinions "whatever weight he or she deems appropriate." Newmeyer 
v. Newmeyer, 745 P.2d 1276, 1278 (Utah 1987) (affirming district court opinion that 
determined the value of property at the mid-point of the respective experts' valuations'); 
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accord Weston v. Weston, 111 P.2d 408,410 (Utah Ct. App. 1989). The decision of what 
weight to give a particular valuation approach involves no legal issue, but is a pure issue of 
fact. See, e.g., Beaver County v. Utah State Tax Comm % 916 P.2d 344, 355 (Utah 1996) 
(question of weighing of one indicator of value over another has consistently been treated as 
a question of fact) {citing cases); Salt Lake City Southern R.R. v. Utah State Tax Comm yn, 
1999 UT 90, \ 13, 987 P.2d 594 (choice of valuation methodology is a question of fact). 
Once again, Utah law in this regard is no different than that of other jurisdictions. 
See, e.g.,Kahn v. Household Acquisition Corp., 591 A.2d 166,175 (Del. 1991) (noting that 
"the role of the Chancery judge as an informed trier of fact imparts a high level of deference 
to the review of valuation findings."). No other standard of review would be workable. 
Were it otherwise, the appellate courts would constantly be required to independently 
recalculate and redetermine the value of marital assets in divorce cases, the value of real 
estate in tax appeals and condemnations, the value of stock and other intangibles in fair value 
proceedings, and of other property in every other type of case which requires a lower court 
to make a factual finding of value. 
B. The Minority Shareholders Were Obliged to Marshal All Evidence 
Supporting the District Court's Findings and Demonstrate That When 
Viewed in the Light Most Favorable to the District Court's Findings, the 
Evidence Did Not Support the Findings 
Since the determination of fair value is a finding of fact, the Minority Shareholders' 
appeal from the district court's determination of value must comply with Utah Rule of 
11 
Appellate Procedure 24(9). Namely, the Minority Shareholders must first marshal all the 
evidence in support of the district court's findings, and "then demonstrate that even when 
reviewing the evidence in a light most favorable to the court below, the evidence is 
insufficient to support the findings." Reed v. Reed, 806 P.2d 1182,1184 (Utah 1991); Utah 
R. App. P. 24(9). This standard applies regardless of "whether the case is characterized as 
one in equity or one in law." Terry v. Price Municipal Corp,, 784 P.2d 146, 147 (Utah 
1989), quoting Reid v. Mutual of Omaha Ins. Co., 776 P.2d 896 (Utah 1989). 
The Minority Shareholders make no attempt to comply with this standard. Instead, 
they essentially reargue the facts. One would never know this from the Minority 
Shareholders' statement of the facts, however. In many instances, the Minority Shareholders 
simply disregard explicit factual findings by the district court.3 The Minority Shareholders' 
failure to comply with Utah R. App. P. 24(9) should only serve to enhance the presumption 
of correctness that attaches to the district court's findings under Utah R. Civ. P. 52(a). In 
3Two examples suffice. First, the district court specifically found that the value of Zinetics 
had not been suppressed by Medtronic or Synectics. Mem. Dec. at 6-10. Second, the district 
court specifically found that Reilly's guideline companies could not be "reasonably 
characterized as comparable to Zinetics." Id. at 12. The Minority Shareholders challenge 
these findings in their Opening Brief, however, without either marshaling all the evidence 
in support of the findings or demonstrating that such evidence is insufficient to support the 
findings. See, e.g., ^f 11-13 of Statement of Facts at pp. 7-8 of Appellants' Opening Brief 
(devoting two pages to arguing that Medtronic "suppressed" Zinetics' efforts at product 
development), and f 36 at p. 15 (claiming that Reilly's market value model was based on 
share prices "of the most similar companies."). 
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Bartell, this Court strongly discouraged appellants from engaging in relitigation of the trial 
at the appellate level: 
Whether the facts have been found by a jury or a judge, 
appellants should recognize that the burden of overturning 
factual findings is a heavy one, reflective of the fact that we do 
not sit to retry cases submitted on disputed facts. 
In this case, [Appellant] has not even attempted to marshal the 
evidence in support of the trial court's findings, nor has she 
attempted to demonstrate that the trial court's findings are 
against the clear weight of the evidence, as required by [State v. 
Walker, 743 P.2d 191, 192-93 (Utah 1987)]. Instead she has 
essentially reargued the factual case submitted below, 
construing all evidence in a light most favorable to her case and 
largely ignoring the evidence supportive of the trial court's 
findings. This leaves us to rely heavily on the presumption of 
correctness that attends these findings under rule 52(a). 
116 P.2d at 886 (emphasis added). 
Here, just as in Bartell, the Minority Shareholders improperly attempt to relitigate 
their case at the appellate level and largely ignore the evidence which supports the district 
court's findings.4 This can only enhance the Rule 52(a) presumption of correctness that 
should be given to the district court's findings. 
Consistent with Rule 24(9), Zinetics has prepared an annotated copy of the district court's 
Memorandum Decision, which cites to the relevant portions of the record that support the 
district court's findings. See Tab 4 to Zin. Add. 
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C. Substantial Evidence Supports the District Court's Finding That the Fair 
Value of Zinetics Was less than the Merger Price 
The Minority Shareholders make the astounding suggestion that "the district court had 
no support in the record for its conclusion that whatever the fair value was, it was not greater 
than the price set by the Appellees." Appellants' Opening Brief dX p. 33. That argument 
completely ignores Merrill Norman's testimony and report. The Minority Shareholders 
nonetheless claim that the district court could not have relied on Norman's investment value 
approach, because it "rejected Norman's opinions." Appellant *s Opening Brief &t p. 33. To 
the contrary, the district court expressly credited Norman's investment model: 
I find that the most reliable valuation method is an investment 
valuation of Zinetics as a subsidiary of Synectics/Medtronic[] 
and otherwise subject to my finding set out in Part I of this 
decision. Mr. Norman's investment valuation analysis, closely 
fits this criteria, particularly the data, projections and analyses 
contained in Schedules F, G, H, I ,J, K, L and N to 
Mr. Norman's report. 
Mem. Dec. at 14-15 (emphasis added). 
The Minority Shareholders also erroneously suggest that if one corrected the Norman 
investment model for the three minor criticisms of Norman's model noted by the district 
court, "one would of necessity conclude . . . values similar to those found by Reilly." 
Appellants' Opening Brief at 34. As the court correctly noted, the opposite is true. The 
district court noted that these criticisms had a "measure of merit" (Mem. Dec. at 16); it did 
not need to resolve whether, and to what degree, the criticisms were valid because even 
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assuming they were correct, the resultant valuation still did not exceed the merger price of 
4.528 cents per share. Id. 
The three criticisms referenced by the district court were: (1) the initial starting point 
projections projecting $407,000 in gross income for August 31,1998, down from $480,000 
from the prior year;5 (2) the failure to account for inflation; and (3) the use of both a small 
company cap and a micro cap adjustment in calculating the discount rate. Mem. Dec. at 15-
16. Each of these criticisms results in only modest adjustments to Norman's investment 
value. 
With respect to the first criticism, Reilly himself testified that the effect of the low 
starting point was to lock in a permanent 10% reduction in earnings. Reilly Am. Test, at Tr. 
585-86. Increasing cash earnings by 10% increases the resultant value by less than 10% due 
to discounting, so the result would be to increase value by less than 10%. This can be seen 
by looking at Schedule J to Norman's report. Every dollar earned by Zinetics decreases in 
value from ninety-four cents in August 1998 to only thirteen cents in 2001. Even increasing 
the resultant value by 10% would add only .17 cents per share to his discounted earnings 
model and .2 cents to the discounted cash flow model. Norman Report, Schedule A, Tab 2 
to Zin. Add. 
5Moreover, while noting there was a "measure of merit" to this criticism in the abstract, the 
district court took pains to point out in a footnote that Norman's starting projection "closely 
matched" Zinetics' actual 1998 revenues. Mem. Dec. at 15, n. 7. 
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The second criticism, failure to account for the effect of inflation, was a small, 
inadvertent error which Norman quantified as adding only $600,000 to his valuation, or lA 
cent per share. Norman Test, at Tr. 731-32. Third, and finally, adjusting Norman's values 
by eliminating a micro-cap discount, affects the value by only .5 to .7 cents per share, at 
most. This can readily be determined by looking at Schedules F and G of the Norman 
Report, which calculate the fair value of Zinetics through capitalization of net income and 
cash flows. Norman Am. Test, at Tr. 242-54, Norman Report, Tab 2 to Zin. Add. 
Accordingly, even if one were to adjust Norman's value by increasing cash flow earnings to 
the future by 10%, eliminating the micro-cap adjustment and correcting to add inflation, the 
resulting value is nowhere near the merger price 4.528 cents per share. 
The Minority Shareholders' main point seems to be that the district court did not 
include in its opinion the calculations it performed in concluding that adjusting Norman's 
investment model for the three criticisms discussed in its decision did not result in a 
valuation in excess of the merger price. But there was no need for the Court to determine fair 
value to the hundredth of a penny so long as it was satisfied that the merger price exceeded 
fair value. This was made clear by the Eighth Circuit in Swope, a case repeatedly cited by 
the Minority Shareholders: 
The Company also argues that the district court also erred in 
failing to provide a precise mathematical calculation of its 
determination of fair value. The ultimate determination of fair 
value is an issue of fact, so we review for clear error . . . 
Because the district court's determination of the stock price falls 
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within the range proposed by the experts discussed in its 
opinion, we hold that there has been no error. The district court 
issued an extraordinarily thorough memorandum, summarizing 
the different valuation methods proposed by each expert and 
weighing the pros and cons of each method. 
sjc sfe * 
It is unfortunate that, after performing such a well-reasoned and 
thorough review of the record, the district court was not more 
explicit in elaborating on how it reached its final calculation of 
price per share. Regardless, the district court is not required to 
provide explicit detail or mathematical precision in fair-value 
cases, since 'the very nature of most cases precludes proof of 
value and damage with the precision of mathematical 
computation.' 
243 F.3d at 494-95 (citations omitted) (emphasis added; accord). 
The district court in this case issued a "well-reasoned and thorough review of the 
record." Its Memorandum Decision also "summarized] the different valuation methods 
proposed by each expert and weigh[ed] the pros and cons of each method." The district court 
concluded that based on Norman's investment value, the value was less than 4.528 cents per 
share (within the range proposed by Norman). That decision, which is supported by ample 
record evidence, should be affirmed. 
D. The District Court Properly Rejected the Minority Shareholders' Market 
Value Model 
The Minority Shareholders claim the district court erred as a matter of law in rejecting 
Reilly's wholly unreliable market valuation of Zinetics. They baldly ask this Court to 
substitute its judgment for that of the district court and to "adopt Mr. Reilly's market 
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analysis," which the district court determined was unreliable, after hearing Reilly's live 
testimony on direct and cross-examination. Appellants' Opening Brief at p.21. These 
misguided arguments ignore applicable law and the standard of review that applies to a 
district court's rejection of conflicting expert testimony. 
1. District Courts Have Broad Discretion to Determine the 
Appropriate Valuation Methods Applicable to the Unique Facts of 
Each Case 
The Minority Shareholders erroneously suggest that the district court was bound to 
calculate the fair value of Zinetics using Reilly's market approach, despite Norman's 
unrebutted testimony that this approach was unreliable. See Appellants' Opening Brief at 19 
(arguing that "[t]he court erred in giving no weight to market valuation."). Since there was 
conflicting testimony on the reliability of Reilly's market value approach, the district court 
was free to give it whatever weight it deemed appropriate. Newmeyer, 745 P.2d at 1278. 
If the Minority Shareholders are suggesting that the district court was required as a 
matter of law to calculate fair value using a market approach, their argument is misguided. 
In Oakridge, this Court identified the three elements to be considered in determining fair 
value: (1) stock market price; (2) net asset value of the corporation; and (3) investment 
value. 937 P.2d at 132-33. While Oakridge holds that the district courts should consider all 
three components, it specifically emphasizes that the lower courts do not have to adopt all 
three components in each case: 
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[W]e agree with the Delaware Court that 'The requirement that 
consideration be given to all relevant factors entering into the 
determination of value does not mean that any one factor is in 
every case important or that it must be given a definite weight 
in the evaluation'. . . . Nonetheless, although "[a]ll three 
components of'fair value' may not influence the result in every 
valuation proceeding, yet all three should be considered." 
937 P.2d at 135 (citations omitted). Here, there is no dispute that the district court in fact 
considered all three components. See Mem. Dec. at 10-16. Having concluded the market 
approach was unreliable, it was not required to give that approach any weight. Moreover, 
the district court's decision to rely instead on investment value is completely consistent with 
this Court's recognition that "courts have traditionally favored investment value . . . as the 
most important of the three elements [investment value, market value and asset value.]." 
Oakridge, 937 P.2d at 133. 
2. The District Court Appropriately Considered Reilly's Market 
Value Model 
a. The District Court Did Not Reject Reilly's Model Because it 
Had Not Been Explicitly Adopted by the Utah Courts 
The district court did not "reject" Reilly's market valuation approach because it 
believed the approach had not been recognized as a valuation tool by Utah courts, as the 
Minority Shareholders suggest. Appellants' Opening Brief'at p. 19. To the contrary, the 
district court explicitly stated that it was not rejecting either expert's market value approach 
for this reason: "I do not, however, interpret Oakridge Energy to restrict a fair value analysis 
to the three methodologies approved in the decision." See Mem. Dec. at 11-12. It 
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nonetheless concluded that "the market approach analyses presented by Petitioner's expert, 
Mr. Merrill Norman, and by Respondents' expert, Mr. Reilly, are both so fundamentally 
flawed that I decline to rely on them." Id. 
b. The District Court's Rejection of Reilly's Market Value 
Model Is a Factual Finding, Not a Legal Determination 
The Minority Shareholders next claim that the district court's rejection of Reilly's 
market value model was a "misapplication of law." Appellants' Opening Brief at p. 18. To 
the contrary, the district court's rejection of the Reilly model as "seriously flawed" and 
"unreliable" did not involve the application of any law whatsoever. The district court was 
faced with conflicting expert testimony on the reliability of Reilly's model. It credited the 
unrebutted testimony of Zinetics' expert, Merrill Norman, that Reilly' s model was unreliable. 
This is a straight-forward factual finding committed to the district court's discretion. 
In Newmeyer, this Court rejected an argument almost identical to the one advanced 
by the Minority Shareholders here. In that case, the appellant appealed from a district court's 
finding that a house was worth $117,000. That amount was exactly halfway between the 
competing values of $112,000 and $122,000 sponsored by the parties' respective experts at 
trial. The appellant claimed that "the court improperly 'split' the difference between the 
values fixed by the experts" and argued that "his expert should have been believed." 
745 P.2d at 1278. The Court gave short shrift to this argument: 
This argument, like the one that preceded it, is nothing but an 
attempt to have this Court substitute its judgment for that of the 
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trial court on a contested factual issue. This we cannot do under 
Utah Rule of Civil Procedure 52(a). In apparent recognition of 
this proposition, [appellant] masks this claim as a legal 
argument by contending that the trial court acted improperly in 
splitting the difference between the experts. That argument is, 
of course, utterly lacking in merit . . . When acting as trier of 
fact, the trial judge is entitled to give conflicting opinions 
whatever weight he or she deems appropriate. 
745 P.2d at 1278-79 (emphasis added). 
Newmeyer disposes of the claim that the district court's rejection of Reilly's model 
was a "misapplication of law." Notably, the Minority Shareholders cite no Utah law 
whatsoever for the proposition that the district court's rejection of Reilly's model was legal 
error. The only case from any jurisdiction that they cite for this proposition is Swope, where 
the Eighth Circuit correctly concluded that the application of marketability and minority 
discounts in fair value proceedings is a matter of law. 243 F.3d at 491. See Appellants' 
Opening Briefed 1. Swope does not help the Minority Shareholders here. At issue is not the 
legal standard applicable to all fair value proceedings, but the uniquely factual issue of 
whether Reilly's market approach was reliable. 
c. The District Court Properly Exercised its Discretion in 
Rejecting Reilly's Market Value Model 
The Minority Shareholders are left with the untenable position that the district court 
abused its discretion in believing Norman's unrebutted expert testimony and rejecting 
Reilly's market value model as "fundamentally flawed." Voluminous evidence supports the 
district court's finding that the model was unreliable. 
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i. Reilly's So-Called Guideline Companies Were Not 
Comparable to Zinetics 
The district court began by noting that none of Reilly's eleven "guideline" companies 
could reasonably be characterized as "comparable" to Zinetics." Mem. Dec. at 12. The 
Minority Shareholders do not even acknowledge this finding, much less the substantial 
evidence that supports it. Norman testified that none of Reilly's guideline companies were 
comparable to Zinetics based on either operational or financial considerations.6 Norman 
Test, at Tr. 682-701 and P.X. 66, Zin. Add. at Tab 3, Norman Report at p. 15, Zin. Add. at 
Tab 2. Norman's testimony was based on the following facts: 
1. None of the guideline companies were in the gastroenterology industry, which 
was the industry in which Zinetics operated. Reilly Am. Test, at Tr. 586-90. The majority 
of Reilly's eleven guideline companies manufactured proprietary, cardiac products used to 
treat, rather than diagnose, conditions which in many cases were life-threatening. Reilly Am. 
Test at Tr. 590. In contrast, Zinetics' products were solely diagnostic. Neisz Dep. Test at 
p. 26-28. Many of Reilly's guideline companies were in the very early stages of developing 
a product that "excited" the market. Norman Test, at Tr. 684-86; P.X. 66, Tab 3 to Zin. Add. 
6The Minority Shareholders distort Norman's testimony to suggest that he agreed with the 
selection criteria Reilly used to select his guideline companies. See Appellants' Opening 
Brief at p. 21. Norman however, specifically testified that the criteria were not valid if they 
did not produce a large enough and reliable sample of companies, and he testified that 
Reilly's criteria produced obviously invalid results because the guideline companies did not 
resemble Zinetics. Norman Test, at Tr. 718, 733. 
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Virtually all had patent protected or highly proprietary products which gave them a 
competitive advantage.7 Id. In contrast, Zinetics sold a long-established, low-growth 
commodity product with virtually no intellectual property protection. Paulsen Am. Test at 
Tr. 31, Neisz Dep. Test, at p. 32-34, Brown Test, at Tr.368-69. 
2. From a financial standpoint, Zinetics and the Reilly guideline companies could 
not have been more dissimilar. Since 1992 Zinetics had enjoyed increasing revenues and 
continual profits. In contrast, every one of Reilly's guideline companies had consistently lost 
money. None of the eleven had ever reported so much as a dime of net profits; only three 
ever had gross profits. Norman Test, at Tr. 709-10 and P.X. 66, Zin. Add. at Tab 3. 
Comparison of the average gross profit margins, operating margins and net profit margins 
of Zinetics and the Reilly guideline companies underscores how dissimilar they are. 
7For example, American Biomed was a development stage company, not a mature operating 
company like Zinetics. Its products were designed for interventional cardiology and 
minimally invasive surgery; it had not yet received FDA approval for its products. See P.Ex. 
66, Slide 1 (Zin. Add. at Tab 3); Norman Test, at Tr. 684. A second company, Angeion 
Corporation, manufactured extremely sophisticated patent-protected implantable 
defibrillators (devices which sold for $20,000 to $25,000 compared to the few hundred 
dollars cost of Zinetics' catheters). Id., Slide 2; Norman Test, at Tr. 686-87. A third 
company, Cardiogenesis, was the maker of very high-tech proprietary systems to treat angina 
patients. Id., Slide 3. Finally, Rochester Medical Corporation developed proprietary 
catheters used in the management of urinary dysfunction. Id., Slide 11. 
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Avg. Gross Avg. Operat. Avg. Net 
Profit Margin Margin Profit Margin 
Guideline Companies -5.60% -228.79% -186.93% 
Zinetics 62.64% 19.47% 19.43% 
See Norman Test, at Tr. 709-10; P.X. 66 - slide entitled Comparison ofWillamette Guideline 
Companies to Zinetics, Zin. Add. at Tab 3. 
Just as the district court rejected Norman's market model because the companies he 
selected were not comparable to Zinetics, the fact that Reilly' s guideline companies were not 
at all comparable to Zinetics was sufficient grounds for rejecting his market model. See, e.g., 
Ford Motor Co. v. Township of Edison, 604 A.2d 580, 589 (N.J. 1992) (affirming trial 
court's discretion to reject expert's proposed comparables noting that "[a]ppellate courts 
have long recognized that the trial court must be granted 'a wide discretion' in determining 
the admissibility of sales sought to be relied on as comparable," (quoting Los Angeles County 
v. Faus, 312 P.2d 680, 684 (Cal. 1957)); Moran v. State of New York,355 N.Y.S.2d 684 
(N.Y. App. Div. 1974) (district court properly rejected comparables whose reliability and 
appropriateness were of little probative value). Norman's unrebutted testimony and Exhibit 
66 support the district court's finding that Reilly's guideline companies could not reasonably 
be deemed comparable to Zinetics. 
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ii. Substantial Evidence Demonstrates That Reilly's Market 
Value Model Was Otherwise Unreliable 
Because all of Reilly's guideline companies were unprofitable, Reilly was forced to 
resort to an arcane and unreliable measurement of the market value of invested capital to 
revenues ("MVIC/Revenue") to predict Zinetics' value. All other valuation multiples, such 
as the traditional and most commonly used price-to-earnings or price-to-cash-flow ratios, 
produced negative values. Reilly Test, at Tr. 589-90; P.X. 66 - slides of each company, Zin. 
Add., Tab 3. Reilly admitted that ordinarily he would place greater weight on the price-to-
earnings ratio or income multiples to value companies. Id. The flaw in the MVIC-to-
revenues approach Reilly used is that it values companies with the same revenue equally 
without regard to profitability; a company with a million dollars in revenue and net income 
of $500,000 is valued identically to a company with a million dollars in revenue and a loss 
of $500,000. Norman Report at p. 10, Zin. Add. at Tab 2. 
The Minority Shareholders suggest that the district court erroneously rejectedReilly's 
market value model based on misplaced concerns about its accuracy over time, rather than 
as of the valuation date. See Appellants' Opening Briefat p. 19. The district court's concern 
was hardly misplaced. Reilly's own market model considered both MVIC/Revenue ratios 
for the last twelve months, and over the last five years, weighting the last twelve months 70% 
and the last five years 30%. See R.Ex. TT at Ex. VI and Reilly Am. Test, at Tr. 450-53. In 
other words, Reilly's model pre-supposed and was dependent upon the accuracy of the 
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MVIC/Revenue ratio both over time and on the valuation date. However, as Norman 
demonstrated, the model produced false values of Zinetics both over time and as of the 
valuation date. Norman Test, at Tr. 681-710. 
Reilly assumed, with no analysis whatsoever, that the median MVIC/Revenue ratio 
for his guideline companies for the most recent twelve-month period ended February 12, 
1998, and for the preceding five years, was somehow an accurate predictor of Zinetics' value 
as of February 12, 1998. Why that should be so was never demonstrated even though the 
validity of Reilly's market approach depends on that assumption being accurate. 
Norman exposed the fallacy of Reilly's key assumption by conclusively 
demonstrating the existence of an inverse relationship between the MVIC/Revenue ratios and 
actual revenues of the Reilly guideline companies. Specifically, the lower the revenues of 
each guideline company, the higher its MVIC/Revenue ratio; the higher the revenue, the 
lower the ratio. In other words, in Reilly's world, the higher a company's revenue 
performance, the lower its market value. Norman Test, at Tr. 682-710; P.X. 66 - Slide of 
Each Guideline Company Relationship between Revenues and MVIC/Revenue Ratio, Zin. 
Add. at Tab 3. The lack of a meaningful relationship between the stock price and the 
revenues of these Guideline companies demonstrated that something other than revenues had 
been driving their stock price. Id. 
The fallacy of Reilly's approach is further demonstrated by looking at variations in 
value using different years. The guideline company that occupied the median position in 
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1998 is critically important to Reilly's analysis. Reilly Am. Test, at Tr. 546-47. Reilly's 
median MVIC/ Revenue ratio for the year ending February 1998 happened to belong to 
Rochester Medical, a company Reilly claimed bore the closest resemblance to Zinetics of any 
of his guideline companies (indeed, of any company in the world!).8 Reilly Am. Test, at Tr. 
529-30, 863-87. 
By selecting Rochester's MVIC/Revenue ratio of 10 (rounded) for 1998, Reilly 
arrived at a purported market value for Zinetics of over $26 million. Id. The absurdity of 
Reilly's approach is highlighted using Rochester Medical's MVIC/Revenue ratio in 1992 to 
value Zinetics in 1992. That year, Rochester Medical had an MVIC/Revenue ratio of nearly 
60, while Zinetics had revenues for eleven months of $673,660. Norman Test, at Tr. 696; 
P.Ex. 66 - slide entitled Rochester Medical Inc. Relationship of MVIC/Revenue and 
Revenues', P.Ex. 20(f), at Ex. 2. This yields a market valuation for Zinetics of nearly 
$40 million, some $12 million higher than Reilly's 1998 valuation, even though Zinetics had 
just barely avoided bankruptcy and in 1992 reported sales which were only one quarter of 
8From an operating standpoint, however, Rochester Medical bore far less resemblance to 
Zinetics than did Medamicus, another one of his guideline companies. Reilly Am. Test, at 
Tr. 590, 602-18; P.Ex. 63 - comparative chart. Further, Medamicus, like Zinetics, was 
heavily dependent on Medtronic as its key customer. Id. Yet, Reilly chose to value Zinetics 
in 1998 using Rochester Medical's 10.36 MVIC/Revenue ratio rather than Medamicus' 
MVIC/Revenue ratio of 1.61. Reilly Report, Appellants' Addenda at Tab C, Exs. V and VI. 
Reilly Am. Test, at Tr. 618-19. 
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its 1997 sales. This result is nonsensical and demonstrates the total unreliability of Reilly's 
market approach. 
Since Rochester Medical was not the guideline company with the median MVIC/ 
Ratio in 1992-93, Reilly might use a different guideline company to determine the value of 
Zinetics on that date. Leaving aside the compelling question of how Rochester Medical 
could be such an accurate predictor of Zinetics' value in 1998, but an utterly inaccurate 
predictor in 1992, Reilly's method still does not work when applied to particular years. For 
example, the median MVIC/Revenue Ratio of Reilly's guideline companies in 1993-1994 
was approximately four. The median ratio of those same Companies for 1994-95 was 
approximately eighteen. Norman Test, at Tr. 696-97, 702-03; P.Ex.66, Slide entitled 
Willamette Guideline Companies Median MVIC/Rev. Zin. Add. at Tab. 3. Reilly's model 
results in a market value for Zinetics of $6.1 million in 1994 (based on Zinetics' revenues 
of $1.5 million), and a market value the next year of nearly $36 million (based on revenues 
of just over $2 million), a 600% increase. Zinetics obviously did not increase in value by 
600% in one year, especially when its revenues only increased 33%. Reilly's model rests on 
flawed assumptions that produce absurd results. Norman's powerful debunking of Reilly's 
model stands unrebutted, despite the fact that the district court made clear it would give 
Reilly the opportunity to respond to Norman's criticisms. See Tr. at 645. The district court 
quite correctly and not surprisingly rejected Reilly's conclusions as "unreliable" and 
"seriously flawed." 
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Hi. Reilly's Treatise Undermines, Not Supports, His Model 
The Minority Shareholders further argue that proof of the validity of Reilly's model 
is that he has authored a treatise that references the MVIC to Revenue Approach. 
Appellants' Opening Brief at p. 20.9 This bootstrapping logic does not help the Minority 
Shareholders. Reilly's treatise, in fact, confirms the inappropriateness of using the 
MVIC/Revenue ratio to value a manufacturing company like Zinetics. It states: 
Multiples of revenue tend to be most highly correlated with 
return on sales, but the strength of the correlation varies greatly 
from one industry to another. 
* * * 
Capitalization of revenues is applied most frequently to service 
businesses, such as advertising agencies, insurance agencies, 
mortuaries, professional practices, and some types of publishing 
operations. It generally tends not to work very well for 
manufacturing companies. 
See Pratt, Reilly and Schweight, Valuing a Business, The Analysis and Appraisal of Closely 
Held Companies, Chapter 10 at p. 227 (3d ed. 1996) (emphasis added). 
Reilly got it right in his treatise; his testimony was not true to his expressed scholarly 
belief. The MVIC/Revenue model did not work well when applied to a manufacturing 
9The Minority Shareholders inappropriately attempt to buttress Reilly's work by citing the 
Court to his treatise, even though they elected not to introduce it as an exhibit at the trial. It 
is inappropriate for them to do so. See, e.g., Utah v. Pliego, 1999 UT 8, f7, 974 P.2d 279 
(noting appellate review is limited to the evidence contained in the record on appeal and that 
"we will not consider evidence which is not part of the record."). 
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company like Zinetics because it produced demonstrably absurd results. Substantial 
evidence supports the district court's conclusion that Reilly's market value was 
fundamentally flawed and unreliable. 
E. The District Court Properly Rejected the Minority Shareholders' Attempt 
to Manipulate the Value of Zinetics by Encouraging Friends and Relatives 
to Engage in OTC Bulletin Board Trades 
The Minority Shareholders take the district court to task for refusing to give any 
credence to the market manipulated trades in which they and their friends and cronies 
engaged in an attempt to influence the fair value proceeding. See Norman Test, at Tr. 
725-27. Since the Minority Shareholders introduced evidence of these trades, see Testimony 
of Don Hale at Tr. 369, it was appropriate for the district court to consider their relevance. 
The district court properly declined to credit them. Although it mistakenly attributed 
sponsorship of the trades to Reilly instead of his clients, this in no way diminishes the 
correctness of the district court's decision not to give any credence to these bogus trades. 
F. The District Court Properly Gave No Weight to the Minority 
Shareholders' Bogus Ten-cents-a-share Offer or to Medtronic's Price to 
Earnings Ratio 
The Minority Shareholders ask this Court to invade the district court's evaluations of 
credibility and conflicting testimony and deem reversible error its failure to give weight to 
the Minority Shareholders' bogus ten-cents-a-share offer. This ignores that the weight to be 
afforded to evidence is uniquely a matter for the trier of fact. Yelderman v. Yelderman, 
669 P.2d 406, 408 (Utah 1983) (per curiam). Accordingly, the issue on appeal is whether 
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the district court's findings aiv supponod by sufficient evidence in the record, not whether 
there are bits of evidence that .p., U ;erent result. Moreover, substantial 
i, i icnce demonstrates that this offer was a sham ^> . - /
 4<_. Jhaced with conflicting 
evide *• ,... \ m. mc district court, which viewed and lir; *• • ' ..-bumcr. \ i .rst-hand, 
acted well with •.--. • , .-i: m not giving weighn«-. this evidence, Vv •' £.. .V-w//c?yer? 
745 P.2d at 886. 
Likewise, the Minority Shareholder IHJKI IK. hizarre argument that since 
Medtromc's price/earnings ratio was between 50 and >t\ iN- -lislncl court, erred by not 
applyin * *lr^  • earnings ratio to Zinetics. This argument, uiisuppoilal by any expert 
testimony, is nonsen s = - . , K u; a company does not depend upon the i dc n n i \ u i 11s 
owner or its buyer. Pre-merger, Zinr*.
 ; ^  ,.,u o\\^. and Medtronic was not Zinetics. 
Such an approach to fair value is prohibited • . . which expressly excludes 
appreciation or depreciation "in anticipation of the come1 • , ^mg n s c t 0 ^1C 
merger. This moan-, iliai lair value is not measured by unique benefit , .,» ;ne 
acquiring corporation, fhikriti^v/^s ' |\^dai 133-34. 
^ Hhcrt* Is \ o Need for an Aclvkiii v < >iniuir• i «IHI Discounts 
i;, .only Shareholders erroneously claim that •. .wi, ^ nether the district 
court factors or marketability discount into its !:?• ; MS 
represents a marked shift ; •" * • - • \ i \ a I *, i a im in their docketing statement th; • 
court erred in applying a market ah - i-.^ ount and control premium, Se^ Appellant'; 
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Docketing Statement at p. 7, Issue No. 2. What is clear is that the district court had no need 
to decide the issue of discounts because under Norman's investment model, the fair value of 
Zinetics stock on a non-discounted basis was far less than the merger price. Norman's 
investment value model produced a range of values from 1.68 cents per share to 2.01 cents 
per share, assuming a marketable, minority interest. Norman Report at Schedule A, Zin. 
Add., Tab 2. To eliminate a minority discount, he noted that one would simply increase 
these figures by a control premium factor of 36.81%, which yields a range of values from 
2.30 to 2.75 cents per share, or from 50.8% to 60.7% of the merger price.10 Even adjusting 
for the three criticisms of Norman's investment model potentially noted by the district court, 
the fair value of Zinetics was still far less than the merger price. See pp. 13-17 infra. The 
district court adopted the Norman investment valuation model. Mem. Dec. at 15. 
Accordingly, there was simply no need for the district court to address the issue of discounts. 
Utah courts do not issue advisory opinions. See, e.g., Justheim v. Division of State Lands, 
659 P.2d 1075, 1077 (Utah 1983) ("It is not our function to render advisory opinions."). 
There is no reason to depart from that well-settled rule here. 
10Ironically, the Minority Shareholders specifically told the district court they were not 
entitled to a control premium adjustment and were not asking for one. See Tr. at 272-73. 
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CONCLUSION 
The district court's factual finding that the fair value of Zinetics was less than the 
merger price is amply supported in the record. The decision of the trial court should be 
affirmed. 
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ADDENDA 
Tabl 
(Title 16. Corporations) 
(Chapter 10a. Revised Business Corporation Act) 
Part 13. Dissenters1 Rights 
16-10a-1301 Definitions. 
16-10a-1302 Right to dissent 
16-10a-1303 Dissent by nominees and beneficial owners. 
16-10a-1320 Notice of dissenters' rights. 
16-10a-1321 Demand for payment - Eligibility and notice of intent 
16-10a-1322 Dissenters9 notice, 
16-10a-1323 Procedure to demand payment 
16-10a-1324 Uncertificated shares. 
16-10a-1325 Payment 
16-10a-1326 Failure to take action. 
16-10a-1327 Special provisions relating to shares acquired after announcement of proposed corporate action. 
16-10a-1328 Procedure for shareholder dissatisfied with payment or offer. 
16-10a-1330 Judicial appraisal of shares - Court action. 
16-10a-1331 Court costs and counsel fees. 
16-10a-1301 Definitions, 
For purposes of Part 13: 
(1) "Beneficial shareholder" means the person who is a beneficial owner of shares held in a voting trust 
or by a nominee as the record shareholder. 
(2) "Coiporation" means the issuer of the shares held by a dissenter before the corporate action, or the 
surviving or acquiring corporation by merger or share exchange of that issuer. 
(3) "Dissenter" means a shareholder who is entitled to dissent from corporate action under Section 
16-10a-1302 and who exercises that right when and in the manner required by Sections 16-10a-1320 
through 16-1 Oa-1328. 
(4) "Fair value" with respect to a dissenter's shares, means the value of the shares immediately before the 
effectuation of the corporate action to which the dissenter objects, excluding any appreciation or 
depreciation in anticipation of the corporate action. 
(5) "Interest" means interest from the effective date of the corporate action until the date of payment, at 
the statutory rate set forth in Section 15-1-1, compounded annually. 
(6) "Record shareholder" means the person in whose name shares are registered in the records of a 
corporation or the beneficial owner of shares that are registered in the name of a nominee to the extent 
the beneficial owner is recognized by the corporation as the shareholder as provided in Section 
16-10a-723 . 
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(7) "Shareholder" means the record shareholder or the beneficial shareholder. 
1992 
16-10a-1302 Right to dissent 
(1) A shareholder, whether or not entitled to vote, is entitled to dissent from, and obtain payment of the 
fair value of shares held by him in the event of, any of the following corporate actions: 
(a) consummation of a plan of merger to which the corporation is a party if: 
(i) shareholder approval is required for the merger by Section 16-10a-l 103 or the articles of 
incorporation; or 
(ii) the corporation is a subsidiary that is merged with its parent under Section 16-10a-l 104; 
(b) consummation of a plan of share exchange to which the corporation is a party as the corporation 
whose shares will be acquired; 
(c) consummation of a sale, lease, exchange, or other disposition of all, or substantially all, of the 
property of the corporation for which a shareholder vote is required under Subsection 16-10a-1202 (1), 
but not including a sale for cash pursuant to a plan by which all or substantially all of the net proceeds of 
the sale will be distributed to the shareholders within one year after the date of sale; and 
(d) consummation of a sale, lease, exchange, or other disposition of all, or substantially all, of the 
property of an entity controlled by the corporation if the shareholders of the corporation were entitled to 
vote upon the consent of the corporation to the disposition pursuant to Subsection 16-10a-1202 (2). 
(2) A shareholder is entitled to dissent and obtain payment of the fair value of his shares in the event of 
any other corporate action to the extent the articles of incorporation, bylaws, or a resolution of the board 
of directors so provides. 
(3) Notwithstanding the other provisions of this part, except to the extent otherwise provided in the 
articles of incorporation, bylaws, or a resolution of the board of directors, and subject to the limitations 
set forth in Subsection (4), a shareholder is not entitled to dissent and obtain payment under Subsection 
(1) of the fair value of the shares of any class or series of shares which either were listed on a national 
securities exchange registered under the federal Securities Exchange Act of 1934, as amended, or on the 
National Market System of the National Association of Securities Dealers Automated Quotation System, 
or were held of record by more than 2,000 shareholders, at the time of: 
(a) the record date fixed under Section 16-10a-707 to determine the shareholders entitled to receive 
notice of the shareholders1 meeting at which the corporate action is submitted to a vote; 
(b) the record date fixed under Section 16-10a-704 to determine shareholders entitled to sign writings 
consenting to the proposed corporate action; or 
(c) the effective date of the corporate action if the corporate action is authorized other than by a vote of 
shareholders. 
(4) The limitation set forth in Subsection (3) does not apply if the shareholder will receive for his shares, 
pursuant to the corporate action, anything except: 
(a) shares of the corporation surviving the consummation of the plan of merger or share exchange; 
(b) shares of a corporation which at the effective dite of the plan of merger or share exchange either will 
be listed on a national securities exchange registered under the federal Securities Exchange Act of 1934, 
as amended, or on the National Market System of the National Association of Securities Dealers 
Automated Quotation System, or will be held of record by more than 2,000 shareholders; 
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(c) cash in lieu of fractional shares; or 
(d) any combination of the shares described in Subsection (4), or cash in lieu of fractional shares. 
(5) A shareholder entitled to dissent and obtain payment for his shares under this part may not challenge 
the corporate action creating the entitlement unless the action is unlawful or fraudulent with respect to 
him or to the corporation. 
1992 
16-10a-1303 Dissent by nominees and beneficial owners. 
(1) A record shareholder may assert dissenters' rights as to fewer than all the shares registered in his 
name only if the shareholder dissents with respect to all shares beneficially owned by any one person 
and causes the corporation to receive written notice which states the dissent and the name and address of 
each person on whose behalf dissenters' rights are being asserted. The rights of a partial dissenter under 
this subsection are determined as if the shares as to which the shareholder dissents and the other shares 
held of record by him were registered in the names of different shareholders. 
(2) A beneficial shareholder may assert dissenters' rights as to shares held on his behalf only if: 
(a) the beneficial shareholder causes the corporation to receive the record shareholder's written consent 
to the dissent not later than the time the beneficial shareholder asserts dissenters' rights; and 
(b) the beneficial shareholder dissents with respect to all shares of which he is the beneficial shareholder. 
(3) The corporation may require that, when a record shareholder dissents with respect to the shares held 
by any one or more beneficial shareholders, each beneficial shareholder must certify to the corporation 
that both he and the record shareholders of all shares owned beneficially by him have asserted, or will 
timely assert, dissenters' rights as to all the shares unlimited on the ability to exercise dissenters' rights. 
The certification requirement must be stated in the dissenters' notice given pursuant to Section 
16-10a-1322. 
1992 
16-10a-1320 Notice of dissenters1 rights. 
(1) If a proposed corporate action creating dissenters' rights under Section 16-10a-1302 is submitted to a 
vote at a shareholders' meeting, the meeting notice must be sent to all shareholders of the corporation as 
of the applicable record date, whether or not they are entitled to vote at the meeting. The notice shall 
state that shareholders are or may be entitled to assert dissenters' rights under this part. The notice must 
be accompanied by a copy of this part and the materials, if any, that under this chapter are required to be 
given the shareholders entitled to vote on the proposed action at the meeting. Failure to give notice as 
required by this subsection does not affect any action taken at the shareholders' meeting for which the 
notice was to have been given. 
(2) If a proposed corporate action creating dissenters' rights under Section 16-10a-1302 is authorized 
without a meeting of shareholders pursuant to Section 16-10a-704 , any written or oral solicitation of a 
shareholder to execute a written consent to the action contemplated by Section 16-10a-704 must be 
accompanied or preceded by a written notice stating that shareholders are or may be entitled to assert 
dissenters' rights under this part, by a copy of this part, and by the materials, if any, that under this 
chapter would have been required to be given to shareholders entitled to vote on the proposed action if 
the proposed action were submitted to a vote at a shareholders' meeting. Failure to give written notice as 
provided by this subsection does not affect any action taken pursuant to Section 16-10a-704 for which 
the notice was to have been given. 
1992 
16-10a-1321 Demand for payment - Eligibility and notice of intent. 
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(1) If a proposed corporate action creating dissenters' rights under Section 16-10a-1302 is submitted to a 
vote at a shareholders' meeting, a shareholder who wishes to assert dissenters' rights: 
(a) must cause the corporation to receive, before the vote is taken, written notice of his intent to demand 
payment for shares if the proposed action is effectuated; and 
(b) may not vote any of his shares in favor of the proposed action. 
(2) If a proposed corporate action creating dissenters' rights under Section 16-10a-1302 is authorized 
without a meeting of shareholders pursuant to Section 16-10a-704, a shareholder who wishes to assert 
dissenters' rights may not execute a writing consenting to the proposed corporate action. 
(3) In order to be entitled to payment for shares under this part, unless otherwise provided in the articles 
of incorporation, bylaws, or a resolution adopted by the board of directors, a shareholder must have been 
a shareholder with respect to the shares for which payment is demanded as of the date the proposed 
corporate action creating dissenters' rights under Section 16-10a-1302 is approved by the shareholders, if 
shareholder approval is required, or as of the effective date of the corporate action if the corporate action 
is authorized other than by a vote of shareholders. 
(4) A shareholder who does not satisfy the requirements of Subsections (1) through (3) is not entitled to 
payment for shares under this part. 
1992 
16-10a-1322 Dissenters9 notice. 
(1) If proposed corporate action creating dissenters' rights under Section 16-10a-1302 is authorized, the 
corporation shall give a written dissenters' notice to all shareholders who are entitled to demand payment 
for their shares under this part. 
(2) The dissenters' notice required by Subsection (1) must be sent no later than ten days after the 
effective date of the corporate action creating dissenters' rights under Section 16-10a-13 02, and shall: 
(a) state that the corporate action was authorized and the effective date or proposed effective date of the 
corporate action; 
(b) state an address at which the corporation will receive payment demands and an address at which 
certificates for certificated shares must be deposited; 
(c) inform holders of uncertificated shares to what extent transfer of the shares will be restricted after the 
payment demand is received; 
(d) supply a form for demanding payment, which form requests a dissenter to state an address to which 
payment is to be made; 
(e) set a date by which the corporation must receive the payment demand and by which certificates for 
certificated shares must be deposited at the address indicated in the dissenters' notice, which dates may 
not be fewer than 30 nor more than 70 days after the date the dissenters' notice required by Subsection 
(1) is given; 
(f) state the requirement contemplated by Subsection 16-10a-1303 (3), if the requirement is imposed; 
and 
(g) be accompanied by a copy of this part. 
1992 
16-10a-1323 Procedure to demand payment 
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(1) A shareholder who is given a dissenters1 notice described in Section 16-10a-1322, who meets the 
requirements of Section 16-10a-1321, and wishes to assert dissenters1 rights must, in accordance with 
the terms of the dissenters' notice: 
(a) cause the corporation to receive a payment demand, which may be the payment demand form 
contemplated in Subsection 16-10a-1322 (2)(d), duly completed, or may be stated in another writing; 
(b) deposit certificates for his certificated shares in accordance with the terms of the dissenters' notice; 
and 
(c) if required by the corporation in the dissenters' notice described in Section 16-10a-1322 , as 
contemplated by Section 16-10a-1327, certify in writing, in or with the payment demand, whether or 
not he or the person on whose behalf he asserts dissenters' rights acquired beneficial ownership of the 
shares before the date of the first announcement to news media or to shareholders of the terms of the 
proposed corporate action creating dissenters' rights under Section 16-10a-1302 . 
(2) A shareholder who demands payment in accordance with Subsection (1) retains all rights of a 
shareholder except the right to transfer the shares until the effective date of the proposed corporate action 
giving rise to the exercise of dissenters' rights and has only the right to receive payment for the shares 
after the effective date of the corporate action. 
(3) A shareholder who does not demand payment and deposit share certificates as required, by the date 
or dates set in the dissenters' notice, is not entitled to payment for shares under this part. 
1992 
16-10a-1324 Uncertificated shares. 
(1) Upon receipt of a demand for payment under Section 16-10a-1323 from a shareholder holding 
uncertificated shares, and in lieu of the deposit of certificates representing the shares, the corporation 
may restrict the transfer of the shares until the proposed corporate action is taken or the restrictions are 
released under Section 16-10a-1326 . 
(2) In all other respects, the provisions of Section 16-10a-13l3 apply to shareholders who own 
uncertificated shares. 
1992 
16-10a-1325 Payment. 
(1) Except as provided in Section 16-10a-1327 , upon the later of the effective date of the corporate 
action creating dissenters' rights under Section 16-10a-13 02 , and receipt by the corporation of each 
payment demand pursuant to Section 16-10a-1323 , the corporation shall pay the amount the corporation 
estimates to be the fair value of the dissenter's shares, plus interest to each dissenter who has complied 
with Section 16-10a-1323 , and who meets the requirements of Section 16-10a-1321 , and who has not 
yet received payment. 
(2) Each payment made pursuant to Subsection (1) must be accompanied by: 
(a) (i) (A) the corporation's balance sheet as of the end of its most recent fiscal year, or if not available, a 
fiscal year ending not more than 16 months before the date of payment; 
(B) an income statement for that year; 
(C) a statement of changes in shareholders' equity for that year and a statement of cash flow for that 
year, if the corporation customarily provides such statements to shareholders; and 
(D) the latest available interim financial statements, if any; 
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(ii) the balance sheet and statements referred to in Subsection (i) must be audited if the corporation 
customarily provides audited financial statements to shareholders; 
(b) a statement of the corporation's estimate of the fair value of the shares and the amount of interest 
payable with respect to the shares; 
(c) a statement of the dissenter's right to demand payment under Section 16-1 Oa-1328 ; and 
(d) a copy of this part. 
1992 
16-10a-1326 Failure to take action. 
(1) If the effective date of the corporate action creating dissenters' rights under Section 16-10a-1302 does 
not occur within 60 days after the date set by the corporation as the date by which the corporation must 
receive payment demands as provided in Section 16-10a-1322 , the corporation shall return all deposited 
certificates and release the transfer restrictions imposed on uncertificated shares, and all shareholders 
who submitted a demand for payment pursuant to Section 16-10a-1323 shall thereafter have all rights of 
a shareholder as if no demand for payment had been made. 
(2) If the effective date of the corporate action creating dissenters* rights under Section 16-10a-1302 
occurs more than 60 days after the date set by the corporation as the date by which the corporation must 
receive payment demands as provided in Section 16-10a-1322, then the corporation shall send a new 
dissenters' notice, as provided in Section 16-10a-1322, and the provisions of Sections 16-10a-1323 
through 16-10a-1328 shall again be applicable. 
1992 
16-10a-1327 Special provisions relating to shares acquired after announcement of proposed 
corporate action, 
(1) A corporation may, with the dissenters' notice given pursuant to Section 16-10a-1322 , state the date 
of the first announcement to news media or to shareholders of the terms of the proposed corporate action 
creating dissenters' rights under Section 16-10a-1302 and state that a shareholder who asserts dissenters' 
rights must certify in writing, in or with the payment demand, whether or not he or the person on whose 
behalf he asserts dissenters' rights acquired beneficial ownership of the shares before that date. With 
respect to any dissenter who does not certify in writing, in or with the payment demand that he or the 
person on whose behalf the dissenters' rights are being asserted, acquired beneficial ownership of the 
shares before that date, the corporation may, in lieu of making the payment provided in Section 
16-10a-1325 , offer to make payment if the dissenter agrees to accept it in full satisfaction of his 
demand. 
(2) An offer to make payment under Subsection (1) shall include or be accompanied by the information 
required by Subsection 16-10a-1325 (2). 
1992 
16-10a-1328 Procedure for shareholder dissatisfied with payment or offer. 
(1) A dissenter who has not accepted an offer made by a corporation under Section 16-10a-1327 may 
notify the corporation in writing of his own estimate of the fair value of his shares and demand payment 
of the estimated amount, plus interest, less any payment made under Section 16-10a-1325 , if: 
(a) the dissenter believes that the amount paid under Section 16-10a-1325 or offered under Section 
16-10a-1327 is less than the fair value of the shares; 
(b) the corporation fails to make payment under Section 16-10a-1325 within 60 days after the date set by 
the corporation as the date by which it must receive the payment demand; or 
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(c) the corporation, having failed to take the proposed corporate action creating dissenters' rights, does 
not return the deposited certificates or release the transfer restrictions imposed on uncertificated shares 
as required by Section 16-10a-1326. 
(2) A dissenter waives the right to demand payment under this section unless he causes the corporation 
to receive the notice required by Subsection (1) within 30 days after the corporation made or offered 
payment for his shares. 
1992 
16-10a-1330 Judicial appraisal of shares - Court action. 
(1) If a demand for payment under Section 16-10a-1328 remains unresolved, the corporation shall 
commence a proceeding within 60 days after receiving the payment demand contemplated by Section 
16-10a-1328 , and petition the court to determine the fair value of the shares and the amount of interest. 
If the corporation does not commence the proceeding within the 60-day period, it shall pay each 
dissenter whose demand remains unresolved the amount demanded. 
(2) The corporation shall commence the proceeding described in Subsection (1) in the district court of 
the county in this state where the corporation's principal office, or if it has no principal office in this 
state, the county where its registered office is located. If the corporation is a foreigncorporation without 
a registered office in this state, it shall commence the proceeding in the county in this state where the 
registered office of the domestic corporation merged with, or whose shares were acquired by, the foreign 
corporation was located. 
(3) The corporation shall make all dissenters who have satisfied the requirements of Sections 
16-10a-1321,16-10a-1323 , and 16-10a-1328 , whether or not they are residents of this state whose 
demands remain unresolved, parties to the proceeding commenced under Subsection (2) as an action 
against their shares. All such dissenters who are named as parties must be served with a copy of the 
petition. Service on each dissenter may be by registered or certified mail to the address stated in his 
payment demand made pursuant to Section 16-10a-1328 . If no address is stated in the payment demand, 
service may be made at the address stated in the payment demand given pursuant to Section 
16-10a-1323 . If no address is stated in the payment demand, service may be made at the address shown 
on the corporation's current record of shareholders for the record shareholder holding the dissenter's 
shares. Service may also be made otherwise as provided by law. 
(4) The jurisdiction of the court in which the proceeding is commenced under Subsection (2) is plenary 
and exclusive. The court may appoint one or more persons as appraisers to receive evidence and 
recommend decision on the question of fair value. The appraisers have the powers described in the order 
appointing them, or in any amendment to it. The dissenters are entitled to the same discovery rights as 
parties in other civil proceedings. 
(5) Each dissenter made a party to the proceeding commenced under Subsection (2) is entitled to judgment: 
(a) for the amount, if any, by which the court finds that the fair value of his shares, plus interest, exceeds 
the amount paid by the corporation pursuant to Section 16-10a-1325 ; or 
(b) for the fair value, plus interest, of the dissenter's after-acquired shares for which the corporation 
elected to withhold payment under Section 16- 10a-1327 . 
1992 
16-10a-1331 Court costs and counsel fees. 
(1) The court in an appraisal proceeding commenced under Section 16-10a-1330 shall determine all 
costs of the proceeding, including the reasonable compensation and expenses of appraisers appointed by 
the court. The court shall assess the costs against the corporation, except that the court may assess costs 
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against all or some of the dissenters, in amounts the court finds equitable, to the extent the court finds 
that the dissenters acted arbitrarily, vexatiously, or not in good faith in demanding payment under 
Section 16-10a-1328. 
(2) The court may also assess the fees and expenses of counsel and experts for the respective parties, in 
amounts the court finds equitable: 
(a) against the corporation and in favor of any or all dissenters if the court finds the corporation did not 
substantially comply with the requirements of Sections 16-10a-1320 through 16-10a-1328 ; or 
(b) against either the corporation or one or more dissenters, in favor of any other party, if the court finds 
that the party against whom the fees and expenses are assessed acted arbitrarily, vexatiously, or not in 
good faith with respect to the rights provided by this part. 
(3) If the court finds that the services of counsel for any dissenter were of substantial benefit to other 
dissenters similarly situated, and that the fees for those services should not be assessed against the 
corporation, the court may award to those counsel reasonable fees to be paid out of the amounts awarded 
the dissenters who were benefited. 
1992 
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Accounting, Valuation and Economic Loss Consultants 
January 21 , 1999 
Alain M. Baudry, Esq. 
Maslon, Edelmanf Borman & Brand 
3300 Norwest Center 
90 South Seventh Street 
Minneapolis, Minnesota 55402-4140 
Re: Valuation of Zinetics Medical, Inc. 
Dear Mr. Baudry: 
At your request, we have studied the financial statements of Zinetics Medical, Inc. (Zinetics) 
and performed various analytical inquiries to develop an understanding of Zinetics' 
operations so that we could establish a basis for valuing a 100% ownership interest and an 
18.56% ownership interest in Zinetics as of February 12, 1998. Zinetics has 128,806,800 
outstanding shares of stock, which represent a 100% ownership interest. A total of 
23,565,251 shares of Zinetics' outstanding stock represent a minority interest of 18.56%. 
This report describes valuation methods that result in an estimate of fair value of these 
common shares of Zinetics as of February 12, 1998 (the valuation date). This valuation 
contemplates facts and conditions existing as of the valuation date. Events and conditions 
subsequent to that date have not been considered, except that we have considered the 
financial results of Zinetics for the first six months of its 1997-1998 fiscal year, through 
February 27, 1998 (approximately 15 days after the valuation date) for ease of analysis. 
Executive Summary 
Based on the valuation methods described in this report, and supporting calculations and 
assumptions shown in Schedules A through R, we estimate the fair value of a 100% 
ownership interest in the stock of Zinetics at February 12, 1998 to be the following (See 
Schedule A): 
Under a minority/marketable value - $3,734,574 or $.0290 per share. 
Under a minority/non-marketable value - $2,542,311 or $.0197 per share. 
Under a control/marketable value - $5,109,208 or $.0397 per share. 
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Under a control/non-marketable value - $3,478,094 or $.0270 per share. 
The 18.56% minority interest of Zinetics' stock at February 12, 1998 is found by 
multiplying the above per share values by the number of shares owned by the minority 
shareholders, 23,565,251. This translates to an estimate of the fair value of the minority 
interest in the stock of Zinetics at February 12, 1998 to be the following: 
Under a minority/marketable value - $683,392 or $.0290 per share. 
Under a minority/non-marketable value - $464,235 or $.0197 per share. 
Under a control/marketable value - $935,540 or $.0397 per,share. 
Under a control/non-marketable value - $636,262 or $.0270 per share. 
The accompanying valuation has been prepared on the basis of discussions with Zinetics' 
management, Medtronic, Inc.'s management, research of publicly available information, 
industry-specific information, Zinetics' financial statements for fiscal years ending August 
31 , 1993 through 1997 and for the six month period ending February 27, 1998, and 
miscellaneous other financial documents provided by Zinetics. 
Our valuation assumes that Zinetics would continue to stay affiliated with Medtronic Inc. or 
Synectics Inc. after the valuation date. 
Standard of Value 
The standard of value used in this appraisal is fair value. In Utah, fair value is the value of 
the shares immediately before the effect of the corporate action to which the dissenters 
object. In our analysis we have appraised the stock of Zinetics on a minority, non-
marketable basis. 
Economic Overview and Outlook 
Profile of the United States (Economic Report of the President) 
The United States currently enjoys the fruits of some of the most favorable economic 
conditions in over a generation. Inflation is stable. Economic growth is high and 
unemployment rates are low. 
Economic growth exceeded analysts' expectations in 1997. Spending increased in 
households and firms as low inflation, lower long-term interest rates, and declining costs of 
business equipment contributed to a favorable environment for both producers and 
consumers. Federal government spending declined while state government spending 
increased slightly. 
The Gross Domestic Product (GDP) is expected to grow over the long-term at 2.4% per 
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year. United States imports and exports have increased significantly over the past five 
years. 
As the economies of countries become more global, more variables enter into the future 
performance of the United States economy. With this in mind, most economists project 
stable inflation, continued low unemployment, and increases in the Gross Domestic Product. 
Profile of the Medical Products and Supplies Industry (Standard and Poor's) 
The Medical Products and Supplies Index (Standard and Poor's) has increased in tandem 
with the recent market rallies.* Investors have shown movements towards the recession 
resistant medical stocks as the effects of the Asian Market turmoil were uncertain. Despite 
the effects of negative foreign exchange, the industry overall should continue to post strong 
earnings over the next few quarters. Global health care markets are expanding, new 
products are being introduced and cost-streamlining measures are working. Several 
takeovers or acquisitions have recently occurred in the industry. Tighter competition from 
these mergers will continue to encourage developing innovative, cost-effective products. 
Companies in this industry should enjoy healthy earnings growth. This growth is expected 
to be tempered by growth in managed care. Managed care has prompted a cost-efficiency 
movement, demonstrated by more conscientious buying patterns at hospitals and other 
purchasers, especially with respect to more expensive products. Tighter hospital budgets 
and consolidations have also affected producers. Because of the need to compete more 
effectively and to reduce costs, several business combinations are expected, as the 
marketplace becomes more competitive. 
There has been a global movement to force suppliers to comply with local country clinical 
and regulatory approvals. Several countries have begun to prohibit use of products that are 
not approved by the FDA or the European Union Regulatory Agency (CE Marked). As other 
countries become more "westernized," this trend is expected to continue. Companies will 
be forced to comply or leave the market. This approval process is costly and many small 
companies will be unable to comply. 
In 1997, President Clinton signed legislation that will speed up and streamline the FDA 
approval process for new drugs and devices. This new law allows independent outside 
experts to study safety and efficacy of lower-risk products. This law is expected to cause 
an increase in new product development as the evaluation costs become lower. 
The nation's continuing insistence on quality healthcare, an aging population (the primary 
consumers of medical products), and rising research and development outlays should spawn 
a steady flow of new products in the future. Specialty or niche-oriented companies 
focusing on successful specialty products, especially high technology, should outperform 
the industry average. 
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Company Background 
Profile of the Company 
Zinetics Medical, Inc. was first incorporated in 1983 under the name of Nuestro Research, 
Inc. by Jeffery D. Owen, Linda M. Owen and H. Mack Brown. Zinetics is engaged in the 
business of designing, manufacturing, and distributing pH sensor catheters primarily used 
for gastrointestinal monitoring. In 1984, Nuestro Research changed its name to Zinetics 
Medical Technology Corporation to have the company name represent its products. In 
1987, increased working capital needs led Zinetics to add another shareholder. Kearns 
Tribune Corporation infused capital into Zinetics in exchange for stock. Two years later, 
Kearns Tribune Corporation again received stock for more working capital. At this point 
Kearns Tribune Corporation became the majority shareholder. 
In 1988, Zinetics entered into a reverse merger to obtain more capital and became Zinetics 
Medical, Inc. Although Zinetics has maintained its public status, it has never traded in an 
active market. Zinetics is considered a bulletin board stock. In 1991, Synectics Medical AB 
(Synectics) purchased the Zinetics shares owned by the Kearns Tribune Corporation, 
approximately 81.44% of the total shares outstanding, for less than $200,000. Synectics, 
at the same time, offered to buy the shares of the minority shareholders at the same price 
per share but was turned down. 
Synectics is a medical products supplier and is also Zinetics' largest customer. In 1996, 
approximately 69% of Zinetics' sales were through Synectics. Medtronic, Inc., a major 
medical product manufacturer and supplier, acquired Synectics in April 1996, thereby also 
acquiring 81.44% of the outstanding Zinetics shares owned by Synectics. Synectics 
continues to operate as a subsidiary of Medtronic, Inc. 
Zinetics' main product lines include: 
• Zinetics 24 - a single use antimony pH sensor. 
• Zinetics 2 4 M - a multi-use version of the Zinetics 24 for use outside the U.S. 
• Zinetics Manometric Catheters - for use in esophageal and anorectal studies. 
• Zinetics Accusite pH™ - an enteral feeding system with pH site locator. 
• Zinetics GrapHprobe® - a gastric pH catheter for gastric pH monitoring. 
• Zinetics Critical Care pH Systems - enteral feeding and gastric pH systems that include a 
monitor for gastric pH monitoring. 
Approximately 15-20% of Zinetics' catheter sales are made along with Synectics' 
equipment sales. Customers purchasing Synectics equipment are encouraged to purchase 
replacement catheters from Zinetics and are extended discounts from full list price. 
Medtronic considers the products manufactured and sold by Zinetics to be Class I or Class 
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ll-A medical products. These products do not enjoy intellectual property protection. 
Zinetics is not assured of maintaining its large market share in the future. Zinetics is very 
dependent upon Synectics' sales and few barriers to entry exist to prevent entrance by new 
competitors. 
Financial Performance 
Since the acquisition of the 81.44% ownership by Synectics, Zinetics has operated 
profitably for many years. Schedules B and C provide detailed financial information for 
Zinetics in the form of income statements and balance sheets. Zinetics' revenues have 
increased from $1,213,344 in1993 to a projected $2,842,027 in 1998. This is an average 
annual growth rate of 18.5%. Gross profit was $645,460 in 1993 and $1,634,856 
(projected) in 1998. This is an average annual growth rate of 20.4%. Gross margin has 
increased from approximately 53% in 1993 to 57% for the first two quarters of fiscal year 
1998. 
Zinetics has enjoyed growth in its assets, primarily cash and cash equivalents, since 1993. 
Total assets have grown from $501,793 in 1993 to $1,738,077 on February 27, 1998. 
Current assets totaling $1,551,499 represented 89.27% of total assets as of February 
27,1998 and exceed amounts required to sustain current operations. Total liabilities have 
decreased from $199,578 in 1993 to $178,394 on February 27, 1998. Total liabilities have 
ranged from10.26% (February 27, 1998) to 39.77% (August 31,1993) of total assets. 
Stockholders' Equity has increased from $302,162 on August 31,1993 to $1,559,683 on 
February 27, 1998. This is mainly due to increases in retained earnings. 
A large portion of Zinetics' growth is due from growth in sales to Synectics, a related entity. 
Sales to Synectics as a percent of Zinetics' total sales grew from 59.3% in 1994, to 63.1 % 
in 1995, to 68.7% in 1996, and then dropped to 67.7% in 1997. Zinetics' management 
believes that sales to Synectics' will be close to 70.0% of Zinetics' total sales in 1998 and 
will continue to increase into fiscal year 1999. This is approximately 21.5% growth from 
1994 to 1998 in sales to Synectics. In comparison, non-Synectics sales have fluctuated 
from year to year and averaged 6.1 % growth over the same period. Non-Synectics' sales 
decreased by an average of 2.0% per year for fiscal years 1994 through 1996, but have 
increased in the most recent periods resulting in a positive growth rate. 
Valuation Approach and Methods 
The consideration of financial data and relevant factors affecting fair value would include, 
among other things, the elements of appraisal listed in Internal Revenue Service Rulings 59-
60 and 66-49, which provide guidelines for the valuation of the stock of closely-held 
corporations. The rulings state that the following factors, although not all inclusive, are 
fundamental and require careful consideration: 
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1. The nature of the business in which the company operates, the risks to which 
it is subject, and its historical patterns of growth; 
2. The general economic outlook, the condition and outlook of the specific 
industry, and the position of the company in its industry; 
3. The tangible book value and financial condition of the company; 
4. The earnings history and financial condition of the company; 
5. The dividend-paying capacity of the company; 
6. The existence of intangible values; 
7. Recent sales, if any, of the company's stock and the size of the block of 
stock to be valued; 
8. The market price of stocks of companies engaged in a similar line of business 
where such stocks are traded on an exchange or over the counter relative to a 
reasonable denominator; and 
9. Other special facts and circumstances of each case which can be judged as 
important in the overall value. 
In examining the above relevant factors, we viewed the recent sales of stock and the size of 
these trades. A summary of Zinetics stock trades is found on Schedule P. We feel that use 
of these particular sales provides a value that is not indicative of Zinetics' true value. These 
recent trades are not reliable for the following reasons: 
• The trades occurred in context of minority/majority negotiations. 
• Many of these transactions directly involved minority shareholders (including the 
largest single block sold) or individuals with business relationships with the 
minority shareholders. These parties were privy to negotiations with Medtronic. 
• Zinetics' stock trading levels (volume) are very thin. The average volume traded 
was .0585% of the outstanding shares. On any given day volume had not 
exceeded .2530%. 
• The transactions had inconsistent pricing, including prices in excess of the 
announced merger price. 
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No universal formula determines an appropriate fair market value for the common shares of 
a closely held company. Value can be estimated by considering other opportunities and 
investment alternatives available to the parties in a transaction. We have considered various 
generally accepted valuation methods including the asset-based approach, market approach, 
and income approach and have based our valuation upon a weighted average of several of 
these methods as further described below. 
Asset-Based Approach to Value 
The asset-based approach to value assumes that an asset's value is indicated by the cost of 
reproducing or replacing it, less an allowance for physical deterioration and obsolescence. 
The approach is commonly used for assets that are not sold on an active market, such as 
land improvements and special purpose equipment. For business valuations, the asset 
approach generally applies to companies with little value beyond the value of their tangible 
assets, such as holding companies. Zinetics generates the majority of its earnings using 
human and intellectual capital and not just tangible assets. Little or no earnings come 
directly from the Company's tangible assets. Therefore, the asset-based approach is not 
relied upon. 
Market Approach to Value 
The market approach to value assumes that value can be estimated from analyzing 
comparative public companies (and private companies whenever possible) and/or 
comparative transactions to determine a company's value. This approach requires a 
thorough search and analysis of comparatives, adjustments, and calculations using both 
public and private data. A description of our comparative group of companies follows. 
The range of values resulting from this approach indicates that this approach is less reliable 
than other approaches, such as the income approach to value, in determining the value for 
Zinetics. Because of the difficulty in identifying truly comparable companies, we chose not 
to place as much reliance upon the market approach to value. We assigned a 30% 
weighting to three market methods in our final calculation of the value of Zinetics. These 
three methods follow the description of the comparative group. 
Comparative Group of Companies 
In choosing a comparative group of companies we examined two simitar industries, the 
medical supplies and instruments industry and the medical equipment and appliances 
industry. We selected the following companies as our comparative group. While no 
individual company within the group of comparatives is precisely comparable to Zinetics, as 
a whole they are representative of the industry. Operating and financial information for 
these companies was found using various sources such as Hoovers Online, Standard and 
Poor's, and Media General Financial Services. 
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United States Surgical - The world's largest maker of surgical stapling products and a 
leading maker of laparoscopic and breast biopsy instruments. They also make instruments 
for electrosurgery, ultrasound, spine surgery and vascular therapy. Products are sold in over 
90 countries. 
Arrow International - Maker of cardiac and critical care products to diagnose and treat 
critically ill patients. Approximately 84% of its sales come from its disposable catheters 
used to access the central vascular system for monitoring, and fluid administering including 
drugs and blood products. The remaining 16% of its sales come from balloon pumps and 
catheters used in heart surgery or angioplasties. 
ZOLL Medical Corp. - Maker of noninvasive cardiac defibrillators and pacemakers for 
emergency resuscitation and heartbeat regulation. ZOLL also makes disposable electrodes 
for use in cardiac treatments. Through a subsidiary, ZOLL produces and sells electronic data 
collection and billing software and hardware for ambulance services. 
St. Jude Medical - Developer and marketer of cardiovascular devices, including mechanical 
and tissue heart valves as well as annuloplasty rings. Pacemakers, implantable defibrillators, 
angiography catheters, guidewires, guiding sheaths, and catheters used for diagnostic heart 
mapping are a few of the company's products. Products are sold in over 100 countries. 
Maxxim Medical - Maker of sterile medical specialty products and disposables. It is one of 
the top non-latex glove makers. Approximately 75% of sales come from their custom 
procedure trays, infection control apparel, and other surgical products. The remaining 25% 
is made up of its disposable products such as guidewires, needles, introducers, catheters, 
high pressure syringes, and cardiology and radiology trays. 
C.R. Bard, Inc. - A leading producer of vascular, urological, oncological and surgical 
products. They are best known for their urological devices. Its Foley catheter remains the 
number one bladder drainage device in the United States. Its balloon-angioplasty catheters, 
meshes, and fabrics for blood vessel repair, biopsy systems and imaging and detection 
products, arthoscopic products, meshes, and soft-tissue reconstruction equipment account 
for more than 60% of sales. Approximately one-third of sales occur outside the U.S. 
Abbott Laboratories - A pharmaceuticals company that also produces nutritional 
supplements and hospital and laboratory equipment. Its pharmaceuticals unit produces 
antibiotics, antihypertensives, and HIV and AIDS treatments. Nutritional products include 
the infant formula Similac and the adult supplement Ensure. Its medical products include 
diagnostic and drug-delivery systems (the world's #2 diagnostics company). One-third of 
sales are to foreign markets. 
Baxter International - The world's leading medical technology manufacturer. Its products 
include tissue heart valves, blood transfusion systems, hemophilia treatments, home dialysis 
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systems, heart surgery equipment, and over 800 intravenous products. Approximately one-
half of its sales are in foreign markets. 
Adjustments to Data Obtained from the Comparative Group of Companies. 
We obtained various ratios and multiples for each of these companies. However, these 
companies are not identical to Zinetics. Therefore, we need to adjust the multiples. It is 
appropriate to adjust the multiples for differences in size, growth, historical trends, 
operating characteristics and management depth. Theoretically, if the company being 
valued is weaker in these areas than the comparative companies, the multiples derived from 
the comparative companies should be lowered. In our opinion, Zinetics is weaker than the 
comparative companies for many reasons, size being the primary difference. We, therefore, 
adjusted the comparative company ratios and multiples to reflect size and stability 
differences between the comparative companies and Zinetics. 
To adjust the comparative group's ratios and multiples to better fit Zinetics, we have applied 
a 42.72% downward adjustment (See Schedule Q) to the medians of the ratios and 
multiples of the comparative companies (See Schedule M). The median was chosen over the 
mean to avoid the effects of out-lying multiples. This adjustment was based upon an 
analysis of approximately 108 companies in the medical equipment and appliances industry 
and the medical supplies and instruments industries. These companies, as a whole, 
experience similar market pressures and demands, marketing, sales, and distribution 
challenges as well as similar product development challenges as does Zinetics. 
Market Methods 
The methods we relied upon under this approach are as follows: 
Price/Earnings Ratio (P/E Ratio) - The price/earnings ratio is the most frequently used market 
approach when valuing a privately owned or closely held company with significant 
operations. A company's price/earnings ratio represents the relationship between the 
market price of a company's stock and its earnings per share. Using this method, a 
comparative company's (or group of companies' average or median) stock price is divided 
by earnings per share for a period of time to arrive at a value multiple. This multiple is then 
applied to the earnings of the subject company to arrive at an estimate of value of the 
interest being valued (See Schedule M). 
Market Cap/Revenue Multiple - Historically, this method is one of the least used methods of 
valuation under the market approach. Because revenue is a measure of operating results 
before interest and other operating expenses, this ratio is sensitive to differences in financial 
leverage. This method is often used as a "rule of thumb" to check values derived from 
other valuation methods. It is most often used in service industries. Under this method, a 
comparative company or group's market cap (stock price multiplied by outstanding shares) 
is divided by its revenues. This multiple is then applied to the subject company's revenues 
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to estimate a market cap value (See Schedule M). A significant weakness associated with 
this method is the fact that it ignores the profitability of the subject company. All things 
being held equal, a company that has revenue of $1 million and net income of $500,000 
will have the same indicated value as a company that has revenue of $1 million but a net 
loss of $100,000 using this method. In addition to the problems encountered by using 
revenue instead of earnings, market cap is similar to book value in that it is date specific. A 
company's market cap can vary substantially from day to day and from hour to hour. This 
valuation method does not adequately recognize the financial leverage and expense 
structure specific to Zinetics. 
Price/Cash Flow Ratio - Under this method, a comparative company's (or the average or 
median of a group of companies) stock price is divided by its per share cash flow for a 
chosen period of time. This ratio is then applied to the subject company's cash flow to 
estimate a market value (See Schedule M). There are very few industries where this multiple 
is relied upon for estimating value. It is most frequently used as a substitute for the 
Price/Earnings ratio method when the useful life of the subject company's assets is 
significantly different from its depreciable life, when the subject company or the comparable 
companies have negative or marginally positive earnings or when the industry of the subject 
company is usually valued using the price to cash flow method (such as real estate 
developers). 
Income Approach to Value 
The income approach to value assumes that the primary measure of a business' value is the 
present value of future cash flows or returns available to the owner. This approach requires 
an analysis of the subject company's business, financial statements, and of the market in 
which it functions. Adjustments often must be made to the financial statements. 
Projections of the subject company's future net income and cash flows are often required to 
determine the present value of future cash flows. These cash flows or returns are estimated 
using expected normalized future earnings of Zinetics, taking into consideration the ability to 
transfer these cash flows or earnings between buyer and seller. We assigned a 70% 
weighting to the income method in our final determination of Zinetics' value. 
The income approach to value consists of basically two approaches, discounting and 
capitalization, which are applied to cash flows and net earnings (totaling four methods). A 
capitalized return is normally used when a company's current operations are similar to its 
expected future operations. A discounted return is often used when future operations are 
expected to differ from current operations. A brief description of the methodology and 
values derived from each income method of valuation is given below. 
Discounted Cash Flows - A forecast or projection of a discrete number of future period cash 
flows and a terminal value of the company's cash flow are determined and discounted using 
a discount rate derived using the build-up method (See Schedule H) to adjust future values 
ADD 19 
Alain M. Baudry, Esq. 
Maslon, Edelman, Borman, & Brand 
January 21 , 1999 
Page 11 of 16 
to the valuation date. The terminal cash flow figure used in the calculation represents 
expected normalized future cash flows for periods beyond the discrete periods in the 
projection. A marketability discount is applied to this present value figure to arrive at a 
relevant value. We assigned a 30% weight to this valuation method. Using only this 
method, Zinetics' value is $.0149 per share (See Schedule J). 
Capitalized Cash Flows - A forecast of the next year's cash flow or an average of past 
year's cash flows is determined and a capitalization rate is applied which assumes certain 
growth (See Schedule H). The cash flow figure used in the calculation represents expected 
normalized future cash flows. (See Schedule G). 
Discounted Earnings - A forecast or projection of a discrete number of future period 
earnings and a terminal value of the subject company's earnings are determined and 
discounted using a discount rate determined using the build-up method (See Schedule H) to 
adjust values to the valuation date. The build-up method is described later in this report. The 
terminal earnings figure used in the calculation represents expected normalized future 
earnings for periods beyond the discrete periods in the projection. (See Schedule I). 
Capitalized Earnings - A forecast of the next year's earnings or an average of past years' 
earnings is calculated and a capitalization rate is applied which assumes certain growth (See 
Schedule H). The earnings figure used in the calculation represents expected normalized 
future earnings. (See Schedule F). 
Adjustments to Financial Statements 
Before calculating the values of Zinetics under these methods, an appropriate earnings 
stream must be calculated. In order to determine an appropriate earnings stream we had to 
make some adjustments to the February 27, 1998 income statements to show a normalized 
six-month period. These adjustments include the following: 
1. General & Administrative Supplies - an adjustment was made to reduce the 
build-up of supplies in the first half of the year. 
2. Repairs and Maintenance - an adjustment was made to reduce the timing 
effects of the repair expense. 
3. Travel Expense - an adjustment was made to bring travel expense to previous 
years' levels. 
4. Contributions - an adjustment was made to eliminate this discretionary 
expense. 
5. Bonuses - an adjustment was made to normalize the accrual of year-end 
bonuses to previous years' levels. 
6. Management Fees - an adjustment was made to adjust management fees to 
the same levels as prior years. 
7. R&D Testing - an adjustment was made to increase testing expenses to prior 
years' levels. 
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8. Depreciation - an adjustment was made to accrue depreciation at the rate of 
previous years. 
9. Interest Expense - an adjustment was made to increase interest expense to 
prior years' levels. 
10. Bad Debt Expense - an adjustment was made to accrue bad debt expense at 
the same level as the prior years. 
11. Extraordinary Item - an adjustment was made to accrue the payments 
received as an extraordinary item. This adjustment assumes that the full 
$14,400 per year will be received indefinitely and is an operating item. This 
adjustment tends to overstate the valuation under all applied methods of 
valuation. We admit that this payment will not continue indefinitely, but for 
ease of calculation we assume that it will. 
12. Net Operating Losses - an adjustment is made to net income in order to 
calculate income taxes. These adjustments are in accordance to footnotes in 
the audited financial statements and conversations with Zinetics' accountant. 
An assumed combined 40% tax rate is used to calculate any taxes due. 
Using this adjusted earnings stream we have projected the future earnings and cash flows of 
the Company. Schedules L1 and M1 show the projected future net income and projected 
future cash flows of the Company. As specific projections for extended amounts of time 
are generally not meaningful, a terminal value is assumed for year six and beyond based on 
normalized expected growth of past earnings and projected earnings for years one through 
five. 
Discount and Capitalization Rates 
One of the most significant components of the income approach to value is determination of 
the appropriate discount and capitalization rates. The appropriate discount rate must have as 
its foundation yields available on competing financial assets in public markets. Securities 
with different risk characteristics provide different rates of return commensurate with those 
uncertainties. 
We have used a build-up method to determine the appropriate discount rate. The primary 
basis of a build-up method is the assumption that investors are risk adverse and therefore 
require higher rates of return to bear additional risk. The initial component of the build-up 
method is the risk free rate of return. The risk free rate is increased by cumulative 
discounts relative to the premium required of investments in large company, small company, 
and micro company stocks. The return on large company stocks is based upon historical 
returns across all industries. We found, through analysis of Beta values of our comparative 
group of companies, that the medical products industry is less volatile and risky than all 
industries as a whole. We adjusted the required rate of return for the lower perceived risk in 
the medical products industry. 
We then added a 1 % premium for risk associated with Zinetics. This premium adjustment 
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accounts for various issues specific to Zinetics such as limited product diversity, reliance on 
a key employee, and very strong dependency on a single customer for sales. 
As mentioned above, when determining the appropriate company-specific risk premium, the 
value of key employees should be considered. The value of business can be diminished by 
the loss of a key person or persons who have been intimately involved in the operation of 
the business. A willing buyer contemplating the purchase of a business will assess the 
transferability of the expertise and contacts of the key person(s). Employment contracts 
and non-compete agreements can be utilized to resolve concerns and are usually calculated 
as part of the overall price paid for a business. Zinetics' president, Steve Davis, and other 
long-time personnel of Zinetics play an important role in the operations of Zinetics. If; Mr. 
Davis or other long-time personnel were to leave, Zinetics would suffer. This reality was 
considered in our determination of company-specific risk. 
The capitalization rate is determined by subtracting long-term expected earnings growth 
from the discount rate determined as described above. We have assumed a long-term 
earnings growth rate of 5.5%. 
Marketability 
AH other things being equal, an interest in a business is worth more if it is readily marketable 
or, conversely, worth less if it is not. Investors prefer liquidity to a lack of liquidity. Even 
though the common stock of Zinetics is publicly traded on a non-NASDAQ over-the-counter 
bulletin board stock exchange, it is thinly traded. There is not a ready market for the stock. 
In our opinion, the fair value of Zinetics' stock would include a marketability discount. In 
the values that reflect the non-marketable nature of Zinetics' stock, we have applied a 
31.93% discount. This discount is derived from several published studies (See Schedule O). 
Control Premium 
The market value of a security is impacted by the elements of control of lack of control 
inherent in the block of stock being valued. In this valuation, the 18.56% block of stock is 
clearly a minority position. In the valuation we have presented several values, some of 
which include control premiums. We have applied a 36.81 % control premium when the 
value is identified to reflect a control position value. This premium is based on several 
published studies (See Schedule O). 
Conditions and Assumptions 
The above valuation is based on past and present results of operations and the existing 
financial condition at the valuation date. Our valuation estimate is subject to the following 
conditions, limitations, and assumptions: 
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Our analysis is intended solely to assist you in the determination of the fair value of a 
100% interest and an 18.56% interest in the common stock of Zinetics as of 
February 12, 1998. 
The terms of our engagement are such that we have no obligation to update this 
report or to revise the valuation because of events and transactions occurring 
subsequent to the date of the report. 
The valuation of a business enterprise is a matter of informed judgment. The 
accompanying valuation has been prepared on the basis of information and 
assumptions set forth in this report and the attached schedules. We have relied on 
publicly available data and sources that we have not verified. 
Norman/Loebbecke Associates has no present or contemplated future interest in Zinetics or 
the shares whose value we have determined, or any other interest which might prevent us 
from performing an unbiased valuation. 
Conclusion 
Based upon the above assumptions and the conclusions stated above, the value of Zinetics 
Medical, Inc. as of February 12, 1998 is $2,542,311 or $.0197 per share. The value of an 
18.56% minority interest in the common shares of Zinetics as of the valuation date is 
$464,235 or $.0197 per share. Using any single valuation method rather than the weighted 
average value, share values ranged from $.0168 per share to $.0512 per share. 
Alternative Valuations 
The valuation detailed above was performed assuming Zinetics is affiliated with Medtronic 
and Synectics. There are other possible scenarios in which Zinetics can be valued, although, 
not all are necessarily applicable in dissenting shareholder actions. 
Steve Davis, Zinetics' current president, provided a projection of Zinetics' sales and costs 
for the future as if Zinetics were to separate itself from Synectics. We have not relied upon 
his projections nor included the values resulting from these projections in our value summary 
(Schedule A) but have calculated the values resulting from what Mr. Davis represents future 
sales and costs would be. The resulting values derived from his projections ranged from 
$716,004 to $3,850,485 under the methods used (See Schedules R and S). 
As Zinetics is currently controlled by Synectics, we thought that it might also be appropriate 
to value Zinetics as if it were a separate entity. This valuation is similar to the valuation 
performed above. The value of Zinetics as a separate entity is shown on Schedule T and is 
supported on Schedules U-Y. The value of Zinetics as a separate entity is slightly lower 
than the value of Zinetics as a part of Synectics. As a separate entity, Zinetics is valued at 
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the following at the valuation date: 
Under a minority/marketable value - $276,522 or $.0117 per share. 
Under a minority/non-marketable value - $188,243 or $.0080 per share. 
Under a control/marketable value - $378,306 or $.0161 per share. 
Under a control/non-marketable value - $257,532 or $.0109 per share. 
Assumptions used to calculate this scenario are listed on the bottom of Schedule U. Using 
any single valuation method rather than the weighted average value under this scenario, 
share values ranged from $.0057 per share to $.0178 per share (See Schedule T). To 
calculate Zinetics' value under this scenario, Norman/Loebbecke Associates, used their own 
assumptions to prepare the projected income statements and cash flow statements based 
upon discussions with Steve Davis and representatives of Medtronic. 
Analysis of Outstanding Offer 
As part of the Medtronic purchase of Synectics, Medtronic converted the minority 
ownership interest of Zinetics (18.56%) into the right to receive $.04528 per share. This 
amount was paid to the minority shareholders and the minority shareholders exercised their 
dissenter's rights under the Revised Utah Business Corporation Act. 
Based upon the foregoing valuation, the present outstanding offer of $.04528 exceeds the 
value of the Company as of the valuation date. In fact, in our opinion the $.04528 offer is 
almost double the value of Zinetics as of February 12, 1998. 
It appears the minority shareholders have been more than amply compensated for their 
shares. 
Analysis of Willamette Valuation 
We have reviewed the valuation report of Robert Reilly of Willamette Management 
Associates (Willamette) and have been asked to give a few general observations concerning 
it at this time. We take exception to Willamette's findings in that: 
• The comparative group of companies used are not representative in that they are 
negative earning companies many of which are start-up companies or are new to the 
market. 
• The comparative group of companies contains a wide range of company sizes 
without any attempt to adjust for the inequity among sizes. 
• Values derived under the income method appear to be high based upon assumptions 
for which no disclosure of rationale or basis is given. There is insufficient 
information to understand the basis of the projections. 
• Values derived under the market method come from a single multiple only and results 
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of values using other multiples are not entertained. Had they been incorporated, 
many of these measures produce negative or unreliable results. 
• There is a weak correlation between the value supported by the market approach and 
the income approach. 
We wish to gain more understanding of the assumptions and rationale used by Willamette in 
determining the value of Zinetics (through depositions or other means) before a complete 
analysis of their report will be offered by Norman/Loebbecke Associates. 
We would like to thank you for giving us the opportunity to assist.you in this endeavor. 
Please feel free to contact us with any questions or comments regarding this report. 
Very truly yours, 
NORMAN/LOEBBECKE ASSOCIATES 
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Schedule B 
Zlnetfcs Medical, Inc. 
Income Statements for the Period Ending as Stated 
Contributions 
Moving expenses 
Other expenses 
Other office expenses 
Service charges 
Other taxes 
Bonus expense 
Other expense 
Management fees 
Employee Incentives 
Miscellaneous 
Total Setting, General & Administrate 
Research & Development: 
RAD testing 
R&D supplies 
Total Research & Development 
Depredation and AmorOratten: 
Depreciation expense 
Amortization expense 
Total Depreciation and Amortization 
Operating Income 
Other Income (Expense): 
Interest Income 
Interest expense 
Bad debt expense 
Total Other Income (Expense) 
Income Before Extraordinary Item 
Extraordinary Rem (Recovery) 
Net Income Before Taxes 
Provision for Income Taxes 
Net Income 
For the 
Sbt Months Ended 
February 27, 
1998 
347 
7,210 
(104) 
513,231 
745 
6.622 
7,367 
27,000 
1.908 
28,908 
228,769 
21,471 
(155) 
21,316 
250,085 
(5.047) 
245,038 
85.764 
S 159.274 
% 
0.03% 
0.53% 
-0.01% 
37.69% 
0.05% 
0.49% 
0.54% 
1.98% 
0.14% 
2.12% 
16.80% 
1.58% 
-0.01% 
1.57% 
18.37% 
-0.37% 
18.00% 
6.30% 
11.70% 
For the 
Vear Ended 
August 31, 
1997 
1,009,155 
-
60,499 
481,789 
32,899 
(889) 
(2.438) 
29,572 
611,361 
13,200 
524,561 
44.053 
S 480.508 
For the 
Year Ended 
August 31, 
% 1996 
40.76% 
2.44% 
19.46% 
1.33% 
-0.04% 
-0.10% 
1.19% 
20.66% 
0.53% 
21.19% 
1.78% 
19.41% 
6.471 
795 
197 
12,439 
60,668 
9,443 
540 
866.143 
2,635 
5.619 
8,254 
41,725 
3.816 
45,641 
175,163 
15,492 
(3,113) 
(1.847) 
10.532 
185,694 
14,400 
200.094 
28.908 
$ 171.186 
For the 
Year Ended 
August 31, 
% 1995 
0.34% 
0.04% 
0.01% 
0.66% 
3.21% 
0.50% 
0.03% 
45.82% 
0.14% 
0.30% 
0.44% 
221% 
0.20% 
2.41% 
9.27% 
0.82% 
-0.16% 
-0.10% 
0.56% 
9.82% 
0.76% 
10.58% 
1.53% 
9.06% 
10 
3,000 
596 
7,935 
255 
16.415 
5,559 
41,781 
(14.799) 
899.033 
1,814 
9.598 
11.412 
38,762 
4.145 
42,906 
253,144 
291 
(15.762) 
(8.500) 
(23,971) 
229,172 
14,400 
243,572 
81.169 
$ 162,383 
For the 
Year Ended 
August 31, 
% 1994 
0.00% 
0.15% 
0.03% 
0.39% 
0.01% 
0.80% 
0.27% 
2.05% 
-0.72% 
44.03% 
0.09% 
0.47% 
0.56% 
1.90% 
0.20% 
2.10% 
12.40% 
0.01% 
-0.77% 
-0.42% 
-1.17% 
11.22% 
0.71% 
11.93% 
3.98% 
7.95% 
482 
8.383 
6 
482 
16,163 
1,813 
14 
606.275 
492 
492 
11.279 
3.816 
15.095 
332,218 
3 
(10.679) 
(10,675) 
321,542 
14.400 
335.942 
51.773 
$ 284.169 
For the 
Year Ended 
August 31, 
% 1993 
0.03% 
0.54% 
0.00% 
0.03% 
1.05% 
0.12% 
0.00% 
39.31% 
0.03% 
0.03% 
0.73% 
0.25% 
0.98% 
21.54% 
-0.69% 
-0.69% 
20.85% 
0.93% 
21.78% 
3.36% 
18.42% 
6.844 
2.431 
448,449 
9.371 
3.816 
13.187 
183.824 
(13,059) 
(17.072) 
(30,131) 
153.694 
13.516 
167.209 
14.110 
S 153.100 
% 
0.56% 
0.20% 
36.96% 
0.77% 
0.31% 
1.09% 
15.15% 
-1.08% 
-1.41% 
-2.48% 
1267% 
1.11% 
13.78% 
1.16% 
12 62% 
Schedule B 
Zfnetics Medical, Inc 
Income Statements for the Period Ending as Stated 
Revenue 
Product tales 
Other Income 
Total Revenue 
Cost of Goods Sold 
Cost of goods aold 
Rework/replace 
Freight 
Total Cost of Ooods Sold 
Gross Profit 
Setting, General ft Administrative: 
Advertising and media 
Trade show cost 
Sales brochures/video 
Meetings 
Salaries and wages 
Sales and commissions 
Commissions - International 
Employer contribution - 401K 
Payroll taxes 
Group hearth insurance 
Car rental 
Insurance - auto 
Auto expense 
Service-gas 
Outside services 
Rent expense 
Laundry ft uniforms 
Telephone 
Personal property taxes 
LtaMHty Insurance 
Property Insurance 
Education/training 
Computer access/supplies 
General & administrative supplies 
Manufacturing supplies 
Sales ft mktg auppltes 
OAA supplies 
Postage 
Equipment lease 
Dues, fees and subscriptions 
Mfg tooling 
Bank charges 
Professional fees 
Service contract 
Consultation service 
Repairs ft maintenance 
Travel expense 
Mesls ft entertainment 
Employee benefits 
For the 
Six Months Ended 
February 27, 
1998 
$ 1,361,675 
1,361,675 
568,917 
-14.483 
583,400 
778,275 
2,615 
3,073 
113 
1,436 
267,846 
4,923 
« 
7,302 
44,602 
15,279 
725 
• 8,185 
• 8,226 
26,021 
6,057 
12,814 
2,179 
10,314 
-4,257 
-11.669 
-7,781 
1,276 
1,606 
3,333 
6,284 
351 
2,328 
11.539 
138 
163 
9,607 
15,903 
7,833 
-
% 
10000% : 
000% 
100 00% 
4178% 
000% 
106% 
42.84% 
5716% 
019% 
0 23% 
001% 
011% 
19 67% 
0 36% 
054% 
3 28% 
1 12% 
0 05% 
060% 
060% 
191% 
0 44% 
0 94% 
016% 
0 76% 
0 31% 
000% 
0 86% 
0 57% 
009% 
012% 
0 24% 
0 46% 
0 03% 
017% 
0 85% 
0 01% 
001% 
0 71% 
117% 
0 58% 
For the 
t*ear Ended 
August 31, 
1997 
$2,475,568 
2,475,568 
$ 924.125 
924,125 
1,551,443 
% 
100 00% 
000% 
100 00% 
37 33% 
000% 
000% 
37 33% 
62 67% 
For the 
Year Ended 
August 31, 
1996 
1,889 404 
1.020 
1,890,424 
773.831 
-21.493 
795,324 
1,095,100 
5,068 
12,299 
-4,234 
354,260 
9,518 
12.287 
6,815 
81,599 
22,856 
956 
-12,534 
1,466 
14,855 
47,217 
7,799 
18,845 
1,219 
23,074 
• 4,746 
821 
11,746 
-14,073 
1,705 
2,394 
8,236 
8.544 
491 
3,278 
34,192 
2,542 
813 
9.572 
26,728 
8 532 
275 
For the 
Year Ended 
i 
% 
99 95% 
0 05% 
100 00% 
40 93% 
000% 
1 14% 
42 07% 
57 93% 
0 27% 
0 65% 
022% 
18 74% 
050% 
0 65% 
0 36% 
4 32% 
121% 
0 05% 
0 66% 
0 08% 
0 79% 
2.50% 
0 41% 
100% 
0 06% 
122% 
0 25% 
0 04% 
0 62% 
0 74% 
0 09% 
0 13% 
0 44% 
0 45% 
0 03% 
017% 
181% 
0 13% 
0 04% 
0 51% 
141% 
0 45% 
0 01% 
August 31, 
1995 
2,041,826 
187 
2,042,013 
808,727 
-26.790 
835.518 
1,206.495 
11,968 
9,373 
546 
-
377,188 
9,342 
14,163 
6,685 
79,407 
64,616 
530 
-
9,455 
1,990 
12.497 
80.462 
5.832 
19,942 
1,536 
23,700 
-2,945 
(3,423) 
9,138 
65 
4,392 
1,241 
1,967 
6,138 
4,954 
• 
277 
15,574 
830 
1,055 
12,813 
43,786 
7,292 
4 
For the 
Year Ended 
i 
% 
9999% 
0 01% 
100 00% 
39 60% 
000% 
131% 
40 92% 
59 08% 
0 59% 
046% 
0 03% 
18 47% 
0 46% 
069% 
033% 
389% 
316% 
003% 
0 46% 
010% 
0 61% 
3 94% 
029% 
0 98% 
0 08% 
116% 
014% 
-017% 
045% 
000% 
022% 
006% 
010% 
030% 
024% 
001% 
0 76% 
0 04% 
005% 
063% 
214% 
036% 
000% 
August 31, 
1994 
1,542,357 
. 1,542,357 
570,155 
(57) 
18.180 
588,278 
954,079 
2,831 
14,999 
123 
-
235,875 
2,074 
61,803 
40,167 
2,500 
6,412 
44,935 
1,927 
13,760 
1.823 
22.393 
2,439 
3,957 
18,429 
1,613 
3,271 
4,444 
-
409 
24,578 
889 
7,938 
3,990 
42,195 
13,259 
For the 
Year Ended 
; 
% 
100 00% 
000% 
100 00% 
36 97% 
000% 
1 18% 
38 14% 
6186% 
018% 
0 97% 
0 01% 
15 29% 
013% 
4 01% 
260% 
000% 
016% 
0 42% 
291% 
0 12% 
089% 
012% 
145% 
016% 
0 26% 
1 19% 
0 10% 
0 21% 
029% 
0 03% 
159% 
006% 
0 51% 
026% 
2 74% 
0 86% 
August 31, 
1993 
1.213.344 
. 
1.213.344 
557,105 
-10.779 
567,864 
645,460 
5.263 
3,823 
273 
-
203,814 
60,110 
28,697 
4,076 
42,856 
2 097 
9.242 
20.707 
1,009 
440 
1,195 
3 545 
1.173 
1.411 
30.281 
4,327 
11.822 
3.015 
% 
100 00% 
000% 
100 00% 
45 91% 
000% 
0 89% 
46 80% 
53 20% 
0 43% 
0 32% 
002% 
16 80% 
4 95% 
2 37% 
0 34% 
3 53% 
017% 
0 76% 
171% 
008% 
004% 
010% 
029% 
0 10% 
012% 
250% 
036% 
0 97% 
025% 
Schedule C 
Zinetics Medical, Inc. 
Balance Sheets as of the Period Stated 
Assets 
Current Assets: 
Cash • First Security Bank 
Cash - Merrill Lynch 
Cash - Comerica 
Cash - sweep 
Cash - petty 
Accounts receivable - trade 
Allowance for doubtful accounts 
Accounts receivable - Synectics 
Accounts receivable - other related 
Accounts receivable - employees 
Accounts receivable - stockholders 
Accounts receivable - other 
Inventory - finished goods 
Inventory - work In process 
Inventory - raw material 
Prepaid Income tax 
Prepaid other 
Prepaid Insurance 
Total Current Assets 
Property and Equipment 
Furniture, fixtures & equipment 
Computers & software 
Leasehold Improvements 
Accumulated depreciation 
Total Property and Equipment 
Other Assets: 
Patents & trademarks 
Accumulated Amortization 
Deposit - workers comp. 
Deferred Income tax benefit 
Total Other Assets 
Total Assets 
As of 
February 27, 
1998 
$ (10.571) 
. 
. 
949.383 
200 
367,862 
(9,646) 
-
-
8,525 
. 
. 
64,220 
-
180,677 
-
-
849 
1,551,499 
305,066 
123.069 
31,073 
(313,284) 
145.924 
57,070 
(41,802) 
1,295 
24,091 
40,654 
$ 1,738177""' 
% 
-0.61% 
0.00% 
0.00% 
54.62% 
0.01% 
21.16% 
-035% 
0.00% 
0.00% 
0.49% 
0.00% 
0.00% 
3.69% 
0.00% 
10.40% 
0.00% 
0.00% 
0.05% 
89.27% 
17.55% 
7.08% 
1.79% 
-18.02% 
8.40% 
3.28% 
-2.41% 
0.07% 
1.39% 
2.34% 
100.00% 
As of 
August 31 , 
1997 
835,674 
133,215 
208,469 
67.580 
151,867 
11.163 
1,407,968 
291,774 
112.113 
25,979 
(286.284) 
143,582 
57.070 
(39.894) 
1,295 
24.091 
42.562 
$1,594.112 
H I D ' , , . i . ' j ' l 1 -111] 
% 
0.00% 
0.00% 
0.00% 
52.42% 
0.00% 
8.36% 
0.00% 
13.08% 
0.00% 
0.00% 
0.00% 
0.00% 
4.24% 
0.00% 
9.53% 
0.00% 
0.70% 
0.00% 
88.32% 
18.30% 
7.03% 
1.63% 
-17.96% 
9.01% 
3.58% 
-2.50% 
0.08% 
1.51% 
2.67% 
100.00% 
As of 
August 31 , 
1996 
$ (4.301) 
-
-
498,062 
200 
124,951 
(9,646) 
148,959 
15,322 
200 
-
47 
34,488 
-
81.877 
-
-
10,789 
900,947 
259.746 
82,515 
20,429 
(229,602) 
133,088 
57,070 
(36,078) 
1,295 
24.091 
46,378 
$ 1 , 0 8 0 , 4 1 ~ 
% 
-0.40% 
0.00% 
0.00% 
46.10% 
0.02% 
11.57% 
-0.89% 
13.79% 
1.42% 
0.02% 
0.00% 
0.00% 
3.19% 
0.00% 
7.58% 
0.00% 
0.00% 
1.00% 
83.39% 
24.04% 
7.64% 
1.89% 
-21.25% 
12.32% 
5.28% 
-3.34% 
0.12% 
2.23% 
4.29% 
100.00% 
i l l • , .',.Hi.MI .111 
As of 
August 3 1 , 
1995 
% (2,988) 
-
-
279,819 
-
208,538 
(16,040) 
220,817 
-
1,557 
-
-
9,722 
-
75,573 
9,977 
J319 
13,446 
800,740 
237,632 
61,637 
15,548 
(187,877) 
126,940 
57,070 
(32,262) 
1,295 
24,045 
50,148 
$ 977,828 " 
% 
-0.31% 
0.00% 
0.00% 
28.62% 
0.00% 
21.33% 
-1.64% 
22.58% 
0.00% 
0.16% 
0.00% 
0.00% 
0.99% 
0.00% 
7.73% 
1.02% 
0.03% 
1.38% 
81.89% 
24.30% 
6.30% 
1.59% 
-19.21% 
12.98% 
5.84% 
-3.30% 
0.13% 
2.46% 
5.13% 
100.00% 
As of 
August 31, 
1994 
$ 207,679 
55 
624 
-
-
156,447 
(27,117) 
250,185 
-
3,202 
-
-
9,785 
-
55,279 
-
6,600 
13,085 
675,824 
239,939 
-
108,754 
(282,420) 
66,273 
58,024 
(28,117) 
2,470 
26,462 
58,839 
"$ 800,936 
i ' l inn i ' i in 
% 
25.93% 
0.01% 
0.08% 
0.00% 
0.00% 
19.53% 
-3.39% 
31.24% 
0.00% 
0.40% 
0.00% 
0.00% 
1.22% 
0.00% 
6.90% 
0.00% 
0.82% 
1.63% 
84.38% 
29.96% 
0.00% 
13.58% 
-35.26% 
8.27% 
7.24% 
-3.51% 
0.31% 
3.30% 
7.35% 
100.00% 
As of 
August 31 , 
1993 
$ 122,832 
131 
21,837 
-
-
146,090 
(32,000) 
-
-
926 
86.135 
-
1,431 
-
54,731 
-
-
11.321 
413,434 
196,799 
. 
108,754 
(271.141) 
34,412 
58,024 
(24,301) 
2.470 
17.700 
53,893 
$ 501,739" 
% 
24.48% 
0.03% 
4.35% 
0.00% 
0.00% 
29.12% 
-6.38% 
0.00% 
0.00% 
0.18% 
17.17% 
0.00% 
0.29% 
0.00% 
10.91% 
0.00% 
0.00% 
2.26% 
82.40% 
39.22% 
0.00% 
21.68% 
-54.04% 
6.86% 
11.56% 
-4.84% 
0.49% 
3.53% 
10.74% 
100.00% 
Schedule C 
© 
Zinetlcs Medical, Inc. 
Balance Sheets as of the Period Stated 
Liabilities & Stockholder's Equity 
Current Liabilities: 
Accounts payable - trade 
Accounts payable - Synectlcs 
Accrued wages payable 
Accrued workers comp payable 
Accrued employee vacation 
Accrued payroll taxes 
Accrued other 
401kwlthholdlng 
401k loan 
Income tax payable 
Insurance note payable 
Current portion of capital leases 
Total Current Liabilities 
Long-Term Liabilities: 
Capital Leases 
Deferred Income taxes 
Total Long-Term Liabilities 
Stockholder's Equity: 
Common stock 
Treasury stock 
Additional paid In capital 
Beginning retained earnings 
Current earnings 
Total Stockholder's Equity 
Total Liabilities & Stockholder's Equity 
As of 
February 27, 
1998 
$ 40,146 
-
33,217 
1,038 
28,566 
34 
618 
2,231 
. 
46,213 
-
-
152,063 
11.070 
15,261 
26,331 
128,902 
(10,000) 
47,714 
1,233,792 
159,275 
1,559,683 
$ 1,738,077"" 
% 
2.31% 
0.00% 
1.91% 
0.06% 
1.64% 
0.00% 
0.04% 
0.13% 
0.00% 
2.66% 
0.00% 
0.00% 
8.75% 
0.64% 
0.88% 
1.51% 
7.42% 
-0.58% 
2.75% 
70.99% 
9.16% 
89.74% 
100.00% 
As of 
August 31, 
1997 
$ 28,064 
65,893 
8,262 
54,976 
6,802 
6,407 
170,404 
8,039 
15,261 
23,300 
128,902 
(10,000) 
47,714 
1,233.792 
1,400,408 
$1.594.112 
% 
1.76% 
0.00% 
4.13% 
0.00% 
0.00% 
0.00% 
0.52% 
0.00% 
0.00% 
3.45% 
0.43% 
0.40% 
10.69% 
0.50% 
0.96% 
1.46% 
8.09% 
-0.63% 
2.99% 
77.40% 
0.00% 
87.85% 
100.00% 
As of 
August 31, 
1996 
% 23,423 
16,797 
17,275 
1,151 
28,602 
6,901 
7,280 
2,113 
450 
17,255 
6,569 
8,458 
136,274 
15,310 
8,929 
24,239 
128,902 
(10,000) 
47,714 
582,098 
171,186 
919,900 
$ 1,080,413"" 
% 
2.17% 
1.55% 
1.60% 
0.11% 
2.65% 
0.64% 
0.67% 
0.20% 
0.04% 
1.60% 
0.61% 
0J8% 
12.61% 
1.42% 
0.83% 
2.24% 
11.93% 
-0.93% 
4.42% 
53.88% 
15.84% 
85.14% 
100.00% 
•BnaaHOBanai 
As of 
August 31, 
1995 
$ 21,613 
51,511 
32,474 
1,608 
49,752 
12,648 
642 
5,596 
250 
-
8,705 
13,701 
198,500 
23,407 
7,207 
30,614 
128,902 
(10,000) 
47.714 
419,714 
162,383 
748,714 
$ 977,828" 
% 
2.21% 
5.27% 
3.32% 
0.16% 
5.09% 
1.29% 
0.07% 
0.57% 
0.03% 
0.00% 
0.89% 
1.40% 
20.30% 
2.39% 
0.74% 
3.13% 
13.18% 
-1.02% 
4.88% 
42.92% 
16.61% 
76.57% 
100.00% 
As of 
August 31, 
1994 
$ 45,383 
31,081 
6,649 
1.153 
31,374 
-
9,519 
5,301 
-
55,092 
8,748 
6.030 
200,331 
9,346 
4,928 
14,274 
128,902 
(10.000) 
47,714 
135,546 
284,169 
586,331 
$ 800,936" 
% 
5.67% 
3.88% 
0.83% 
0.14% 
3.92% 
0.00% 
1.19% 
0.66% 
0.00% 
6.88% 
1.09% 
0.75% 
25.01% 
1.17% 
0.62% 
1.78% 
16.09% 
-1.25% 
5.96% 
16.92% 
35.48% 
73.21% 
100.00% 
As of 
August 31, 
1993 
$ 15,939 
81,677 
30.228 
-
18.202 
5.836 
3.801 
6,581 
-
13,909 
3,043 
4,984 
184,201 
15,377 
-
15,377 
128.902 
(10.000) 
47,714 
(17,554) 
153.100 
302,162 
$ 501,739"" 
% 
3.18% 
1658% 
6.02% 
0.00% 
3.63% 
1.16% 
0.76% 
131% 
0.00% 
2.77% 
0.61% 
0.99% 
36.71% 
3.06% 
0.00% 
3.06% 
25.69% 
-1.99% 
9.51% 
-350% 
3051% 
6022% 
100.00% 
ADD 30 
Schedule 0 
Zlnellcs Medical Inc. 
Income Statement and Ad j^stnenU 
For the 
Six Months Ended 
February 27. 
1998 
Other ofTloa expenses 
Service charges 
Ofior taxes 
Bonus expense 
Other expense 
Management fees 
Employes Incentrvos 
Total Seflng. General & AdmWstitvi 
Research & Development t 
R&D tesfng 
R&D supples 
Total Research & Development 
Depredation and Amorlzaf.on: 
Depredator) expense 
Amorbeton expense 
Total Depredaton and Amortarton 
Opera trig Income 
Other Income (Expense): 
Interest expense 
Bed debt expense 
Total Other Income (Expense) 
Income Before Exfrsordnary Item 
Extaordr Mry Item (Recovery) 
Net Income Before Taxes 
Income Tax Expense 
Net Income 
Ad]. 
Adj. 
February 27. 
1998 
0.00% 
0.00% 
0.00% 
0.00% E 
0.00% 
0.00% F 36.084 
4.493 
228.769 16.80% 
21.471 1.58% 
(155) -0.01% I 
0.00% J 
(390) 
(1.362) 
4.493 
36.084 
7.210 
(104) 
513.231 
745 
6.622 
7.367 
27.000 
1.908 
26.908 
0.53% 
-0.01% 
37.69% 
0.05% O 
0.49% 
0.54% 
1.98% H 
0.14% 
2.12% 
38.154 
548 
548 
1,834 
1.834 
7,210 
(104) 
551.385 
1.293 
6.622 
7,915 
28,834 
1.908 
30,742 
(40,536) 188.233 
21.471 
(545) 
(1.362) 
21,316 
250,085 
(5.047) 
245,038 
85.764 
$ 159.274 
1.57% 
18.37% 
-0.37% K 
18.00% 
6.30% L 
11.70% 
(1.752) 
(42,286) 
12,247 
(30,041) 
(12.016) 
19.564 
207.797 
7.200 
214.997 
73.748 
$(18.025) $ 141.249 
For the 
Year Ended 
August 31, 
1997 
0.00% 
0.00% 
0.00% 
0.00% 
0.00% 
0.00% 
0.00% 
0.00% 
0.00% 
0.00% 
60.499 2.44% 
481,789 19.46% 
32.899 1.33% 
(889) -0.04% 
(2.438) -0.10% 
JML 
Adj. 
August 31, 
1997 
. 
1.009.155 
m 
• 
0.00% 
40.76% 
0.00% 
0.00% 
-
- 1.009.155 
. 
-
60.499 
481,789 
32.899 
(889) 
(2.438) 
29.572 
511.361 
13.200 
524,561 
44,053 
$ 480.508 
1.19% 
20.66% 
0.53% 
21.19% 
1.78% 
19.41% 
29.572 
511.361 
13.200 
524.561 
44,053 
$- $ 480.608 
A To adjust for tie apparent build-up In supples for f » year. 
B To adjust for t * apparent repaJrbulM-up In the first half of the year. 
C To adjust twet expense to past year's travel patterns 
D To adjust contlbuf ons to zero representing a dscreHonary expense. 
E To adjust for the accrual of bonuses at year end. 
F To adjust management feet to past year's levels. 
0 To adjust R&D tesfng to prior year's levels. 
H To adjust for the accrual of depredaton at last yeafs levels. 
1 To adjust Wertst expense to pest year's levels. 
J To adjust bad debt expense to past year's levels. 
K To adjust for tie accrual of tr« exlraordnary Item. 
L To adjust Income taxes for fto effect of the above adjustments. 
For the 
Year Ended 
August 31. 
1996 
795 
-197 
12.439 
-60.668 
9.443 
540 
866.143 
2.635 
5.619 
Adj. 
August 31. 
% Ad. 1996 
0.04% 
0.00% 
0.01% 
0.66% 
0.00% 
3.21% 
0.50% 
0.03% 
45.82% 
0.14% 
0.30% 
795 
-197 
12,439 
-60.668 
9.443 
540 
866,143 
2.635 
5.619 
For the 
Year Ended 
August 31. 
1995 
7.935 
255 
-16,415 
5.559 
41.781 
* (14.799) 
899.033 
1.814 
9.598 
** 
August 31. 
% Ad. 1995 
0.39% 
0.01% 
0.00% 
0.80% 
0.27% 
2.05% 
0.00% 
-0.72% 
44.03% 
0.09% 
0.47% 
7,935 
255 
. 
16.415 
5.559 
41.781 
. (14,799^ 
899,033 
1.814 
9.598 
8,254 11.412 0.56% 11.412 
41.725 
3.816 
2.21% 
0.20% 
45.541 2.41% 
175.163 957% 
41.725 
3.816 
45.541 
175.163 
38.762 
4.145 
42.906 
253.144 
1.90% 
050% 
2.10% 
1Z40% 
38.782 
4.145 
42.906 
253.144 
15.492 0.82% 
(3.113) -0.16% 
(1,847) -0.10% 
10.532 0.56% 
185.694 
14.400 
9.62% 
0.76% 
15.492 
(3.113) 
(1.847) 
10.532 
185.694 
14.400 
291 0.01% 
(15.762) -0.77% 
(8.500) -0.42% 
(23.971) -1.17% 
229.172 1152% 
14.400 0.71% 
291 
(15.762) 
(8.500) 
(23.971) 
229.172 
14.400 
200.094 
28.908 
10.58% 
1.53% 
200.094 
28.908 
243.572 
81.189 
11.93% 
3.98% 
243.572 
81.189 
Schedule E 
Zinetics Medical Inc. 
Cash Flow Statement 
For the Periods Ending as Stated 
For the 
Six Months Ended 
February 27, August 31, August 31, 
1998 1997 1996 
Adjusted Net Income After Taxes $ 141,249 $ 480,508 $ 171,186 
Add: Depreciation and Amortization 30,742 60,499 45,541 
Less: Additions to Working Capital 
Current Year Current Assets (1,551,499) (1,407,968) (900f947) 
Current Year Current Liabilities 152,063 170,404 136,274 
Prior Year Current Assets 1,407,968 900,947 800,740 
Prior Year Current Liabilities (170,404) (136,274) (198,500) 
Total (additions) subtractions to working capital (161,872) (472,891) (162,433) 
Less: Additions to Depreciable Assets 
Current Year Depreciable Assets (541,664) (512,322) (445,146) 
Prior Year Depreciable Assets 512,322 445,146 397,227 
Total (additions) subtractions to depreciable assets (29,342) (67,176) (47,919) 
Add: Additions to Long-Term Debt 
Current Year Long-Term Debt 26,331 23,300 24,239 
Prior Year Long-Term Debt (23,300) (24,239) (30,614) 
Total additions to Long Term Debt 3,031 (939) (6,375) 
Adjustments to Cash Flow 
Decrease (Increase) in Working Capital Needs 144,048 341,000 162,433 
Decrease (Increase) in Capital Asset Needs (20,658) 17,176 (2,081) 
Total Adjustments to Cash Flow 123,390 358,176 160,352 
Total Cash Flow $ 107,198 $ 358,177 $ 160,352 
ADD 32 
Schedule F 
Zinetics Medical Inc. 
Capitalization of Adjusted Net Income After Taxes 
As a Part of Synectics 
Year Schedule 
Adjusted 
Earnings 
Constant 
$ Index 
Constant 
$ Earnings 
Weight 
Factor 
Weighted 
Earnings 
8/31/98 
8/31/97 
K 
B 
$ 407,756 
480,508 
100.00% 
103.45% 
$ 407,756 
497,099 
2 
1 
815,513 
497,099 
Total $ 1,312,612 
Total Weighting Factors 
Weighted Average Net Income 
Divide by: Capitalization Rate (See Schedule H) 
Minority/Marketable Operating Value of Company 
3 
437,537 
19.02% 
$ 2,300,992 
ADD 
Schedule G 
Zinetics Medical Inc. 
Capitalization of Adjusted Cash Flows 
As a Part of Synectics 
Adjusted Constant Constant 
Year Schedule Cash Flow $ Index $ Cash Flow 
8/31/98 L $ 402,963 100.00% $ 402,963 
8/31/97 E 358,177 103.45% 370,544 
Total 
Total Weighting Factors 
Weighted Average Net Cash Flow 
Divide by: Capitalization Rate (See Schedule H) 
Minority/Marketable Operating Value of Company 
Weight 
Factor 
2 
1 
3 
Weighted 
Cash Flow 
$ 805,927 
370,544 
1,176,470 
3 
392,157 
16.08% 
$ 2,438,392 
ADD 
Schedule H 
Zinetics Medical Inc. 
Calculation of Capitalization and Discount Rate 
As a Part of Synectics 
Capitalization Rate 
Risk-free Rate 
Average Equity Risk Premium 
Average Small Stock Risk Premium 
Micro-Cap Size Premium 
Industry Risk Premium 
Zinetics Medical Specific Risk Premium 
Composite Cash Flow Discount Rate 
Additional Increment for Earnings Discount Rate 
Net Earnings/Cash Flow Discount Rate 
Less: Expected Earnings Growth Rate 
Net Income Capitalization Rate 
Adjustment for Current Year Net Income/Net Cash Flow Capitalization Rate 
Current Year Net Income/Net Cash Flow Capitalization Rate 
Related Industry Beta Factors 
Company 
United States Surgical 
Arrow International 
ZOLL Medical Corp. 
St. Jude Medical 
Maxxim Medical 
C.R. Bard Inc. 
Abbott Laboratories 
Baxter International 
Average 
For 
Earnings 
5.37% 
7.40% 
4.70% 
4.13% 
-0.65% A 
1.00% 
21.95% 
3.00% 
24.95% 
5.50% 
19.45% 
102.30% 
19.02% 
For 
Cash Flow 
5.37% 
7.40% 
4.70% 
4.13% 
-0.65% 
1.00% 
21.95% 
0.00% 
21.95% 
5.50% 
16.45% 
102.30% 
16.08% 
Beta 
1.00 
0.80 
1.00 
0.70 
0.90 
1.10 
0.80 
1.00 
0.91 
Industry Risk Premium 
Beta Adjusted Premium for Equity Risk (Beta x Premium for Equity Risk) 
Less: Premium for Equity Risk 
Industry Risk Premium 
6.75% 
7.40% 
-0.65% A 
ADD 35 
Schedule I 
Zinetics Medical Inc. 
Discounted Net Income 
As Part of Synectics 
Projected 
2/27/98 8/31/98 8/31/99 8/31/00 8/31/01 8/31/02 8/31/03 8/31/04 8/31/05 8/31/06 8/31/07 Terminal | 
Profit (Loss) 
tftalizatlon Rate 
mlnal Value 
>sent Value Factor 
«ent Value Amount 
mutative Present Value 
$141t249 $ 266,507 $404,025 $427,911 $450,873 $472,242 $491,344 $509,734 $529,466 $550,613 $ 573,254 $ 492,014 
19.45% 
2,529,310 
0.94 0.79 0.63 0.51 0.41 0.33 0.26 0.21 0.17 0.13 0.13 
249,518 320,252 271,492 228,831 191,843 159,768 132,669 110,235 91,759 76,466 337,385 
$2,170,219 
Schedule J 
Zinetics Medical Inc. 
Discounted Cash Flows 
As Part of Synectics 
Projected 
t Cash Row 
pftalkatlon Rate 
minal Value 
ssent Value Factor 
ssent Value Amount 
mutative Present Value 
2/27/98 | 8/31/98 
$107.198 $295.765 
8/31/99 
$382.958 
8/31/00 
$415.417 
8/31/01 
_$447,736_ 
8/31/02 
$479,301 
8/31/03 
$509.451 
8/31/04 
$536,710 
8/31/05 
$562,456 
8/31/06 
$589.446 
8/31/07 
$617.750 
Terminal | 
$ 541.987 
16.45% 
3,294,251 
0.94 0.81 0.67 0.55 0.45 0.37 0.30 0.25 0.20 0.17 0.17 
278,908 311,346 276,978 244,689 214,817 187,254 161,785 138,969 119,438 102,655 547,424 
2,584,265 
> 
o 
-4 
Schedule K 
ZJnetles Medcal Inc 
Projected Income Statement 
AsPartofSynedlcs 
Fiscal Year 
Endng 
31»Auo-98 
Rscal Year 
Ending 
31-Aup-99 
Rscal Year 
Ending 
31-Auo-OO 
Fiscal Year 
31-Aup>01 
Rscal Year 
Ending 
31-Aug-02 
Rscal Year 
Ending 
31-AQQ-03 
Rscal Year 
Ending 
31-Auo>04 
Fiscal Year 
Ending 
31-AW-05 
Rscal Year 
Ending 
31-Aufr06 
Rscal Year 
Ending 
31-AucM>7 
$2,846,854 10000% $ 3.131,539 100 00% $ 3,413,376 100 00% $ 3.666.448 100 00% $ 3.944,499 100 00% $ 4,181.169 100 00% $ 4,411,134 10000% $4,653,746 100 00% $4,909,702 100 00% $5,179,738 10000% $5,484,821 100.00% 
1.048.233 38 82% 1.243.221 3970% 1,355,111 3970% 1.463,520 39 70% 1,565.966 39 70% 1.659.924 39 70% 1.751,220 39 70% 1.847,537 3970% 1.949.152 39 70% 2,058.355 3970% 2.189,435 31.70% 
P r e * 1,798.621 6318% 
lG«narat.&Adrrinfstrtt!v» 1.291,452 4538% 
cMtonandAnorfeafton 80.000 2 .11% 
Bng Income 
1,888.316 60 30% 2.058,267 6030% 2,222.926 60 30% 2.378,533 60 30% 2.521,245 6030% 2,659.914 6030% 2 806 209 60 30% 2.960,550 60 30% 3.123,381 6030% 3.293.166 60.30% 
1,363.150 4353% 1.485,843 4353% 1.604.711 43 53% 1,717,041 43 53% 1.820.063 4353% 1.920.168 43 53% 2 025 776 43 53% 2.137.193 43 53% 2,254,739 4353% 2,378,750 4 3 3 3 % 
70,345 2 3 5 % 60,357 2.35% 90,358 1 4 5 % 100.358 2 54% 110,358 2 64% 120,358 2 7 3 % 130.358 2 80% 140.358 2 68% 150.358 2,90% 180.35a 2 * 3 % 
447.169 15 7 1 % 454.814 14 52% 492,066 1442% 527,860 14.32% 561,135 14 23% 590.624 1413% 619.389 14 04% 650 076 13 97% 682 999 13 9 1 % 718.264 13 87% 758.059 13.84% 
•rest Expense 
>d Debt Expense 
M M income (Expense) 
te before Exbe.oftfnery Rem 
sroneiy Bern 
to vOTOfo income Taxes 
w Texts 
49.434 
( M 8 7 ) 
(2.6811 
42.266 
489.435 
14.400 
503.835 
(263.838) 
96,079 
$ 407.756 
1.74% 
- 0 1 8 % 
-009% 
1.48% 
17.19% 
0 5 1 % 
17 70% 
- 9 2 6 % 
3 37% 
14.32% $ 
41.64947 
(10.114 87) 
(3.131.54) 
26.40306 
483,217 
14.400 
497.617 
(263.836) 
93,592 
404.025 
133% 
-032% 
•010% 
0 9 1 % 
1543% 
0 4 6 % 
15 89% 
•8 42% 
2 9 9 % 
1290% $ 
45.39792 
(11,02521) 
(3.41338) 
30,959.34 
523,026 
14.400 
537,426 
(263,636) 
109,515 
427.911 
1.33% 
-032% 
-010% 
0.91% 
1532% 
0 4 2 % 
1574% 
-7.72% 
3 2 1 % 
1254% $ 
49,029 78 
(11.907 23) 
(3.686 45) 
33.43606 
561,296 
14,400 
575696 
(263.638) 
124,623 
450.873 
133% 
-032% 
-010% 
0 9 1 % 
15 23% 
0 3 9 % 
15 62% 
-7.15% 
3 39% 
12 23% $ 
52.461 84 
(12,740 73) 
(3.944 50) 
35.776 61 
596.912 
14.400 
811,312 
(263,836) 
139.069 
472.242 
133% 
-0 32% 
-010% 
0 9 1 % 
1513% 
0 37% 
15 50% 
-8 68% 
3 53% 
1197% $ 
55,609 55 
(13.505 18) 
(4.181 17) 
37,92321 
628.748 
14.400 
643.148 
(263.638) 
151.604 
491.344 
1.33% 
-0 32% 
-010% 
0 9 1 % 
15 04% 
0.34% 
1538% 
-8 3 1 % 
3 63% 
1175% $ 
56,86808 
(14,247 96) 
(4.41113) 
40,00896 
659,396 
14,400 
673.798 
(263.638) 
164.064 
509.734 
133% 
-0 32% 
-010% 
0 9 1 % 
14 95% 
0 3 3 % 
1527% 
-5 96% 
3 7 2 % 
1156% 
61,694 82 
(15.031 60) 
(4.653 75) 
42.209 46 
692,285 
14.400 
706.685 
(263,638) 
177.219 
$ 529.466 
133% 
-0 32% 
-010% 
0 9 1 % 
14 66% 
0 3 1 % 
1519% 
-5 67% 
3 8 1 % 
1138% 
65,299 04 
(15858 34) 
(4.909 70) 
44,531 00 
727,530 
14.400 
741.930 
(263.636) 
191.317 
$ 550.613 
1 3 3 % 
-0 32% 
- 0 1 0 % 
0 9 1 % 
14 62% 
0 2 9 % 
1 5 1 1 % 
-5 37% 
3 9 0 % 
1 1 2 1 % 
86.690 48 
(18.730 55) 
(3.179 74) 
46.98020 
765.264 
14.400 
779.664 
(263.638) 
206.410 
$ 573.254 
1,33% 
-032% 
-010% 
0 9 1 % 
^ 4 77% 
0.28% 
1505% 
-509% 
3 9 8 % 
j j07% 
72,67946 
(17.85073) 
(5.46482) 
49.564.11 
805,823 
14.400 
620.023 
328.009 
$ 492.014 
1.33% 
-0.32% 
-0,10% 
0 .91% 
14.74% 
0 3 6 % 
15.01% 
0 0 0 % 
6.00% 
9 0 0 % 
00 
Schedule L 
Zlnetlcs Medical Inc. 
Projected Cash Flow Statement 
As of the Periods Stated 
As a Part of Synectlcs 
sted Net Income After Taxes 
Depreciation and Amortization 
c Additions to Working Capital 
c Additions to Depreciable Assets 
Additions to Long-Term Debt 
il Cash Flow 
August 31 , 
1998 
$ 407.756 
60,000 
(17.824) 
(50,000) 
3.031 
$ 402.963 
August 31, 
1999 
$ 404.025 
70.345 
(40.995) 
(51,726) 
1,308 
$ 382.958 
August 31, 
2000 
* 427.911 
80,357 
(40.585) 
(53,512) 
1,247 
$ 415,417 
i 
% 
$ 
August 31, 
2001 
450.873 
90,358 
(39.322) 
(55.360) 
1.188 
447.736 
August 31, 
2002 
$ 472.242 
100.358 
(37.159) 
(57,272) 
1,132 
$ 479,301 
i 
% 
$ 
August 31 , 
2003 
491,344 
110.358 
(34.080) 
(59.249) 
1.079 
509.451 
August 31, 
2004 
$ 509.734 
120.358 
(33.115) 
(61,295) 
1.028 
$ 536.710 
August 31, 
2005 
$ 529.466 
130,358 
(34,936) 
(63,411) 
979 
$ 562.456 
August 31 , 
2006 
% 550,613 
140,358 
(36,858) 
(65.601) 
933 
$ 589,446 
August 3 1 , 
2007 
$ 573,254 
150,358 
(38,885) 
(67,866) 
889 
$ 617.750 
$ 
$ 
Terminal 
492,014 
160,358 
(41,024) 
(70,209) 
847 
541,987 
> 
Schedule M 
Zinetics Medical Inc. 
Comparative Valuation Ratios 
As a Part of Synectics 
Company Ticker 
United States Surgical 
Arrow International 
ZOLL Medical Corp. 
St. Jude Medical 
Maxxim Medical 
C.R. Bard Inc. 
Abbott Laboratories 
Baxter International 
USS 
ARRO 
ZOLL 
STJ 
MAM 
BCR 
ABT 
BAX 
Price/Earnings Price/Cash Flow Market Cap/Revenue 
23.64 15.02 1.90 
18.73 19.58 2.80 
8.04 0.77 
52.79 2.82 
15.44 4.01 0.38 
24.60 18.06 1.47 
23.94 19.07 4.22 
47.08 22.93 2.30 
Average 32.22 16.51 2.08 
Median 
Adjusted Median 
Zinetics at 8/31/97 
Minority/Marketable Value 
$ 
$ 
23.94 
13.71 
480,508 
6,589,007 
$ 
$ 
18.06 
10.34 
358,177 
3,704,311 
$ 
$ 
2.10 
1.20 
2,475.568 
2,976,931 
Schedule N 
Zinetics Medical Inc. 
Price Indices 
1 
Year 
1988 
1989 
1990 
1991 
1992 
1993 
1994 
1995 
1996 
1997 
Consumer Price Index 
1988-1997 
Index 
118.3 
124.0 
130.7 
136.2 
140.3 
144.5 
148.2 
152.4 
156.9 
160.5 
Average 
Annual 
Growth 
4.82% 
5.40% 
4.21% 
3.01% 
2.99% 
2.56% 
2.83% 
2.95% 
2.29% 
Average Compounded Growth Rate 
3.45% 
Medical Commodities Price Index 
1988-1997 
Average 
Annual 
Year Index Growth 
1988 
1989 
1990 
1991 
1992 
1993 
1994 
1995 
1996 
1997 
139.9 
150.8 
163.4 
176.8 
188.1 
195.0 
200.7 
204.5 
210.4 
215.3 
7.79% 
8.36% 
8.20% 
6.39% 
3.67% 
2.92% 
1.89% 
2.89% 
2.33% 
Average Compounded Growth Rate 
4j4%_ 
Sources: 
Statistical Abstract of the U.S., 1998 and 1994 
Federal Reserve Bulletin, March 1998 
ADD 41 
Schedule O 
Zinetics Medical Inc. 
Calculation of Marketability Discount 
Marketability Discount 
Study 
SEC, Overall Average 
SEC, Nonreporting OTC Companies 
SEC, Institutional Investor Study 
Milton Gelman 
Management Planning Study 
Robert Trout 
Robert Moroney 
Michael Maher 
Hall/Polacek Study 
Standard Research Associated, Inc. 
Silber Study 
Willamette Management Associates, Inc. 
Average Marketability Discount 
Average 
Discount 
25.80% 
32.60% 
26.00% 
33.00% 
28.00% 
33.50% 
35.60% 
35.40% 
23.00% 
45.00% 
34.00% 
31.20% 
31.93% 
Control Premium 
Study 
G. Roach Studies, 1992 
G. Roach Studies, 1993 
G. Roach Studies, 1994 
G. Roach Studies, 1995 
G. Roach Studies, 1996 
G. Roach Studies, 1997 
Mergerstat Study, 1992 
Mergerstat Study, 1993 
Mergerstat Study, 1994 
Mergerstat Study, 1995 
Mergerstat Study, 1996 
Houlihan, Lokey, Howard & Zukin, Q3 1997 Study 
Average 
Premium 
32.30% 
36.10% 
33.50% 
39.20% 
31.10% 
37.80% 
41.30% 
38.70% 
40.70% 
44.10% 
36.90% 
30.00% 
Average Control Premuim 36.81% 
Schedule P 
Zinetics Medical Inc. 
Summary of Stock Trades 
Date 
12/18/96 
10/13/97 
10/15/97 
10/30/97 
11/3/97 
11/6/97 
11/10/97 
12/12/97 
1/7/98 
1/8/98 
2/10/98 
2/12/98 
Volume 
5,000 
79,400 
5,000 
39,700 
325,900 
325,900 
35,000 
55,000 
5,000 
5,000 
20,000 
4,000 
High/Ask 
$ 0.02 
0.12 
0.09 
0.13 
0.14 
0.14 
0.10 
0.10 
0.13 
0.13 
0.15 
0.18 
Low/Bid 
$ 0.02 
0.09 
0.13 
0.14 
0.14 
0.10 
0.09 
0.13 
0.13 
0.15 
0.18 
Close 
$ 0.02 
0.12 
0.09 
0.13 
0.14 
0.14 
0.10 
0.09 
0.13 
0.13 
0.15 
0.18 
as % of 
Out. Shares 
0.0039% 
0.0616% 
0.0039% 
0.0308% 
0.2530% 
0.2530% 
0.0272% 
0.0427% 
0.0039% 
0.0039% 
0.0155% 
0.0031% 
Source: America Online 
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Schedule Q 
Zinetics Medical, Inc. 
Size Discount Calculation 
For Comparative Company Ratios 
PSIC 
2834 
3841 
3841 
3845 
3841 
3841 
3842 
3845 
Company 
Abbott Laboratories 
Baxter International 
United States Surgical 
St. Jude Medical 
C.R. Bard Inc. 
Arrow International 
Maxxim Medical 
ZOLL Medical Corp. 
Market Value-$150 MM 
Market Value-$100 MM 
Market Value - $50 MM 
Ticker 
ABT 
BAX 
USS 
STJ 
BCR 
ARRO 
MAM 
ZOLL 
Supplies 
1.49 
1.22 
0.86 
Market 
Value (Mm 
$50,144,063 
14,122,500 
2,224,819 
2,802,950 
1,778,550 
687,300 
199,138 
43,400 
Average 
Equipment 
1.30 
1.29 
1.02 
Comparable 
Inverted Cum. 
Weighted Ave. 
Supplies 
Industry 
MC/Rev Ratio 
3.19 
.3.19 
2.01 
2.31 
1.90 
2.17 
1.49 
0.78 
2.13 
Discount 
30.05% 
| 42.72% | 
59.62% 
Comparable 
Inverted Cum. 
Weighted Ave. 
Equipment 
Industry 
MC/Rev Ratio 
4.48 
4.48 
1.95 
2.21 
1.95 
1.49 
1.62 
0.93 
2.39 
Discount 
45.58% 
46.00% 
57.30% 
ADD 44 
Schedule R 
Zinetics Medical Inc. 
Capitalization of Adjusted Net Income After Taxes 
As a Separate Entity Using Steve Davis1 Projections 
Year 
Adjusted Constant 
Earnings $ Index 
Constant Weight 
$ Earnings Factor 
Value per 
Weighted Share 
Earnings (23,565,251) 
8/31/98 $ 230,843 100.00% $ 230,843 1 $ 230,843 
Total 1 $ 230,843 
Total Weighting Factors 
Weighted Average Net Income 
Divide by: Capitalization Rate (See Schedule Y) 
Minority/Marketable Operating Value of Company 
Excess Cash 
Minority/Marketable Value 
Minority/Non-marketable Value 
Control/Marketable Value 
Control/Non-Marketable Value 
1 
230,843 
21.95% 
$ 1,051,787 
$ 1,051,787 $ 0.0446 
$ 
$ 
$ 
716,004 
1,438,932 
979,553 
$ 
$ 
$ 
0.0304 
0.0611 
JL-S516-
ADD 45 
Schedule S 
Zinetics Medical Inc. 
Discounted Net Earnings 
As a Separate Entity Using Steve Davis1 Projections 
> 
ON 
Net Profit (Loss) 
NOL Carryforward 
Combined Effective Tax Rate 
Net Income After Taxes 
Capitalization Rate 
Terminal Value 
Present Value Factor 
Present Value Amount 
Minority/Marketable Value 
Minority/Non-marketable Value 
Control/Marketable Value 
Control/Non-Marketable Value 
Projected 
| 8/30/98 8/30/99 8/30/00 8/30/01 8/30/02 
$ 230,843 $ 535,506 $ 642,339 $ 771,420 $ 925,704 
Terminal | 
$ 1,110,845 
(131,819) 
40.00% 
191,233 
0.94 
(263,638) 
40.00% 
426,759 
0.79 
(263,638) 
40.00% 
490,859 
0.63 
(263,638) 
40.00% 
568,307 
0.51 
(263.638) 
40.00% 
660,878 
0.41 
(263,638) 
40.00% 
771,962 
21.95% 
3,517,280 
0.41 
179,043 338,272 311,430 288,432 268,475 1,428,858 
$ 
$ 
$ 
$ 
2,814,510 
1,915,978 
3,850,485 
2,621,218 
$ 
$ 
$ 
$ 
0.1194 
0.0813 
0.1634 
0.1112 
Schedule T 
Zinetics Medical Inc. 
Summary of Fair Market Value as of February 12,1998 
As a Separate Entity 
Schedule Value 
Income Approach to Value 
Discounted Cash Flows 
Discounted Earnings 
Value 
per Share Weight 
Indicated Value on a Minority/Marketable Basis (100% of Stock) 
Excess Cash 
Minority/Marketable Value 
Minority/Non-marketable Value 
Control/Marketable Value 
Control/Non-Marketable Value 
100% 
Value per 
Weighted Share 
Value (23,565,251) 
X $ 418,732 $ 0.0178 50.0% 
W 134,313 0.0057 50.0% 100% $ 276,522 
$ 276,522 
$ 276,522 $ 0.0117 
$ 188,243 $ 0.0080 
_$ 378,306 $ 0.0161 
$ 257,532 $ 0.0109 
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Schedule U 
Zlnetlcs Medical Inc. 
Projected Income Statement 
As a Separate Entity 
rvenue 
art of Good* Sold 
t>M Profit 
fling. General. & Administrative 
•prectatton and Amortization 
Derating Income 
!hef Income 
Interest Income 
Interest Expense 
Bed Debt Expense 
>tit Other Income (Expense) 
come before Extraordinary Item 
rtraordlnaiy Item 
come before Income Taxes 
CX. Carryforward 
come Taxes 
et Income 
ssumptioris 
Owwnfc 
iMenaaK C^M^rf am •"?• 
•v ^ •••Jrt, 7 * 1 * WWeMHIsW» etlflsmWH eat 
4*4%. 
Fiscal Year 
Ending 
31-Auo-98 
$ 2.848,854 
1.048,233 
1.798,621 
1,291,452 
80,000 
447,169 
49,434 
(141,921) 
(Z681) 
(95,169) 
352,000 
14,400 
366,400 
(263,638) 
41,105 
$ 325,295 
w^wrttwM «T SI Jl% «t 
4 A tntvtt*i9. 
(7S J t% Wrwncxfr 
% 
100.00% 
36.82% 
63.18% 
45.36% 
2,11% 
15.71% 
1.74% 
-4.99% 
•0.09% 
-3.34% 
12.36% 
0.51% 
12.87% 
-9.26% 
1.44% 
11.43% 
Fiscal Year 
Ending 
31-Aug-99 
$ 3,169,696 
1,144,369 
2,025,327 
1,351,339 
62,069 
611,919 
29,633 
(313,409) 
(3,170) 
(286,945) 
324,974 
14,400 
339,374 
(263,638) 
30,294 
% 
100.00% 
36.10% 
63.90% 
42.63% 
1.96% 
19.31% 
0.93% 
-9.89% 
-0.10% 
-9.05% 
10.25% 
0.45% 
10.71% 
-8.32% 
0.96% 
$ 309.080 9.75% 
to^pnv M M K (445 w*») 
Fiscal Year 
Ending 
31-Aufl-00 
$ 2,626,136 
1,143,252 
1,482,884 
1,322,886 
64,210 
95,788 
24,552 
(310,916) 
(2.626) 
(288,990) 
(193,202) 
14,400 
(178,802) 
(263,638) 
* 
$ (178.802) 
mfrddwfOtA 
VeTBOM t W * CeWleKsJ 
% 
100.00% 
43.53% 
56.47% 
50.37% 
2.45% 
3.65% 
0.93% 
-11.84% 
-0.10% 
-11.00% 
-7.36% 
0.55% 
-6.81% 
-10.04% 
0.00% 
-6.81% 
wffotti of 9yn+c«Cat ttl#9 
Fiscal Year 
Ending 
31*Aug-01 
$ 2,793,694 
1,205,249 
1,588,445 
1,458,058 
66,424 
63,964 
26,118 
(311.684) 
(2.794) 
(288,360) 
(224,396) 
14,400 
(209,996) 
(263,638) 
-
$ (209.996) 
Wbdd«dR&0 
% 
100.00% 
43.14% 
56.86% 
52.19% 
2.38% 
2.29% 
0.93% 
-11.16% 
-0.10% 
-10.32% 
-8.03% 
0.52% 
-7.52% 
-9.44% 
0.00% 
-7.52% 
Fiscal Year 
Ending 
31-Aug-02 
$2,971,943 
1.271,201 
1,700,742 
1.525,792 
68,715 
106,235 
27,785 
(312,502) 
(2.972) 
(287,689) 
(181,454) 
14,400 
(167.054) 
(263,638) 
-
$ (167.054) 
% 
100.00% 
42.77% 
57.23% 
51.34% 
2.31% 
3.57% 
0.93% 
-10.52% 
-0.10% 
-9.68% 
-6.11% 
0.48% 
-5.62% 
-8.87% 
0.00% 
-5.62% 
Fiscal Year 
Ending 
31-Aug-03 
$3,161,564 
1,341,361 
1,820,204 
1,597,849 
71,085 
151,270 
29,557 
(313,372) 
(3.162) 
(286,976) 
(135,705) 
14,400 
(121,305) 
(263,638) 
-
* (121.305) 
% 
100.00% 
42.43% 
57.57% 
50.54% 
2.25% 
4.78% 
0.93% 
-9.91% 
-0.10% 
-9.08% 
-4.29% 
0.46% 
-3.84% 
-8.34% 
0.00% 
-3.84% 
Fiscal Year 
Ending 
31-Aug-04 
$3,363,285 
1,415,997 
1,947,287 
1,674,502 
73,537 
199,249 
31,443 
(314,297) 
(3.363) 
(286,217) 
(86.968) 
14,400 
(72,568) 
(263.638) 
-
$ (72.568) 
% 
100.00% 
42.10% 
57.90% 
49.79% 
2.19% 
5.92% 
0.93% 
-9.34% 
-0.10% 
-8.51% 
-2.59% 
0.43% 
-2.16% 
-7.84% 
0.00% 
-2.16% 
Fiscal Year 
Ending 
31-Aug-05 
$3,577,875 
1,495,396 
2,082,480 
1,756,047 
76.073 
250,360 
33,450 
(315.281) 
(3.578) 
(285,410) 
(35.050) 
14,400 
(20,650) 
(263.638) 
-
* f 2 0 , 6 5 0 ) 
% 
100.00% 
41.80% 
58.20% 
49.08% 
2.13% 
7.00% 
0.93% 
-8.81% 
-0.10% 
-7.98% 
-0.98% 
0.40% 
-0.58% 
-7.37% 
0.00% 
-0.58% 
Fiscal Year 
Ending 
31-Aug-06 
$ 3.806,158 
1.579,860 
2,226,298 
1,842,794 
78,697 
304,806 
35,584 
(316,328) 
(3.8061 
(284,551) 
20.256 
14,400 
34,656 
(263,638) 
-
$ 34.656 
% 
100.00% 
41.51% 
58.49% 
46.42% 
2.07% 
6.01% 
0.93% 
- * 3 1 % 
•0.10% 
-7.48% 
0.53% 
0.38% 
0.91% 
-6.93% 
0.00% 
0.91% 
00 
Schedule U 
Zlnetlcs Medical Inc. 
Projected Income Statement Continued 
As a Separatre Entity 
Revenue 
Cost of Goods Sold 
Gross Profit 
Selling, General. & Administrative 
Depredation and Amortization 
Operating Income 
Other Income 
Interest Income 
Interest Expense 
Bad Debt Expense 
Total Other Income (Expense) 
Income before Extraordinary Item 
Extraordinary Item 
Income before Income Taxes 
NOL Carryforward 
Income Taxes 
Net Income 
Assumptions 
Zlndki pletfrup SOHefMNtotejf 
4 M X . 
Fiscal Year 
Ending 
31-Aug-07 
$ 4,049,006 
1.669,714 
2,379,292 
1.935,076 
81.412 
362,804 
37,854 
(317.442) 
(4.049) 
(283.637) 
79,167 
14,400 
93,567 
(263.638) 
* 
$ 93,567 
% 
100.00% 
41.24% 
68.76% 
47.79% 
2.01% 
8.96% 
0.93% 
-7.84% 
-0.10% 
-7.01% 
1.96% 
0.36% 
2.31% 
-6.51% 
0.00% 
2.31% 
Fiscal Year 
Ending 
31-Auq-08 
$ 4,307.349 
1.765,301 
2,542.048 
2,033,247 
84,220 
424,581 
40,269 
(318,627) 
(4.307) 
(282,665) 
141,916 
14,400 
156,316 
(156,316) 
• 
$ 156.316 
% 
100.00% 
40.98% 
59.02% 
47.20% 
1.96% 
9.86% 
0.93% 
-7.40% 
-0.10% 
-6.56% 
3.29% 
0.33% 
3.63% 
-3.63% 
0.00% 
3.63% 
WvOtt of hhtoncM NOL 
Fiscal Year 
Ending 
31-Aug-09 
$ 4,582,175 
1,866.986 
2,715.188 
2,137,681 
87.125 
490,382 
42.839 
(319.888) 
(4.582) 
(281,631) 
208,751 
14,400 
223,151 
(223,151) 
* 
$ 223.151 
% 
100.00% 
40.74% 
59.26% 
46.65% 
1.90% 
10.70% 
0.93% 
-6.98% 
-0.10% 
-6.15% 
4.56% 
0.31% 
4.87% 
-4.87% 
0.00% 
4.87% 
Fiscal Year 
Ending 
31-Aug-10 
$ 4,874.536 
1.975.160 
2.899.376 
2,248,778 
90,131 
660,467 
45,572 
(321,229) 
(4.875) 
(280,532) 
279,935 
14.400 
294.335 
(294,335) 
-
$ 294.335 
% 
100.00% 
40.52% 
59.48% 
46.13% 
1.85% 
11.50% 
0.93% 
-6.59% 
-0.10% 
-5.76% 
5.74% 
0.30% 
6.04% 
-6.04% 
0.00% 
6.04% 
Fiscal Year 
Ending 
31-Aug-11 
$ 5,185,550 
2,090,235 
3.095,315 
2,366.963 
93,240 
635,111 
48,480 
(322.656) 
(5.186) 
(279,362) 
355,750 
14,400 
370,150 
(96,573) 
109,431 
$ 260.719 
% 
100.00% 
40.31% 
59.69% 
45.65% 
1.80% 
12.25% 
0.93% 
-6.22% 
-0.10% 
-5.39% 
6.86% 
0.28% 
7.14% 
-1.86% 
2.11% 
5.03% 
Terminal 
$5,516,409 
2.212.653 
3,303.756 
2,492,690 
96,350 
714,716 
51,573 
(324,173) 
(5.516) 
(278,117) 
436,600 
14,400 
451,000 
180,400 
$ 270.600 
% 
100.00% 
40.11% 
59.89% 
45.19% 
1.75% 
12.96% 
0.93% 
-5.88% 
-0.10% 
-5.04% 
7.91% 
0.26% 
6.18% 
0.00% 
3.27% 
4.91% 
Schedule V 
Zinetics Medical Inc. 
Discounted Earnings 
As a Separate Entity 
Net Profit (Loss) 
Capitalization Rate 
Terminal Value 
Present Value Factor 
Present Value Amount 
Cumulative Present Value 
2/27/98 1 
$214.997 
I 8/31/98 
$ 110.298 
Projected 
8/31/99 8/31/00 8/31/01 8/31/02 8/31/03 8/31/04 8/31/05 8/31/06 8/31/07 8/31/08 
$309.080 $(178.802) $(209.996) $(167.054) $(121.305) $ (72.568) $(20.650) $34.656 $93.567 $156.316 
8/31/09 
$223.151 
8/31/10 
$294.335 
8/31/11 
$260.719 
Terminal | 
$ 270.600 
22.45S 
1.205.210 
0.93 0.77 0.60 0.47 0.37 0.29 0.23 0.18 0.14 0.11 0.08 0.07 0.05 0.04 0.04 
102.545 239,004 (108,076) (99,152) (61,656) (34.996) (16.365) (3,638) 4.772 10,071 13.151 14,666 15/121 1^469 48,396 
$ 134.313 
Schedule W 
Zinetics Medical Inc. 
Discounted Cash Flows 
As a Separate Entity 
2/27/98 
Projected 
8/31/98 8/31/99 8/31/00 8/31/01 8/31/02 8/31/03 8/31/04 8/31/05 8/31/06 8/31/07 8/31/08 8/31/09 8/31/10 8/31/11 Terminal I 
ash Flow 
titration Rate 
rral Value 
nt Value Factor 
nt Value Amount 
ilatlve Present Value 
$107,198 $ 242.273 $306.038 $ (551.584) $(187,630) $(144.625) $ (98.856) $ (50.146) $ 1.694 $56.864 $115.577 $178.059 $244.553 $315.316 $281.188 $290.355 
19.45% 
1.492.635 
0.94 0.79 0.63 0.51 0.41 0.33 0.26 0.21 0.17 0.13 0.11 0.09 0.07 0.05 0.05 
226,829 242.582 (35,266) (95.228) (58,752) (32.144) (13.051) 
$ 418,732" 
353 9,476 15.417 19,011 20,887 21,556 15,387 81.677 
Schedule X 
Zinetics Medical Inc. 
Projected Cash Flow Statement 
As of the Periods Stated 
As a Separate Entity 
sted Net Income After Taxes 
Depreciation and Amortization 
: Additions to Working Capital 
: Additions to Depreciable Assets 
: Additions to Long-Term Debt 
August 31, August 31, August 31, August 31. August 31, August 31, August 31, August 31, August 31, August 31, August 31, August 31, August 31, August 31 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Terminal 
$325,295 $309,080 $(178,802) $(209,996) $(167,054) $(121,305) $ (72.568) $(20,650) $ 34,656 $ 93,567 $156,316 $223,151 $294,335 $260,719 $270,600 
60,000 62,069 64.210 66,424 68,715 71,085 73,537 76,073 78,697 81.412 84.220 87.125 90.131 93,240 96.350 
(17.824) (46,489) 78,273 (24.128) (25.668) (27.306) (29.048) (30,901) (32.873) (34.970) (37,201) (39.575) (42.100) (44.786) (47.644) 
(20.000) (20.691) (21,405) (22,144) (22.909) (23.700) (24,518) (25.364) (26.240) (27.146) (28.084) (29.053) (30,056) (31.094) (32,168) 
2,000 2.069 2,140 2,214 2.291 2.370 2,452 2,536 2,624 2.715 2.808 2.905 3,006 3,109 3,217 
it Cash Row $349.471 $306.038 $ (55.584) $(187.630) $(144,625) $ (98.856) $ (50.146) $ 1.694 $ 56.864 $115.577 $178.059 $244,553 $315.316 $281,188 $290,355 
Schedule Y 
Zinetics Medical Inc. 
Calculation of Capitalization and Discount Rate 
As a Separate Entity 
Capitalization Rate 
Risk-free Rate 
Average Equity Risk Premium 
Average Small Stock Risk Premium 
Micro-Cap Size Premium 
Industry Risk Premium 
Zinetics Medical Specific Risk Premium 
Composite Cash Flow Discount Rate 
Additional Increment for Earnings Discount Rate 
Net Earnings/Cash Flow Discount Rate 
Less: Expected Earnings Growth Rate 
Net Income Capitalization Rate 
Adjustment for Current Year Net Income/Net Cash Flow Capitalization Rate 
Current Year Net Income/Net Cash Flow Capitalization Rate 
Related Industry Beta Factors 
Company 
United States Surgical 
Arrow International 
ZOLL Medical Corp. 
St. Jude Medical 
Maxxim Medical 
C.R. Bard Inc. 
Abbott Laboratories 
Baxter International 
Average 
For 
Earnings 
5.37% 
7.40% 
4.70% 
4.13% 
-0.65% A 
4.00% 
24.95% 
3.00% 
27.95% 
5.50% 
22.45% 
102.30% 
21.95% 
For 
Cash Flow 
5.37% 
7.40% 
4.70% 
4.13% 
-0.65% 
4.00% 
24.95% 
0.00% 
24.95% 
5.50% 
19.45% 
102.30% 
___1_9.02%_ 
Beta 
1.00 
0.80 
1.00 
0.70 
0.90 
1.10 
0.80 
1.00 
0.91 
Industry Risk Premium 
Beta Adjusted Premium for Equity Risk (Beta x Premium for Equity Risk) 
Less: Premium for Equity Risk 
Industry Risk Premium 
6.75% 
7.40% 
-0.65% A 
ADD 53 
Schedule A 
Income Approach to Value 
Discounted Cash Flows 
Capitalized Cash Flow 
Discounted Earnings 
Capitalized Earnings 
Market Approach to Value 
Price/Earnings 
Market Cap/Revenue 
Price/Cash Flow 
Zinetics Medical Inc. 
Summary of Fair Market Value as of February 12,1998 
As a Part of Synectics 
Schedule 
J 
G 
1 
F 
M 
M 
M 
Value 
$2,584,265 
2,438,392 
2,170,219 
2,300,992 
6,589,007 
2,976,931 
3,704,311 
Value 
per Share 
$0.0201 
0.0189 
0.0168 
0.0179 
0.0512 
0.0231 
0.0288 
Weight 
30.0% 
5.0% 
30.0% 
5.0% 
15.0% 
10.0% 
5.0% 
70.0% 
30.0% 
Value per 
Weighted Share 
Value (128,806,800) 
$1,663,314 
1,471,260 
Indicated Value on a Minority/Marketable Basis (100% of Stock) 
Excess Cash 
Minority/Marketable Value 
Minority/Non-marketable Value 
Control/Marketable Value 
Control/Non-Marketable Value 
100% $3,134,574 
600,000 
$3,734,574 
$2,542,311 
^5,109,208 
$ 
$ 
$ 
$ 
0.0243 
0.0290 
0.0197 
0.0397 
$3,478,094 $ 0.0270 
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Tab 3 
American Biomed Inc. 
(ABMI) 
IT) 
IT) 
o 
Development Stage 
Company 
Products designed for 
interventional 
cardiology and 
minimally invasive 
surgery 
Not yet received FDA 
Approval on its 
products 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
1996 Net Income 
Dollars 
$0.6 MM 
(2.6 MM) 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
• 1996 Net Income 
% of Sales 
100.00% 
-433.33% 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 21.62 and 5yrAve. 17.52. 
u 
Angeion Corporation 
(ANGND) 
Products treat 
irregular heartbeats. 
Products are patent 
protected and 
regularly enforced. 
45% of company is 
owned by Synthelabo 
which also distributes 
the products. 
• 1998 Revenue 
• 1998 Gross Profit 
• 1998 Oper. Inc. 
• 1998 Net Income 
• 1998 Revenue 
• 1998 Gross Profit 
• 1998 Oper. Inc. 
• 1998 Net Income 
Dollars 
$4.6 MM 
(7.8 MM) 
(36.6 MM) 
(38.8 MM) 
% of Sales 
100.00% 
-169.56% 
-795.65% 
-843.47% 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 31.33 and 5yrAve. 63.85. 
CardioGenesis Corp 
(Sub. of Eclipse Surgical) 
Maker of proprietary 
systems to treat angina 
patients. 
Technology used is 
very high tech. 
Used in minimally 
invasive surgery. 
Currently conducting 
clinical trials. 
1996 Revenue 
1996 Gross Profit 
1996 Oper. Inc. 
1996 Net Income 
Dollars 
$4.0 MM 
1.1 MM 
(11.1 MM) 
(8.8 MM) 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 13.69 and 5yrAve. 42.54. 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
1996 Net Income 
% of Sales 
100.00% 
27.50% 
-277.50% 
-220.00% 
to 
Cardiovascular Dynamics 
(Currently RADX) 
Develops and markets 
catheters used to treat 
certain vascular diseases. 
Uses proprietary 
technology in the 
development of its 
products. 
Products solve three 
principal challenges faced 
by cardiologists. 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
• 1996 Net Income 
Dollars 
$8.5 MM 
(4.6 MM) 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
• 1996 Net Income 
% of Sales 
100.00% 
-54.11% 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 4.18 and 5yrAve. 8.99. 
0< 
V 
P 
P 
< 
Q 
Electro-Catheter Corp. § 
(ECTH) 
• Makes catheters and 
other products used to 
diagnose and treat 
heart and circulatory 
system disorders. 
• Products focus on 
electrophysiology. 
• Currently seeking a 
merger alliance. 
Dollars 
• 1997 Revenue $6.6 MM 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
• 1997 Net Income (1.4 MM) 
1 % of Sales 
• 1997 Revenue 100.00% 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
• 1997 Net Income -21.21% 
• All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. .8 and 5yrAve. .69. 
Endosonics Corp. 
(ESON) 
Makes imaging 
catheters used in the 
treatment of blocked 
arteries. 
Products use digital 
technology to provide 
a 3-D representation 
of the artery to show 
exact location and size 
of blockage. 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
• 1996 Net Income 
Dollars 
$24.4 MM 
8.6 MM 
(7.1 MM) 
(7.2 MM) 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
• 1996 Net Income 
% of Sales 
100.00% 
35.25% 
-29.10% 
-29.50% 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 5.48 and 5yrAve. 9.73. 
Luther Medical Products 
(Not Currently Trading) 
V£> 
Develops soft intra-
vascular catheters and 
split, peel-away 
needles. 
Products are used for 
intravenous therapy. 
Uses approx. 21 
distributors to market 
its products. All Valuation Multiples produce negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 1.7 and 5yrAve. 2.02. 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
• 1997 Net Income 
Dollars 
$5.4 MM 
(0.7 MM) 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
• 1997 Net Income 
% of Sales 
100.00% 
-12.96% 
Med Amicus, Inc. 
(MEDM) 
Makes products aimed to 
monitor pressure in the 
cardiovascular and urinary 
systems. 
Uses fiberoptic 
technology to diagnose 
and treat incontinence and 
other diseases. 
Medtronic and C.R. Bard 
account for 55% of its 
sales. 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 1.61 and 5yrAve. 3.15. 
r 
c 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
1996 Net Income 
Dollars 
$5.7 MM 
2.2 MM 
(1.0 MM) 
(1.1 MM) 
• 1996 Revenue 
• 1996 Gross Profit 
• 1996 Oper. Inc. 
• 1996 Net Income 
% of Sales i 
100.00% 
38.60% 
-17.54% 
-19.30% 
• Maker of technically 
advanced suture-based 
closure devices which 
surgically repair 
catheterization sites. 
• Developed procedures for 
faster recovery from 
vascular treatment. 
• Currently under purchase 
negotiations with Abbott 
Laboratories. 
>se Inc. 
IRC) 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 44.01 and 5yrAve. 99.20. 
ft 
ft 
< 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
1 • 1997 Net Income 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
• 1997 Net Income 
Dollars 
$4.5 MM 
(0.2 MM) 
(11.2 MM) 
(9.7 MM) 
% of Sales 
100.00% 
-4.44% 
-248.88% 
-215.55% 
Possis Medical, Inc. 
(POSS) 
Makes catheter 
systems used to 
remove blood clots, 
and blood vessel 
grafts. 
Systems are minimally 
invasive. 
Some products are still 
in clinical trials. All Valuation Multiples produce negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 31.37 and 5yrAve. 37.91. 
Q 
< 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
1997 Net Income 
Dollars 
$4.8 MM 
(0.1 MM) 
(9.6 MM) 
(8.6 MM) 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
• 1997 Net Income 
% of Sales 
100.00% 
-2.08% 
-200.00% 
-179.16% 
Rochester Medical Corp. 
(ROCM) 
Develops products 
used in the 
management of 
urinary dysfunction. 
Proprietary catheter 
with antibacterial 
properties. 
Sells through 
distributors and 
private-label brands. 
All Valuation Multiples produce 
negative values except for MVIC/Rev, 
used by Willamette, which is 
Lastl2Mos. 10.36 and 5yrAve. 20.19. 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
1997 Net Income 
Dollars 
$7.6 MM 
2.7 MM 
(2.5 MM) 
(2.1 MM) 
• 1997 Revenue 
• 1997 Gross Profit 
• 1997 Oper. Inc. 
• 1997 Net Income 
% of Sales 
100.00% 
35.52% 
-32.89% 
-27.63% 
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MVIC/Rev. 
60.00 
'3-
V* 
S3 
Re
ve
nu
e 
PS 
M
VK
 
50.00 
40.00 
30.00 
20.00 
10.00 
0.00 
1992-3 1993-4 1994-5 1995-6 1996-7 LTM 
Revenue Period 
Revenue $000 
^ ^ ^ ^ 
H* *s> U> £ t 
r^s r^\ r^s rjgs rjjs \ F 7 \T^7 ^F7 VT7 \5r7 
Ol 0> -J 00 V© 
^ 
90 
*a 
© 
**• 
vFQ 
*d erio 
a 
vo 
vo 
1 
u> 
h * 
vo 
vo 
u> 
i 
£*> 
vo 
£ t 
1 
en 
H* 
SO 95
-
ON 
^ 
VO 
^O 
as 
i 
^i 
t* 
H 
<3 
a u
es 
* o o tr 
rt> ster 
S 
^••dk • 
o p 
^ _ 4 
a 
o 
Rochester Medical Inc. 
Relationship of MVIC/Rev. and Revenues 
00 
o 
o 
•< 
70 
60 
50 
40 
30 
20 
10 
0 
/ 
/ 
$9,000 
4- $8,000 
+ $7,000 
$6,0001 
$5,0001 
$4,000 | 
$3,0001 
$2,000 
$1,000 
$0 
1992-3 1993-4 1994-5 1995-6 1996-7 LTM 
Reporting Period MVIC/Rev. Revenue 
American Biomed Inc. 
Relationship of MVIC/Rev. and Revenues 
25 
20 + 
15 
10 + 
5 + 
$900 
$800 
$700 
$600 g 
o 
$500 *% 
3 
$400 § 
> 
$300 & 
$200 
$100 
$0 1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
ON 
G 
< 
MVIC/Rev. Revenue 
Angeion Corp. 
Relationship of MVIC/Rev. and Revenues 
800 
700 
v 600 
Q. 
1 500 
> 400 
O 300 
> 
2 200 
100 
0 
»>*•»—» + 
1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
$5,000 
$4,500 
| $4,000 
I $3,500
 0 
i $3,000 § 
+ $2,500 S 
+ $2,000 | 
+ $1,500 * 
| $1,000 
$500 
$0 
© 
Q 
O 
MVIC/Rev. Revenue 
CardioGenesis Corp. 
Relationship of MVIC/Rev. and Revenues 
C 
25 
20 + 
15 + 
10 + 
-+- h 
$7,000 
+ $6,000 
$5,000 
$4,000 <* o 
3 
$3,000 S 
a: 
+ $2,000 
$1,000 
$0 
1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
MVIC/Rev. Revenue 
Cardiovascular Dynamics 
Relationship of MVIC/Rev, and Revenues 
25 
20 + 
15 + 
10 + 
/ 
$14,000 
$12,000 
4- $10,000 
$8,000 <* o 
$6,000 | 
$4,000 
$2,000 
$0 
1992-3 1993-4 1994-5 1995-6 
Reporting Period 
1996-7 LTM 
MVIC/Rev. Revenue 
Electro-Catheter Corp. 
Relationship of MVIC/Rev. and Revenues 
0.9 $9,000 
$8,000 
$7,000 
| $6,000 
i $5,000 o 
+ $4,000 5 
+ $3,000 OH 
$2,000 
$1,000 
$0 
1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
MVIC/Rev. Revenue 
Endosonics Corp. 
Relationship of MVIC/Rev. to Revenues 
r-
O Q 
$35,000 
$30,000 
$25,000 
-f $20,000 <* 
Q) 
3 
$15,000 § 
a: 
+ $10,000 
+ $5,000 
$0 
1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
MVIC/Rev. Revenues 
Luther Medical Products 
Relationship of MVIC/Rev. and Revenues 
1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
$8,000 
+ $7,000 
| $6,000 
o 
$5,000 § 
$4,000 § 
c 
$3,000 > 
a: 
+ $2,000 
$1,000 
$0 
Q 
MVIC/Rev. Revenues 
MedAmicus Inc. 
Relationship of MVIC/Rev. and Revenues 
1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
$8,000 
$7,000 
$6,000 
o 
$5,000 § 
+ $4,000 § 
c 
+ $3,000 { 
$2,000 
+ $1,000 
$0 
V© 
r-
O 
< 
MVIC/Rev. Revenues 
Perclose Inc. 
Relationship of MVIC/Rev. and Revenues 
2,000 
1,800 
1,600 
1,400 
1,200 
1,000 
800 
600 
400 
200 
0 
/ 
s 
1992-3 1993-4 
-h-
1994-5 1995-6 
Reporting Period 
1996-7 LTM 
$7,000 
$6,000 
$5,000 
$4,000 «* 
3 
$3,000 | 
+ $2,000 
$1,000 
$0 
r* 
P 
C 
< 
MVIC/Rev. Revenue 
Possis Medical Inc. 
Relationship of MVIC/Rev. and Revenues 
P 
P 
120 
100 
80 
60 + 
40 
20 + 
$9,000 
$8,000 
+ $7,000 
| $6,000 § 
o 
+ $5,000 co 
o> 
+ $4,000 | 
> 
$3,000 ^ 
+ $2,000 
| $1,000 
$0 
1992-3 1993-4 1994-5 1995-6 1996-7 
Reporting Period 
LTM 
MVIC/Rev. Revenue 
Willamette Guideline Companies Median 
MVIC/Rev. 
1992-3 1993-4 1994-5 1995-6 1996-7 LTM 
Revenue Period 
Market Value to MC/Rev. 
SIC #3845 - Surgical, Medical, & Dental Instruments and Electromedical and 
Electrotherapeutic Apparatus (125 Companies) 
o 
00 
a 
a 
< 
4.50 
a 
U 
•a 
1.00 
0.50 
0 . 0 0 11111111111n11 M111111ii11111111111111)11111111111111n11111111ii111 ii1111 i imi nun M I N I inni nun H I I I I iiiiii nun 11 
^ ^ & 
r^s r ^ r^s r ^ r+\ rJ\ •* 
V J >3r7 sT7 \F7 V 7 ^T7 p ^ 
Market Value (Millions) 
— Cumulative Weighted Average MC/Rev. Cumulative Median MC/Rev. 
Market Value to MC/Rev. 
SIC #3841 -Surgical, Medical, & Dental Instruments and Surgical and Medical 
Instruments and Apparatus (80 Companies) 
00 
Q 
Q 
«M 
*9 <<* & 
t> 
V* 
OS 
& 
Os 
V> 
fS 
FN 
&> 
F-t 
M 
^ 
^ 
n 
^ 
if) 
is 
^ 
F-4 
f> 
^ 
TT 
f*> 
^ 
00 
f*> 
6« 
FN 
"<t 
^ 
f*> 
Tf 
^ 
"t 
V) 
^ 
FH 
^ V> 
Os 
VO 
«e 
<s 00 
& 
n Os 
& 
VO 
«s FH 
l^-
fi 
FH 
FH 
O 
OS 
Os 
1/5 
r^  
Os 
F H 
^t 
00 r^ r-SO 
<s 
^ FH 
*> f> 
$2
,5 
r-f> 
cT 
FN 
Market Value (Millions) 
Cumulative Weighted Average MC/Rev. -•— Cumulative Median MC/Rev. 
Histogram of Simple Mean of Random Sample Groups 
(Samples limited to Positive ROE, Market Value<$100MM, and Revenue>$500K) 
C 
45% 
40% 
35% 
30% 
25% 
20% 
15% 
10% 
5% 
0% 
p. 
^iiiM^lillWWVf^^r^'fiM 
0.66 1.00 1.33 1.66 2.00 2.33 
Simple Mean Market Cap to Revenue Multiple (±.166) 
2.66 
Comparison of Willamette Guideline Companies to Zinetics 
Medical Inc. 
Fiscal Year 
Willamette Guideline Company Ending Gross Profit Margin Operating Margin Net Profit Margin 
American BioMed, Inc. 
Angeion Corporation 
CardioGenesis Corp. 
Cardiovascular Dynamics, Inc. 
Electro-Catheter Corporation 
EndoSonics Corporation 
Luther Medical Products 
MedAmicus, Inc. 
Perclose 
Possis Medical, Inc. 
Rochester Medical 
Average 
Zinetics Medical Inc. 
Dec-96 
Dec-98 
Dec-96 
Dec-96 
Aug-97 
Dec-96 
1997 
Dec-96 
Mar-97 
Jul-97 
Sep-97 
Sep-97 
Not Available 
-169.56% 
27.50% 
Not Available 
Not Available 
35.25% 
Not Available 
38.60% 
-4.44% 
-2.08% 
35.52% 
-5.60% 
62.64% 
Not Available 
-795.65% 
-277.50% 
Not Available 
Not Available 
-29.10% 
Not Available 
-17.54% 
-248.88% 
-200.00% 
-32.89% 
-228.79% 
19.47% 
-433.33% 
-843.47% 
-220.00% 
-54.11% 
-21.21% 
-29.50% 
-12.96% 
-19.30% 
-215.55% 
-179.16% 
-27.63% 
-186.93% 
19.43% 
Comparison of Willamette Guideline Companies to Industry Data and 00 
Q Comparison of Willamette Valuation Scenarios to Industry Data § 
Fiscal Year Gross Profit Margin Operating Margin Net Profit Margin 
Zinetics Medical Inc. 1997 62.64% 19.47% 19.43% 
Willamette Guideline Companies Average -5.60% -228.79% -186.93% 
Willamette Valuation Scenarios 
Scenario 1 (25% Weighting) (Implies $0.1582 per share) 70% 25% (1st Yr.) 30% (2nd-5th Yrs.) 40% (1st Yr.) 45% (2nd-5th Yrs.) 
Scenario 2 (25% Weighting) (Implies $0,058 per share) 55% 35% 20% 
Scenario 3 (50% Weighting) (Implies $0.1601 per share) 55% (1st Yr.) 70% (2nd-5th Yrs.) 23.3% (1st Yr.) 35% (2nd-5th Yrs.) 20% (1st Yr.) 46.7% (2nd-5th Yrs.) 
Hoover's.com Industry Reports 
Hoover's.com Medical Appliances/Equipment Industry 56.28% 8.05% 3.67% 
Hoover's.com Medical Instruments/Supplies Industry 60.84% 10.11% 5.48% 
Robert Morris and Associates (1998 1-3MM) 
Surgical, Medical & Dental Instruments and Supplies - Manufacturers 42.50% 5.60% 2.40% 
Medical, Dental, & Hospital Equipment and Supplies - Wholesalers 47.80% 5.50% 3.36% 
Zinetics Medical, Inc. 
Imputed Value of Common Stock 1989-1991 
in 
Q 
Q 
< 
Net Sales 
Cost of Sales 
Gross Margin 
Gross Margin % 
SG&A plus R&D 
Loss before Other Income 
Other Income 
Loss before Extraordinary Items 
Recovery of Unauthorized Withdrawals 
Net Loss 
Weighted Ave. No. of Shares Outstanding 
Revenue per Share 
Indicated value per share at 17.52 multiple 
Indicated value per share at 10.36 multiple 
1991 
$ 299,899 $ 
201,141 
98,758 
32.93% 
629,334 
(530,576) 
13,304 
(517,272) 
14,350 
1990 
199,526 $ 
114,688 
84,838 
42.52% 
418,975 
(334,137) 
(41,970) 
(376,107) 
15,026 
1989 
175,723 
123,608 
52,115 
29.66% 
425,498 
(373,383) 
(56,940) 
(430,323) 
21,281 
$ 
$ 
(502,922) $ 
,901,538 
0.00233 $ 
0.04076 
0.02410 
(361,081) 
51,723,456 
0.00386 
0.06758 
0.03996 
$ (409,042) 
38,580,704 
$ 0.00455 
0.07980 
0.04719 
00 
MVIC/Revenue Multiple Calculation on Synectics Purchase § 
1991 1990 1989 
Net Sales $ 299,899 $ 199,526 $ 175,723 
% of Stock Purchased 81.44% 81.44% 81.44% 
Portion of Rev. Allocable to Shares Sold 244,237.75 162,493.97 143,108.81 
MVIC per Sale 255,000.00 255,000.00 255,000.00 
MVIC/Rev. Multiple 1.0441 1.5693 1.7819 
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IN THE DISTRICT COURT OF THE THIRD JUDICIAL DISTRICT 
IN AND FOR SALT LAKE COUNTY, STATE OF UTAH 
ZINETICS MEDICAL, INC., : ANNOTATED 
a Utah corporation, MEMORANDUM DECISION 
(Cites to Record in Bold) 
Petitioner, 
: CASE NO. 980905416 
vs. 
AYYOOB ABBASZADEH, et al9 
Respondents. 
This action brought to determine the fair value of Zinetics, Inc. pursuant to the Utah Revised 
Business Corporation Act (the "Act"), Utah Code Ann., Section 16-10a-101, et seq. was tried before 
me on November 30, 1999 through December 3, 1999. The parties made closing arguments on 
Febraary 28, 2000. William Z. Pentelovitch, Esq. and Alain M. Baudry, Esq. represented the 
petitioner. Respondents appeared through their counsel, Robert A. Peterson, Esq., Rebecca S. Parr, 
Esq., and Karen L. Martinez, Esq. 
Zinetics Medical, Inc. is a corporation engaged in the manufacture of catheters used in the 
diagnosis of gastrointestinal disease. Testimony of Robert Paulsen ("Paulsen Am. Test") Tr. 
at 27.1 
Due to difficulties in the transcription of the videotaped trial, the parties have stipulated to amend the 
transcript to correct inaccuracies. The Amended transcript is referred to as "Am. Test." 
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On February 13,1998, a special meeting of Zinetics' shareholders was held in Salt Lake City. 
At that meeting, an Agreement and Plan of Reorganization was approved authorizing the merger of 
Zinetics with Medtronic G. B., Inc., a wholly-owned subsidiary of Medtronic, Inc. Under the terms 
of the Agreement and Plan of Reorganization, the shares of Zinetics common stock were converted 
into the right to receive cash of 4.528 cents per share. Petitioner's Exhibit ("P.X.") 20(J). The 
respondents are dissenting shareholders who exercised their right under the Act to seek a Court 
determination of the fair value for their shares of Zinetics common stock as of February 12,1998. 
My evaluation of the fair value of the Zinetics common stock requires that I determine organizational 
and performance characteristics most likely to maximize value2 and that I adopt and apply an 
appraisal methodology which generates a value with the most legitimate claim to validity. 
I. Findings relating to Zinetics9 structure and operations 
Zinetics was incorporated in 1983 for the purpose of bringing to the marketplace disposable 
gastrointestinal catheters developed primarily by Dr. Harold Mack Brown, a Professor of Physiology 
at the University of Utah. (Testimony of H. Mack Brown. ("Brown Test") at Tr. 339-40. 
Although revenue figures for Zinetics for the years 1983-1991 were not made part of the record, it 
is undisputed that Zinetics sustained net losses for each of these years. Brown Test, at Tr. 345 and 
P.X. 4 at p. 7. Dr. Brown attributed the losses to a distribution network which he characterized as 
"thin." Brown Test, at Tr. 354, and P.X. 3 at p. 3. Zinetics was also victimized during this period 
2This exercise was directed primarily to assess whether Zinetics should be valued as a subsidiary of 
Medtronics, a stand-alone company, or an entity with hybrid features. This analysis required an evaluation 
of the probability that the performance projection presented for each proposed corporate structure would 
come to pass if implemented by the company. It was not, therefore, a task identical to a traditional "highest 
and best use" analysis. 
2 
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by an embezzlement loss of approximately $400,000 perpetrated by a company manager. Brown 
Test, at Tr. 365. The Kearns-Tribune Corporation was a major investor in Zinetics. Brown Test, 
at Tr. 344-45. Minutes of the meetings of the Board of Directors of the Kearns-Tribune 
Corporation between mid-1987 and November 1991 recount Zinetics' ongoing struggle to achieve 
profitability and chronic need for cash. P.X. 29. 
In November 1991, Synectics Medical, Inc.(ffSynectics") gained a controlling interest in 
Zinetics, acquiring 81.7%of the outstanding shares. P.X. 20(D). Synectics was a wholly-owned 
subsidiary of Medtronic, Inc. At the time Synectics acquired its controlling interest in Zinetics, the 
Kearns-Tribune Corporation owned 105,241,550 shares of Zinetics common stock. Id. Synectics 
bought the shares owned by the Kearns-Tribune Corporation for $255,000, or approximately 2.4 
cents per share. Id. Synectics retained control over Zinetics until Medtronics' acquisition of the 
company in February, 1998. P.X.20(J). While an affiliate of Synectics, Zinetics enjoyed consistent 
revenue growth and profitability. Testimony of Merrill Norman (ff Norman Test"), Am. Test at 
Tr. 200-02, P.X. 22, Schedule B, and P.X. 20(f), Ex. 2. 
Several issues are central to determining the characteristics of Zinetics for purposes of 
assessing its intrinsic value. First, it is necessary to determine whether Zinetics should be valued 
as an affiliate of Synectics or as a stand-alone company. Next, it is necessary to determine whether 
Synectics and Medtronic exploited their control over Zinetics by suppressing product development 
and the intrinsic value of the company until such time as it could effect a "squeeze out" of the 
minority shareholders.3 
3 
I have considered and reject petitioner's assertion that corporate misconduct issues, litigated and dismissed 
with prejudice in an earlier shareholder derivative action, are therefore barred by the doctrine ofres judicata. 
3 
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I find that Zinetics' intrinsic value would most likely be maximized as an affiliate of 
Synectics. I further find that insufficient evidence exists to support a conclusion that decisions made 
by the Zinetics Board of Directors while controlled by Synectics were improperly made with an eye 
toward repressing the value of Zinetics until the minority shareholders could be "squeezed out." 
Of greatest relevance in reaching my finding that Zinetics enjoys greater intrinsic value as 
a Synectics affiliate than as a stand-alone company, is the historical performance of the company. 
It is undisputed that Zinetics did not become profitable until becoming an affiliate of Synectics. This 
fact underscores the importance of a reliable market and effective distribution network to the 
performance of the company. Paulsen Am. Test at Tr. 36-38; Deposition testimony of Johann 
J. Neisz ("Neisz Dep. Test") at pp.48-49; Testimony of Ross Allen (" Allen Am. Test") at Tr. 
672-74. Although it is not unusual for startup companies to struggle, sometimes for years, while 
nurturing an effective and efficient product distribution network, Zinetics demonstrated little or no 
market development or distribution progress until after its affiliation with Synectics. Compare P.X. 
4 at p. 7 to Schedule B of the Norman Report, Tab 2 to Zinetics' Addenda. One can easily 
harvest from the record ample evidence — the minutes of the Kearns-Tribune Board of Directors 
(P.X. 29) is but one example — that Zinetics' product development was well advanced in the pre-
Synectics years (P.X. 4) and that it was the absence of an effective marketing and distribution 
network that created the sole barrier to Zinetics profitability. (P.X. 3) 
I find that the allegations of corporate misconduct have relevance in this action to the central issue of fair 
value which clearly survives a claim preclusion challenge. Although the issue preclusion branch or res 
judicata appears to put respondent's allegations at risk, I interpret the language of the Stipulation and Order 
dismissing the derivative action to express an intention that the corporate suppression claims be preserved 
for presentation in this action. 
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It is likewise clear that Zinetics was largely dependent on Synectics both as a customer for 
its products and as its primary product distribution vehicle to the catheter market. Paulsen Am. 
Test, at Tr. 46-48. As a stand-alone company, Zinetics would no longer be the beneficiary of 
Synectics as either a customer or a distributor. Id. Moreover, Zinetics would be at a competitive 
disadvantage as a stand-alone due to its limited product line. Paulsen Am. Test, at Tr. 62-64; 
Testimony of Steve Davis ("Davis Am. Test") at Tr. 412-15; Neisz Dep. Test, at pp. 21-23; 
Allen Am. Test, at Tr. 673-74. Unlike its major competitors as a stand-alone company, Sandhill 
and Synectics, Zinetics could not offer a full range of gastroenterological diagnostic products and 
would be unable to exploit the appeal of an integrated system to health care providers. Id. 
Synectics/Medtronics acknowledged that maintaining an uninterrupted flow of catheter products was 
a matter of high priority to the company. Paulsen Am. Test, at Tr. 27-29; William Murray 
Testimony ("Murray Am. Test.") at Tr. 23-25. It also conceded that it would take between one 
and two years for Synectics/Medtronics to develop its own catheter manufacturing facilities to a 
level which would make them capable of fully replacing the catheters formerly supplied by Zinetics. 
Neisz Dep. Test, at p. 58-59; Murray Am. Test, at Tr. 25-27.4 Zinetics would clearly own 
competitive leverage over Synectics and Medtronics during this window and could be expected to 
command considerable price increases over the previous transfer pricing structure. I am not 
convinced, however, that any additional revenues which Zinetics might have expected from sales 
4 
Respondents challenge the assertion that Synectics/Medtronic would compete with Zinetics based on the 
"Hotelian Theory" which, according to respondents' expert, Mr. Robert Reilly, would render the move 
"economically irrational." Testimony of Robert Reilly ("Reilly Am. Test.") at Tr. 567-69. Left 
unexplained is how or whether the Hotelian Theory would account for the decision of Sandhill, Zinetics 
former customer, to enter into direct competition with Zinetics. Davis Am. Test, at Tr. 208-09. 
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to Synectics/Medtronics during this period would have been sufficient to finance the development 
of an effective distribution network and research and development initiatives. Paulsen Am. Test, 
at Tr. 33-36,45-47; Neisz Dep. Test, at p. 46-49; Allen Am. Test, at Tr. 546-47 ; Murray Am. 
Test, at Tr. 18-19; Norman Am. Test, at Tr. 281-82. 
I reject, as unsupported by the evidence, the minority shareholders' contention that Zinetics 
could have prospered as a stand-alone company but for Synectics' efforts to frustrate the 
development of products which would have positioned the company to compete effectively against 
Sandhill and Synectics. Murray Am. Test, at Tr. 18-19. The dissenters' assertion of product 
suppression focused on the glass catheter and fluorescent catheter technology. Mr. Steve Davis, 
Zinetics' President, was a proponent of developing a glass catheter to augment Zinetics' product line. 
Davis Am. Test, at Tr. 200-03; Brown Test, at Tr. 360. His glass catheter initiative was opposed 
by Synectics' two representatives on Zinetics three member Board of Directors, Mr. Hans Neisz and 
Mr. William Murray. Neisz Dep. Test, at p. 51. Mr. Murray, who believed that Zinetics generally 
took an overly optimistic view of the potential for the growth of the diagnostic catheter market, 
noted that Mr. Davis never responded to his request that a business plan be prepared for the glass 
catheter. Murray Am. Test, at Tr. 32-33. For his part, Mr. Neisz articulated rational business 
reasons for opposing development of the glass catheter, including concerns about the potential 
market for the product, as well as unease over the product's safety. Neisz Dep. Test, at pp. 51-55. 
Skepticism about the glass catheter was shared by Dr. Milan Heath, Zinetics' Director of Research, 
who had no affiliation with Synectics. Brown Test, at Tr. 362-63. 
Mr. Davis also promoted the development of a catheter which utilized flourescent 
technology. Davis Am. Test, at Tr. 216-18. Mr. Neisz shared with Mr. Davis the view that 
6 
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flourescent technology held promise, but concluded that Zinetics did not have the resources to pursue 
development and manufacture of a flourescent catheter. Neisz Dep. Test, at pp. 55-58. 
I am similarly unpersuaded that Synectics/Medtronics blocked efforts to create a public 
market for Zinetics shares, motivated by a desire to repress share value in anticipation of purchasing 
the minority interests. Murray Am. Test, at Tr. 35-38,41-43. To the extent that efforts to create 
a market for Zinetics' shares were rebuffed by the Synectics/Medtronics appointees to the Zinetics 
board of directors, the rationale for doing so — to avoid the additional filing requirements associated 
with public market-making — is legitimate, even when considered in the light of other alleged acts 
of value suppression. Murray Am. Test, at Tr. 41-43. 
Finally, the claim that the value of Zinetics share was artificially suppressed by the transfer 
pricing structure governing sales between Zinetics and Synectics is unsupported by the evidence. 
I credit Mr. Ross Allen's testimony that the prices paid by Synectics for Zinetics' catheters was in 
line with prices paid by non-affiliated customers for the same product. Allen Am. Test, at Tr. 531-
34 and P.X. 64 and 65. In short, the evidence supports the conclusion that the prices paid by 
Synectics for Zinetics' products were market driven. Allen Am. Test, at Tr. 531-32. 
Respondents' suppression theory is animated by the assumption that a rational corporation 
which owns a controlling interest in an affiliate corporation will engage, as a matter of course, in 
practices designed to minimize the apparent value of the affiliate as part of a strategy to "squeeze 
out" disgruntled minority shareholders at the lowest possible cost. Although this assumption may 
be firmly rooted in realities of the rough and tumble world of market capitalism, it cannot alone 
influence an appraisal of fair value. Respondents must prove a nexus between the 
Synectics/Medtronics' alleged oppressive activities and the corporate action triggering the 
7 
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dissenters' rights such that one can be found to have been "in anticipation" of the other. 
Respondents could present in aid of its nexus claim only the general observation that Zinetics post-
merger revenues experienced an unusual upswing.5 Davis Am, Test, at Tr. 212-15. This is not 
enough. 
In summary, I find that Zinetics should be valued as a subsidiary of Synectics/Medtronics 
without regard to value enhancements related to respondents claim of product suppression.6 
II. Methodology for determining fair value 
Having determined that a fair value determination of Zinetics' shares as of February 12,1998 
must be based on an evaluation of Zinetics as an affiliate of Synectics, I next turn to the task of 
selecting and employing the appropriate valuation methodology. A fair value assessment of a 
corporation requires consideration of market value, investment value, and asset value. Oakridge 
Energy, Inc. v. Clifton, 937 P. 2d 130 (Utah 1997). Asset value is generally viewed as the least 
reliable of these factors of value determination. Id. Neither petitioners nor respondents presented 
evidence of asset value, and I will not consider it as part of my fair value analysis. 
Respondents urge me to place considerable weight on the market value of Zinetics' shares. 
This is appropriate, they urge, because a valuation based on the actual price paid for the shares yields 
a result free of the multifarious assumptions and proj ections which compromise the reliability of the 
5 
Petitioner objects to my consideration of any post-merger events. Because my reliance on post-merger 
evidence is, at most, incidental, it is unnecessary to discuss this issue at length. I note only that as a general 
matter it is seldom appropriate to categorically exclude evidence as irrelevant. Here, and in fair value cases 
generally, post-merger events may be useful in the pursuit of truth (See U.R.E. 102) by, among other things, 
corroborating or impeaching evidence relating to pre-merger conduct or events. 
My findings necessarily mean that I am affording little weight to Mr. Davis's proj ections (P.X. 7-9) to the 
extent that they include predictions of revenues derived from new product development. 
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various investment value techniques. Although respondents concede that Zinetics' shares were thinly 
traded on the over-the-counter market, they nevertheless stand by their conclusion that trading 
activity for the four months prior to February 12,1998 indicates a fair value of 17.2 cents per share. 
Dissenters' expert, Mr. Reilly, characterized this trading history as "noteworthy"and that it 
"reasonably reflected the marketable, minority interest per share market value of the Zinetics 
common stock." I disagree. Trades in Zinetics common stock occurred very infrequently-too 
infrequently in my view to provide reliable data bearing on Zinetics' fair value. Norman Test, at 
Tr. 725-27. The trades which occurred from October 13, 1997 through January 8,1998, are also 
unreliable because they involved sales made by dissenting shareholders who were then involved in 
negotiations with Synectics over the future of the company. Norman Test, at Tr. 726. One trade 
of a block of 325,000 shares was a sale by Mr. Ronald Johnson to his own IRA. Norman Test, at 
Tr. 727. The last two trades occurring in February, 1998, took place after the merger and minority 
share price had been announced. Norman Test, at Tr. 726-27. These market environments are 
clearly not conducive to producing share values which reflect accurately the intrinsic worth of the 
company. Id. To the contrary, they are trades which do not reveal the existence of a free and open 
market for Zinetics shares, but rather an appreciation in value in anticipation of corporate action and 
therefore ineligible for fair value consideration. 
Both parties concentrated their valuation efforts on two valuation methodologies: the market 
approach to value, and the investment approach to value. The market approach attempts to derive 
value by comparing Zinetics to the values of companies with which it shares certain common 
characteristics. It is a method which has not been recognized as a valuation tool by our courts. See, 
Oakridge Energy v. Clifton, supra. I do not, however, interpret Oakridge Energy to restrict a fair 
9 
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value analysis to the three methodologies approved in the decision. While eligible for consideration, 
the market approach analyses presented by both petitioner's expert, Mr. Merrill Norman, and by 
respondent's expert, Mr. Reilly, are both so fundamentally flawed that I decline to rely on them. 
Neither expert could discover even one company which could reasonably be characterized 
as "comparable" to Zinetics. Tellingly, a 1996 appraisal of Zinetics, performed by a Salt Lake City 
accounting firm at the request of Medtronics, concluded that no public companies could be found 
suitable for comparison with Zinetics. P.X. 20 (F) at p. 11. Mr. Norman attempted to cope with 
the paucity of comparable companies by selecting at random companies which manufacture medical 
products irrespective of size or other economic characteristics and applying certain adjustments to 
valuation to accommodate dissimilarities.7 Norman Am. Test, at Tr. 257-59. For example, Mr. 
Norman concluded that a 42.76% downwards adjustment in value was appropriate to make 
allowance for size differences between his set of comparable companies and Zinetics. Norman Am. 
Test, at Tr. 264-65. An adjustment of this magnitude seriously impairs the validity of the 
comparison. As noted by Mr. Reilly, authoritative sources in the field of valuation view adjustments 
in excess of 50% with considerable suspicion. Reilly Am. Test, at Tr. 578-80. And for good 
reason. The necessity of a 50% adjustment suggests that the subjects of the comparison are more 
different than alike. Errors which could be expected to infect the comparison through the application 
7 
Both experts assumed that the appropriate subset of companies from which candidates for comparison to 
Zinetics should be selected was defined by product line, i.e. medical products or catheters. Norman Am. 
Test, at Tr. 254-55; Reilly Am. Test, at Tr. 531. This decision made it more difficult to locate companies 
with other similarities to Zinetics, e.g. sales, net revenues, etc. More reliable market valuation data may have 
emerged had candidates for comparison been selected based on considerations of economic performance 
across product lines with adjustments made, as necessary to accommodate differences in markets for 
dissimilar products. 
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of adjustments geared to account for such substantial dissimilarities would render any meaningful 
comparison futile. The adjustments used by Mr. Norman in his analysis highlight the difficulties 
inherent in reaching a fair value determination based on market comparisons. Mr. Norman 
acknowledges these shortcomings by assigning a lesser weight to the market valuation method than 
his investment method. Norman Am. Test, at Tr. 268-69 and Norman Report, P.X. 22 at 
Schedule A, Tab 2 to Zinetics' Addenda. I have even less confidence in its utility than Mr. 
Norman and extend only modest regard for his market approach findings. 
Mr. Reilly's market approach analysis is also seriously flawed, but for different reasons. Mr. 
Reilly's market approach does not use adjustments to mitigate the effects of structural and 
performance differences between comparable companies and Zinetics. His methodology led to the 
selection of "guideline" publicly traded companies with primary focus on one company, Rochester 
Medical, which he offers up as the most suitable candidate for comparison to Zinetics for valuation 
purposes. Reilly Am. Test, at Tr. 445-47 and R.X. TT. Mr. Reilly valued his guideline companies 
using the ratio of the market value of invested capital (MVIC) to revenues. Id. Petitioners assailed 
Mr. Reilly's use of the MVIC/revenues pricing multiple technique by demonstrating that it yielded 
values which fluctuated inexplicably over time in a manner unrelated to the fundamental financial 
performance of the companies. Norman Test, at Tr. 743-44 and P.X. 66, Tab 3 to Zinetics' 
Addenda. Petitioner's critique is persuasive. Because I do not believe that Mr. Reilly's 
methodology produces values of Zinetics over time which would correspond to historical trends in 
the company' s performance measured by revenue or net income, I conclude that Mr. Reilly's market 
approach, like Mr. Norman's, should be substantially disregarded as unreliable. 
11 
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Our supreme court has adopted the widely accepted view that investment value is the most 
important of the three recognized valuation methods. Oakridge Energy, supra. The Oakridge 
Energy court defined investment value as an estimate of a corporation's earning capacity based on 
an analysis of capitalized earnings. Both Mr. Norman and Mr. Reilly performed valuations based 
on the investment value model, although both styled their analyses "Income Approach to Value". 
In addition to a capitalized earnings analysis, Mr. Norman performed valuations based on discounted 
cash flows, capitalized cash flows, and discounted earnings. Norman Am. Test, at Tr. 234-52, 
Norman Report, Schedules A, F, G, I & J, P.X. 22, Zinetics' Addenda Tab 2. Mr. Reilly limited 
his investment analysis to discounted cash flow. Reilly Am. Test, at Tr. 433-34 and R.X. TT. 
I find that the most reliable valuation method is an investment valuation of Zinetics as a 
subsidiary of Synectics/Medtronics and otherwise subject to my finding set out in Part I of this 
decision. Norman Am. Test, at Tr. 241-42. Mr. Norman's investment valuation analysis closely 
fits this criteria, particularly the data, projections and analyses contained in Schedules F, G, H, I, J, 
K, L and N to Mr. Norman's report. Zinetics' Addenda, Tab 2. The values of Zinetics generated 
by Mr. Norman's investment approach range from $2,584,265 based on discounted cash flows to 
a low of $2,170,219 based on discounted earnings. Id., Schedule A. 
Respondents take issue with Mr. Norman's investment valuation on several fronts. First, they 
note that Mr. Norman inexplicably reduced Zinetics' anticipated earnings 1998 from actual 1997 
earnings.8 Reilly Am. Test, at Tr. 585-86. This is a matter of some consequence since 1998 is the 
8 
Zinetics 1998 actual revenues closely matched Mr. Norman's projections. Norman Am. Test, at Tr. 317, 
730. 
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baseline year for projections of future performance and errors in the baseline year will compound 
overtime. Id. 
Respondents further note that Mr. Norman's projections take into account only expected unit 
price increases and fail to account for inflation. Reilly Am. Test, at Tr. 581-84. 
Respondents also challenge Mr. Norman's discount/capitalization rate calculation by 
asserting that it is improper to increase investor rate of return expectations using both a small 
company and micro cap company adjustment. Reilly Am. Test, at Tr. 578-79. 
Each of these criticisms of Mr. Norman's investment valuation has a measure of merit. When 
the numbers proposed by respondents for revenue, discount rate and capitalization rate are used to 
recalculation Mr. Norman's investment valuations, the results do not exceed the $. 04528 per share 
offered by Medtronics for the respondents' common stock. Norman Test, at Tr. 731-32, Norman 
Report, Schedules A, F, G, I and J. 
Based on the foregoing, I conclude that the fair value of Zinetics' common stock is less than 
$. 04528 per share and that, accordingly, respondents have received fair value for their stock. 
Norman Test, at Tr. 189-90 and P.X. 22, Norman Report. 
Dated this 5th day of May 2000. 
RONALD E. NEHRING 
DISTRICT COURT JUDGE 
155129.1 
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